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ABSTRACT 
The generation of antibody and cell-mediated immune responses, which may be 
mutually exclusive, is critically dependent on the profile of cytokines present during the 
development of the response. Accordingly, cytokines expressed by recombinant vaccinia 
virus (VV) have been shown to have profound effects on antiviral immune responses. 
This thesis describes the selective induction of immune responses by cytokine genes 
expressed by recombinant VY and fowlpox virus (FPV) and the development of novel 
vaccine strategies using recombinant FPV and nucleic acid vaccines (NA V) as potentially 
safe approaches to immunisation. 
Avipoxviruses have recently been studied as potential vectors for the delivery of 
heterologous vaccine antigen. Because these viruses abortively infect mammalian cells, 
yet still effectively present encoded foreign genes to the host immune system, they offer a 
safer but effective alternative to other virus vectors. The construction of recombinant FPV 
expressing influenza virus A/PR/8 hemagglutinin (HA) glycoprotein and the genes for 
IL-6 or IFN-y was described. These recombinants secreted cytokines for prolonged 
periods with minimal cytopathic effect on infected cells in vitro. In mice, vector-expressed 
cytokines dramatically altered immune responses induced against HA. Expression of 
IL-6 augmented both primary systemic and mucosa! antibody responses and primed for 
enhanced recall responses. When given systemically, IL-6 recombinant virus gave 
enhanced protection against morbidity upon lethal challenge with influenza virus. In 
contrast, expression of IFN-y n1arkedly inhibited antibody responses without affecting the 
generation of cell-mediated immunity. The safety of FPV was demonstrated in 
immunodeficient animals and neonates and no side-effects due to cytokine expression 
were observed. 
Intramuscular (i.m.) injections of NA V expressing the HA of influenza virus 
generated protracted but low levels of specific antibodies in mice. Resultant protection 
against infection with HA-encoding VV or lethal doses of influenza virus demonstrated 
the efficacy of NA V vaccination. NA V and FPV, both expressing a common HA antigen, 
V 
were combined in a consecutive immunisation strategy in attempts to augment the immune 
responses elicited by the former. Priming with NA V i.m. and boosting with recombinant 
FPV at the relevant site generated prolonged and greatly enhanced systemic and mucosa! 
antibody responses. Further enhancement of mucosa! antibody responses was obtained 
when IL-6 was co-expressed in the recombinant FPV. The efficacy of this combined 
vaccine strategy was further emphasised by its ability to protect mice against both 
mortality and morbidity upon lethal challenge with influenza vin1s. 
Attenuation of VV has previously been achieved by the expression of cytokines, 
including IL-2, IFN-y and TNF. Localised production of these virus-encoded factors 
during virus replication has also facilitated investigations into their antiviral activities. The 
attenuation of VV expressing IL-7 in both normal and immunodeficient mice, together 
with in vivo effects of IL-7 expression on antiviral responses were reported. 
Virus-encoded IL-7 induced elevated LAK and specific CTL responses but did not 
augment specific antibody levels. The selective enhancement of cell-mediated immune 
responses by virus-encoded IL-7 was mediated by host IL-2. 
In summary, poxvirus vectors encoding cytokines may represent a safe and 
effective vaccine strategy and can be used to selectively manipulate the immune response. 
The efficacy of these vectors was further enhanced by combining vaccine strategies using 
recombinant FPV and NA V. These findings have implications for the development of 
improved vaccination strategies. 
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CHAPTER I 
Introduction and Literature Review 
1.1 OVERVIEW 
The immune system comprises adaptive and innate components. Cytotoxic T 
lymphocytes (CTL) and antibodies are major elements of the former, whereas innate 
components include natural killer (NK) cells, macrophages, complement and cytokines 
(Male and Roitt, 1993). Invasion of foreign materials, often microbes, activates the 
immune system which in attempts to eliminate the invader. The first line of defence is 
usually the activation of non-specific innate immunity. Adaptive defences are elicited later 
and are mediated through two distinct but frequently overlapping modes: generation of 
CTL and production of antibodies by B lymphocytes. The innate and adaptive systems 
function in an integrated manner. For example, innate cellular components may interact 
with specific antibodies in antibody-dependent cell-mediated cytotoxicity (ADCC). 
After the initial encounter with infectious agents, the adaptive immune system 
acquires memory that allows the induction of secondary immune responses faster and at 
greater amplitude than primary responses. Such enhanced secondary responses prevent 
the agent from causing disease following subsequent infections. This ability to establish 
immunologic men1ory is, therefore, important for protection against virulent infections, as 
well as for modification of diseases. Thus, the manipulation of the immune system to 
induce protection has important ramifications for the development of prophylactic and 
therapeutic vaccines. 
1.2 IMMUNITY TO VIRUSES 
Antiviral defences are both innate and specific, and their major purpose is to 
inactivate free virus and to eliminate infected cells that have potential to release infectious 
virions. Antibodies , which will be discussed further in Sections 1.2.4 and 1.4, are 
produced by B lymphocytes and neutralise infectivity of virus. Initial resistance to virus 
infection, however, is mediated by the activation of non-specific NK cells (Bancroft et al., 
1981; Borysiewicz et al., 1985; Rager-Zi sman et al., 1987) and macrophages (Zisman 
et al. 1971). Subsequent activation of CTL may lead to the destruction of virus-infected 
cell and recovery from the virus infection (Gardner et al., 197 4; B landen and Gardner, 
1976· Pfizenmaier et al., 1977; Moskophidis et al., 1987; Owen et al., 1988). ADCC is 
1 
another mode of killing of virus-infected cells that are bound with antibodies. ADCC has 
important antiviral roles in resistance to herpes simplex virus (HSV) infections (Kohl and 
Loo, 1982) and for clearance of a retrovirus, Friend leukemia virus (Collins et al., 1983). 
In addition, the destruction of vin1s-infected cells is also mediated by complement proteins 
that bind to antibodies on infected cells (Hicks et al., 1978; Cooper and Nemerow, 1986). 
In order for the immune system to respond to virus infections, the immune cells must first 
be able to 'see' and recognise the pathogen, and in turn, be activated to a variety of 
anti viral effector functions. 
1.2.1 Antigen processing and recognition 
Unlike antibody, which recognises intact proteins, T lymphocytes recognise 
peptides in association with host major histocompatibility complex (MHC) molecules 
(Zinkernagel and Doherty, 1974). Later, Townsend et al. (1985) showed that 
virus-specific CTL recognises only fragments of the viral antigen and not the whole 
protein. 
There are two classes of MHC molecules which differ in many respects, including 
structure, composition and the nature of the peptide they bind (Cresswell, 1994 ). Class I 
MHC is found on all nucleated cells, whereas only certain types of cells, such as 
antigen-presenting macrophages, dendritic cells and B lymphocytes, express class II 
molecules (Harding, 1991 ). The recent elucidation of structures for class I (Zhang et al., 
1992) and class II (Brown et al., 1993) MHC molecules has led to further insights into 
mechanisms of antigen processing and presentation . 
Class I MHC-restricted CD8+ CTL recognise antigens synthesised within target 
cells (Townsend et al., 1986 and 1989 ; 0 ' Rourke et al., 1990). These antigens are 
degraded in the cytosol by proteosomes which consist of multiple subunits of low 
molecular ma · polypeptides encoded by genes in the MHC (Goldberg and Rock, 1992). 
The peptide fragments are translocated by specific transporter molecules (Monaco, 1992) 
into the endoplasmic reticulum (ER) where the MHC molecules are derived (Townsend 
et al. 1989; Neefjes et al., 1993). The peptides then bind to the class I MHC molecules, 
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and are transported to the Golgi apparatus and ultimately to the target cell surface. Class 
II MHC-restricted CD4+ helper T (Th) lymphocytes, on the other hand, recognise 
exogenously ingested antigens (Nelson et al., 1992). A key feature of this pathway is the 
transient association of class II MHC molecules with another molecule, called the 
invariant chain, in the ER (reviewed by Cresswell, 1994). The contribution of the invariant 
chain in antigen processing is not clearly defined. Nevertheless, upon binding of 
degraded peptides of the internalised protein to the invariant chain-class II MHC 
molecules in the ER, the invariant chain is cleaved from the complex. The peptide-class II 
MHC is subsequently presented on the cell surface. 
The presentation of endogenous and exogenous antigens by class I and II MHC 
molecules, respectively, may not be true for all antigens. For example, influenza virus A 
n1atrix-specific CTL (Nuchtem et al., 1990) and measles virus-specific CTL (Sekaly et al., 
1988) recognise these antigens in association with class II MHC molecules. This peculiar 
class II MHC-restricted cytotoxicity will be detailed in Section 1.2.3.3. 
1.2.2 Lymphocyte activation 
T lymphocytes recognise specific peptide-MHC molecules on antigen presenting 
cells (APC) via a T-cell-surface heterodimer receptor (TCR) and this interaction dictates 
immunological specificity. Contact between the TCR and the peptide-MHC molecules 
alone, although essential to initiate activation of T lymphocytes, is insufficient to trigger 
subsequent effector functions (Mueller et al., 1989). Accessory molecules, including 
ICAM (Van Seventer et al., 1990; Damle et al., 1992), LFA-3 (Moingeon et al., 1989) and 
VCAM-1 (Damle and Aruffo, 1991) are required for co-stimulatory interactions between 
T lymphocytes and APC. The T lymphocyte co-receptors CD4 and CD8 are further 
important accessory receptors that play distinct but important roles in T lymphocyte 
activation and effector functions. Generally , CD4 + lymphocytes are of the helper 
phenotype while CD8+ lymphocytes are cytotoxic (Collins et al., 1993). A 'second 
signal', provided by interactions between co-stimulatory molecules B7-l, B7-2, or B7-3 on 
APC with CD28 , has recently been shown to be vital for T lymphocyte activation (Galvin 
et al., 1992; Goldbach-Mansky et al., 1992; Azuma et al., 1993; Freeman et al., 1993; 
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Harding and Allison, 1993; Van Gool et al., 1993). Without this second signal, T 
lymphocyte clonal anergy or deletion may occur, producing a state of immunological 
tolerance. These 'second signals' appear to stabilise message RNA (mRNA) for 
interleukin 2 (IL-2), interferon-y (IFN-y) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) in T lymphocytes (Lindsten et al., 1989), thereby prolonging delivery 
of activation signals (reviewed by Allison, 1994 ). Other natural ligands for B7 involved in 
T lymphocyte activation are CTLA-4 (Lenschow et al., 1993) and heat-stable antigen (Liu 
et al., 1992). CTLA-4 is also involved in B lymphocyte activation (Linsley et al., 1991). 
Cytolcines are also required for the activation of T lymphocyte effector functions, but this 
will be discussed elsewhere (Section 1.3.5). 
B lymphocyte-antigen recognition is mediated by membrane immunoglobulin (lg) 
antigen receptors (reviewed by Reth, 1992; Moeller, 1993; Sakaguchi et al., 1993). The 
receptor mediates the internalisation of antigen which is subsequently degraded and 
presented in association with class II MHC molecules on the cell surface (Lanzavecchia, 
1990; Hodgkin and Basten, 1995). B lymphocytes usually require stimulatory signals or 
'help' from activated CD4+ Th lymphocytes for their activation to antibody production 
(reviewed by Parker, 1993). During the B-T lymphocyte interaction , Th lymphocytes 
recognise the peptide-class II MHC molecules on B lymphocytes and, through a variety 
of cytokines produced, induce B lymphocytes to proliferation, differentiation and 
subsequent antibody secretion. Cytokines secreted by the T lymphocyte have profound 
effects on the antibody isotype produced (detailed in Section 1.3.7). The B-T lymphocyte 
interaction , like the T lymphocyte-APC interaction, is also coupled with interaction 
between co-stimulatory receptors. These include CD40 (Armitage et al., 1992a; Noelle 
et al., 1992) and the tumour necrosis factor (TNF)-receptor (A versa et al., 1993; Macchia 
et al., 1993) on B lymphocytes that interact with CD40 ligand (CD40L) and TNF-a on T 
lymphocytes. These interactions enable B lymphocytes to respond to cytokines. CDS+ T 
lymphocytes have also been shown to provide help to B lymphocytes for antibody 
ecretion (Paganelli et al., 1995). The interaction between CDS+ T lymphocytes and B 
lymphocyte has not been extensively studied. However, these lymphocytes may be 
, 
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interacting through their TCR recognising the peptide-class I MHC molecules on B 
lymphocytes . This TCR-MHC interaction is also coupled with interactions between 
co-stimulatory molecules, such as the CD40 and CD40L interaction (Lane et al., 1992; 
Cronin et al., 1995). 
1.2.3 Antiviral cell-mediated effector mechanisms 
A variety of cells are activated during a virus infection. T lymphocytes, in 
particular CTL, are crucial for recovery from most virus infections (Blanden, 1970). 
Although CTL are usually of the CD8+ phenotype, CD4+ CTL are important in some 
virus infections (Weyand et al., 1989). Other non-specific early-acting cells, such as NK, 
lymphokine-activated killer (LAK) cells and macrophages are also essential for an 
effective host defence as detailed below. 
1.2.3.1 Natural killer and lymphokine-activated killer cells 
NK cells were discovered due to their cytolytic activities against tumour cells. 
They are distinguished from other lymphoid cells by the absence of B and T lymphocyte 
antigen receptors: murine NK cells are CD3-CD 16+asialo-GM 1 +NKl .1 + (Hackett et al., 
1986; Lanier et al., 1988; Welsh et al., 1991). The receptor used by NK cells to 
recognise tumour or virus-infected cells is not defined. The sensitivity of target cells to 
NK cytotoxicity was shown to be inversely correlated with their expression of class I 
MHC molecules (Karre et al., 1986). There is recent evidence to suggest that NK activity 
is inhibited when target cells encode a specific natural ligand bound in the class I MHC 
peptide groove (Storkus et al., 1991). Loss of class I MHC molecules, or their ligands, 
from the target cell surface render these cells sensitive to NK cell killing (Raulet, 1992). 
Hence displacement of self peptides with viral peptides in virus-infected cells, or 
witching off of cellular MHC expression during virus infection, would confer sensitivity 
of infected cell to NK lysis. 
Antiviral NK cell have been demonstrated in a variety of virus infections, 
including vaccinia virus (VY · Bukowski et al., 1983; Karupiah et al., 1990b) murine 
cytomegalovirus (CMV; Bancroft et al., 1981), human CMV (Borysiewicz et al., 1985) 
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and HSY (Rager-Zisman et al., 1987). Adoptive transfer of NK cells to suckling mice 
lacking NK activity protected the mice against a normally fatal infection with murine 
CMV (Bukowski et al., 1985). Depletion of NK cells by treatment with anti-asialo-GMl 
antibody resulted in an enhanced virus growth after infection with VV (Bukowski et al., 
1983; Karupiah et al., 1990b), murine CMV and murine hepatitis virus (MHV; Bukowski 
et al., 1983). NK cells are activated early in virus infection, probably through the 
induction of interferons (Gidlund et al., 1978). NK cells mediate their antiviral activities 
through killing of virus-infected cells directly or through ADCC (Lanier et al., 1988; 
Ravetch and Kinet, 1991) and by the production of antiviral cytokines such as IFN-y 
(Karupiah et al., 1990a). 
LAK cells were first recognised by their ability to lyse NK-resistant tumour cells 
(Grimm et al., 1982). After incubation with IL-2, mononuclear cells acquire this ability, 
hence this function is defined as 'lymphokine-activated' killer cell activity and is a form of 
non-MHC-restricted cytotoxicity. Inasmuch as the receptors responsible for NK activity 
have proved elusive, structures mediating LAK activity also remain poorly characterised. 
However, several surface adhesion molecules, such as CD2, ICAM-1 and LFA induced by 
IL-2, may be involved (Robertson and Ritz, 1992). Upon activation, LAK cells have also 
been shown to secrete IFN-y and IL-2 (Moretta et al., 1986). LAK activities can also be 
induced by phytohaen1agglutinin (PHA; Moretta et al., 1986), and cytokines such as IL-4 
(Tunru et al., 1993) and IL-7 (Alderson et al., 1990; Hickman et al., 1990; Lynch and 
Miller, 1990; Naume and Espevik, 1991; Stotter et al., 1991; Kos and MUllbacher, 1992). 
LAK cells were once thought to be a distinct cell lineage (Grimm et al., 1983). However, 
some LAK cells were shown to express a~ or y8 TCR and may, therefore, be of the T 
lymphocyte lineage (Moretta et al., 1986). 
The antiviral role of LAK cells has not been extensively studied. One study has 
hown that LAK cells transferred to NK cell-deficient suckling mice can control the 
growth of murine CMV (Bukowski et al., 1988). However, in the same report, LAK cells 
howed no antiviral activities against lymphocytic choriomeningitis virus (LCMV). LAK 
6 
cells have also been found at sites of infections with VV and MHV, but the antiviral role 
of LAK is not established in these cases (Natuk et al., 1989). 
1.2.3.2 Macrophages 
Macrophages have very important early antiviral functions. This early role has 
been demonstrated by increased susceptibility to infection with yellow fever virus as a 
result of macrophage depletion just before, but not after, the virus infection (Zisman et al., 
1971). Depletion by silica or specific antibodies also exacerbates HSY infection (Zisman 
et al., 1970). The mechanisms by which macrophages mediate early antiviral effects are 
unclear. Macrophages are a source of cytokines (Nathan, 1987), such as IFN-y and TNF, 
which have potent antiviral activities. Macrophages also mediate antiviral activities 
through production of virucidal reactive oxygen intermediates (ROI; Chase and 
Klebanoff, 1992). Another molecule secreted by activated macrophages is nitric oxide 
(NO; Ding et al., 1988). Antiviral activities of NO have been demonstrated against 
ectromelia virus (EV) in vivo (Karupiah et al., 1993) and HSY in vitro (Croen, 1993; 
Karupiah et al., 1993). The in vivo antiviral effects of NO in VV infection were less 
marked (M. Rolph, JCSMR, personal communication), although in vitro antiviral activities 
of NO on VV have been demonstrated (Harris et al., 1995). NO has been shown to 
sup'press the catalytic activity of enzymes that are dependent on iron and sulphur 
prosthetic groups, such as reductases, by formation of nitrosyl-iron-sulphur complexes 
(Lancaster and Hibbs, 1990; Pellat et al. , 1990; Nathan, 1992). Inhibition of 
ribonucleotide reductase, required for DNA synthesis, by NO may result in blockade of 
virus replication (Kwon et al., 1991; Lepoivre et al., 1991). Macrophages have also been 
shown to mediate antiviral activities through ADCC, for example in the killing of 
toga virus-infected cells (Macfarlan et al., 1977). 
Together, the non-specific activation of NK, LAK cells and macrophages provides 
a basic host defense mechanism against virus infections before activation of the more 
specific T lymphocyte functions . 
., 
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1.2.3.3 Cytotoxic T lymphocytes 
Recovery from most virus infections is critically dependent on T lymphocytes, in 
particular CTL. Antiviral CTL responses are usually measurable by 5-8 days, by which 
time virus has spread to the lymph nodes or spleen. Thereafter, viral titres usually start to 
decrease. This is certainly the case following infection by EV (Gardner et al., 1974; 
Blanden and Gardner, 1976), LCMV (Moskophidis et al., 1987) or influenza virus 
(Pfizenmaier et al., 1977; Owen et al., 1988). 
CTL activity has usually been related to class I MHC-restricted cytotoxicity 
(Townsend et al., 1985 and 1986) although class II MHC-restricted CTL have also been 
demonstrated. The relative importance of the latter is unclear, given that class II MHC 
molecules are present only on a limited number of cell types (Harding, 1991 ). Class II 
MHC-restricted cytotoxicity against LCMV has been demonstrated in 
~2-microglobulin-gene-knockout mice (~2m-GKO) lacking class I MHC (Muller et al., 
1992). Class II MHC-restricted CTL activities towards influenza virus (Kaplan et al., 
1984 ), HSY (Yasukawa and Zarling, 1984) and measles virus (Van Binnendijik et al., 
1989) in human, and towards influenza virus (Lukacher et al., 1985), vesicular stomatitis 
vin1s (VSV; Browning et al., 1990) and MHV (Heemskerk et al., 1995) in mice have also 
been described. Although CD4+ and CDS+ CTL against influenza vin1s have similar 
cytolytic abilities in vitro (Maimone et al., 1986), cytotoxicity mediated by 
LCMV-specific CD4 + CTL occurs at a lower level than CDS+-mediated cytotoxicity 
in vivo (Muller et al., 1992). 
CTL mediate their cytolytic activity through perforin in a calcium (Ca)-dependent 
manner or through interactions with Fas antigen via a Ca-independent mechanism 
(reviewed by Squier and Cohen, 1994; Liu et al., 1995). Perforin is produced by CD4 + 
CTL (Yasukawa et al., 1993), CDS+ CTL and NK cells (Shinkai et al. , 1988; Liu et al. , 
1989; Lowrey et al., 1989). This molecule may also act as a conduit for other molecules, 
such as granzymes, which in turn, will trigger cell death by apoptosis (Shi et al., 1992; 
Heusel et al., 1994). The role of perforin in cell-1nediated cytolysis has been 
8 
substantiated by impairment of cytotoxic effector functions in mutant mice deficient in 
this protein, leading to their failure to clear LCMV (Kagi et al., 1994). 
In some cases however, perforin expression cannot be detected by PCR during 
target cell killing (Helgason et al., 1992) and some CTL hybridomas are completely 
devoid of perforin (Berke et al., 1993). The absence of perforin expression in these killer 
cells has raised the question of whether perforin is essential for their cytolytic activity. 
Recently, it was shown that a transmembrane signalling mechanism involving a target cell 
surface AP0-1 molecule (also called Fas) and its ligand on CTL (Dhein et al., 1992) kills 
target cells in a Ca-independent manner (Rouvier et al., 1993) through apoptosis (Dhein 
et al., 1992). Further cell-mediated killing mechanisms have been suggested, for example 
cell killing through a novel cytotoxin described by Liu et al. ( 1987). Thus, cytotoxic cells 
may be equipped with multiple cytotoxic mechanisms to kill a wide range of target cells. 
1.2.3.4 Helper T lymphocytes 
CD4+ T lymphocytes are activated during virus infections and may provide 'help' 
for CTL and B lymphocytes. Recently, these helper activities have been correlated to 
types of cytokines secreted by Th lymphocytes (Mosmann et al., 1986; Mosmann and 
Coffman, 1989b; detailed in Section 1.3.5). Helper activity, nevertheless , does not appear 
to be limited to CD4+ T lymphocytes. It can be mediated by cells with other CD4-like 
molecules, such as LAG-3 (Locksley et al., 1993), or by CD8+ T lymphocytes (Paganelli 
et al., 1995) through interaction of CD40L on the T lymphocyte with CD40 on B 
lymphocytes (Cronin et al., 1995). 
The requirement for CD4+ T lymphocyte help in induction of antiviral CTL 
respon e is controversial. In vivo CD4+ lymphocyte depletion has suggested that such 
help i important for induction of CTL responses to Moloney Sarcoma virus (Weyand 
et al., 1989) LCMV (Lei t et al., 1989b ), VV (Zinkemagel et al., 1978; Leist et al., 1989b) 
and EV (Karupi ah et al., 1995). In contra t, other reports using CD4 + lymphocyte 
depletion during EV and VY (Buller et al. 1987), and LCMV (Ahmed et al., 1988) 
infection suggested that T help is not to be necessary for the induction of antiviral CTL 
9 
zn vzvo. T help has also been shown not to be needed for CTL generation against 
influenza virus by in vitro depletion of CD4 + lymphocytes (Liu and MUllbacher, 1989). 
In addition, Bennink and Doherty ( 1978) have shown that no help was required for 
generation of anti-VY CTL. The reasons for the discrepancies in these reports are not 
immediately apparent but may be due to differences in virus virulence or in technical 
approaches, such as the time of CD4+ lymphocyte depletion . In circumstances that are 
independent of Th lymphocyte, 'help' may have come in other forms, such as IL-2 
produced by CDS+ T lymphocytes (Mizuochi et al., 1989), or help provided by activated 
B lyrnphocytes (Liu and MUllbacher, 1989). Although the requirement of Th activity in 
the induction of anti-LCMV CTL responses remains unclear, help is necessary for 
LCMV-specific antibody production (Ahmed et al., 1988). 
Another antiviral mechanism mediated by CD4+ T lymphocytes is through 
induction and secretion of virucidal cytokines, such as IFN-y (Mosmann et al., 1986; 
Mosmann and Coffman, 1989a). As well as providing help to CTL and B lymphocytes, 
CD4+ T lymphocytes may also have direct antiviral cytotoxic effects, such as that shown 
against influenza virus-infected cells (Ada and Jones, 1986). Other examples of CD4+ 
class II MHC-restricted cytotoxicity have been discussed in the previous section 
(Section 1.2.3.3). Taken together, it seems that CD4+ T lymphocytes not only mediate 
antiviral effector functions by providing help for the induction of CTL and protective 
antibodies, but also by release of cytokines and by direct cell cytotoxicity. 
1.2.4 The antiviral roles of antibody and complement 
Antibodies have profound effects on virus replication and virus-infected cells, 
particularly in the prevention of infection. They may reduce infecti vi ty of virus particles 
by preventing virus aggregation and attachment to specific cell receptors (Campbell and 
Cords 1983; Dietzschold et al., 1983). IgG and IgM are predominantly responsible for 
neutrali ation of free virus particles in serum. IgM responses are independent of help 
from Th lymphocytes; indeed, IgM secretion is induced following virus infections, for 
example VSV, coxsackie B 1 virus, togavirus and encephalomyocarditis virus (EMCV), in 
T lymphocyte-deficient nude mice (Bums et al., 1975). IgM i produced during primary 
., 
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but not secondary immune responses, hence production of IgM is correlated with primary 
infections (Charan and Zinkemagel, 1986). Some IgM responses will switch to IgG with 
help from Th lymphocytes, probably through the activities of cytokines (Section 1.3.7). 
While IgM and IgG are important in serum, IgA antibodies are the major subclass 
contributing to antiviral functions at the mucosae (Mestecky and McGhee, 1987). This 
will be reviewed in Section 1.4. Other antiviral effects of antibodies include interference 
of virus replication by cross-linking of antibody with viral determinants expressed on the 
cell surface, as was shown in measles-virus-infected cells (Joseph and Oldstone, 1974; 
Fujinarni and Oldstone, 1979). The killing of virus-infected cells can also be mediated by 
antibodies through ADCC, as well as binding of complement to antibody on virus infected 
cells leading to the triggering the classical pathway of complement-mediated cytotoxicity. 
The innate complement system consists of nearly 30 interacting glycoprotein 
subunits (reviewed by Campbell et al., 1988). The classical pathway of complement is 
activated when the C lq subunit binds to IgG or IgM and triggers a cascade of interactions 
among the other subunits. The alternative pathway is independent of antibody and is 
mediated by direct cleavage of C3 (reviewed by Muller-Eberhard, 1986). There are 
reports demonstrating the roles of complement in natural resistance, for example in 
resistance to LCMV (Welsh et al., 1976b) and retroviruses, such as oncornaviruses 
(Welsh et al., 1975 and 1976a; Cooper et al., 1976). In resistance to the latter, 
complement binds directly to viral proteins and activates the classical pathway (Cooper 
et al., 1976; Welsh et al., 1976a). Lysis of LCMV, however, was mediated by antibody 
(Welsh et al., 1976b ). Together, this information suggests that virus neutralisation by 
antibody and complement, in general, occurs through blanketing virus from its receptors, 
reduction of infectivity by complement-mediated virus aggregation, direct lysis of virions , 
opsonisation by phagocytic cells and killing of infected cells by ADCC. 
1.3 CYTOKINES 
Cytokines are hormone-like molecules and have many common characteristics, 
including low molecular weight, transient and local production , and potent activity (Poo 
et al., 1988; Kupfer et al. , 1991 ). Cytokines play major roles in regulating immunological 
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activity during an immune response: they interact in a network by inducing or suppressing 
each other, transmodulating cytokine surface receptors and acting on cell functions 
(Balkwill and Burke, 1989; reviewed by Kelso, 1989). Many different cytokines are 
involved in host responses to virus ·infections, directly or indirectly, with both beneficial 
and inhibitory effects; however only those having particular relevance to the work 
described in this thesis will be discussed here. 
1.3.1 Interferon-y 
IFN-y is secreted by CDS+ T lymphocytes (J assay et al., 1993; Ruby et al., 
1993), some CD4+ T lymphocytes (Mosmann et al., 1986; Mosmann and Coffman, 
1989a) and NK cells (Cuturi et al., 1989). IFN-y was first described as having antiviral 
activity in homologous cells (Isaacs and Lindenmann, 1957) and these activities will be 
detailed in Section 1.3.4. Subsequently, this factor was shown to mediate a range of 
immunoregulatory activities, including activation of macrophages and NK cells, and 
antibody production (Dijkmans and Billiau, 1988). IFN-y up-regulates both class I and 
class II cellular MHC expression (Wong et al., 1983) and thus plays an important role in 
enhancing adaptive immunity. Increased expression of class I MHC enhances 
recognition of target cells by CTL, while augmented class II MHC expression may elevate 
presentation of antigen by APC to Th lymphocytes. IFN-y also induces macrophages 
(Dijkmans and Billiau, 1988) to antiviral activity through the production of NO, ROI and 
TNF, as discussed earlier (Section 1.2.3.2). NK cell killing activity is also augmented by 
IFN-y (Weigent et al., 1983). IFN-y has been shown to affect expression of other 
cytokines and cytokine receptors, for example in enhancing TNF receptor expression 
(Ruggiero et al., 1986; Tsujimoto et al., 1986), as well as up-regulating the expression of 
its own gene (Hardy and Sawada, 1989). The pivotal role of IFN-y in the regulation of Th 
lymphocyte subsets and antibody production will be discussed in Sections 1.3.5 and 
1.3.7. 
1.3.2 Interleukin 6 
IL-6 is produced by a variety of cells including fibroblasts, monocytes, T 
lymp hocytes, B lymphocytes, mast cells and keratinocytes. It is a pleiotropic factor that 
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has different activities on different cell populations (Van Snick, 1990). Indeed, the 
multiple functions of IL-6 are reflected by the names that have been used to described this 
factor: an antiviral factor, IFN-~2, B-cell stimulatory factor, hybridoma/plasmacytoma 
growth factor, hepatocyte-stimulating factor and CTL differentiation factor (Van Snick, 
1990). IL-6 is not produced constitutively but is expressed upon virus infection (Sehgal 
et al., 1988), activation with lipopolysaccharides (Ulich et al., 1991) or activation by other 
cytokines (Van Snick, 1990). The receptor for IL-6 is expressed constitutively on resting 
T lymphocytes; however, in B lymphocytes, its expression occurs only upon activation 
(Taga et al., 1987). IL-6 is a late acting factor for B lymphocytes enhancing their tenninal 
differentiation (Kishimoto and Hirano, 1988). Muraguchi et al. ( 1988) have shown the 
enhancing effect of IL-6 on lg production in cultures of peripheral blood mononuclear 
cells incubated with the cytokine was only apparent after 4 days. The impact of IL-6 in 
antibody production will further be discussed in Section 1.3 .7. 
The activity of IL-6 on T lymphocytes appears to occur in synergy with IL-1 (Van 
Snick, 1990). This synergy is observed in the induction of CTL responses in accessory 
cell-depleted allogeneic-mixed lymphocyte cultures where IL-6 enhanced IL-2 
responsiveness of the CD8+ T lymphocytes (Renauld et al., 1989). 
1.3.3 Interleukin 7 
IL-7, a stromal cell-derived cytokine, is another factor having pleiotropic effects on 
lymphoid cells of both B and T lineages, NK cells and monocytes. Besides its detection 
in bone marrow stromal cells, mRNA for IL-7 has also been found in liver, kidney, spleen, 
thymus (Namen et al., 1988a; Wiles et al., 1992) and keratinocytes (Heufler et al., 1993). 
IL-7 was first described as a growth factor for precursor B lymphocytes in vitro (Namen 
et al., 1988a and 1988b ). In addition to its effects on B lymphocyte proliferation, IL-7 
may play an important role in both pre-T lymphocyte development as well as on mature T 
lymphocytes (Morrissey et al., 1989; Murray et al., l 989; Welch et al., 1989; Varma 
et al., 1990; Tushinski et al., 1991). IL-7 also acts as a co-factor in promoting V(D)J 
rearrangement of TCR ~ gene in fetal thyrnocytes (Muegge et al., 1993), and plays 
important roles in modulating the early stages of both B and T lymphopoiesis (Henney, 
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1989). The up-regulation of a~ and y8 TCR expression by IL-7 has also been reported 
(Appasamy, 1992; Muegge et al., 1993; Uehira et al., 1993). 
IL-7 enhances the generation of CTL (Alderson et al., 1990; Hickman et al., 1990; 
Kos and MUllbacher, 1992), LAK (Alderson et al., 1990; Hickman et al., 1990; Lynch 
and Miller, 1990; N aume and Espevik, 1991; Stotter et al., 1991; Kos and MUllbacher, 
1992) and NK (N aume and Espevik, 1991) cell activities in vitro. Recombinant IL-7, 
when given to mice, augments splenic CD8+ T lymphocytes, thereby altering the 
CD4+/CD8+ ratio (Faltynek et al., 1992; Komschlies et al., 1994). IL-7 also influences 
the proliferation of cells of the myeloid lineage (Faltynek et al., 1992) and induces 
secretion of IL-1 a, IL-1 ~' IL-6 and TNF-a by monocytes (Alderson et al., 1991 ). Other 
activities of IL-7 include potent co-stimulation of the adhesion pathway involving CD2 
and CD28 (Costello et al., 1993); this factor was later revealed to induce B7 /BB 1 
expression (Y ssel et al., 1993). IL-7 has also been linked to the pathogenesis of 
inflammatory skin diseases and cutaneous T lymphocyte lymphoma (Heufler et al., 1993), 
dermatitis (Uehira et al., 1993), and chronic lymphocytic leukemia (Frishman et al., 
1993). 
The interactions of IL-7 with other cytokines have not been clearly elucidated. 
In vitro proliferation of LAK cells was reported to be independent of IL-2 (Naume and 
Espevik, 1991) or dependent on this factor (Morrissey et al., 1989; Okazaki et al., 1989). 
Induction of LAK cell activity by IL-7 was reported to be inhibited by IL-4 in vitro 
(Stotter and Lotze, 1991), however, Alderson et al. (1990) were not able to confirm this 
finding. IL-7 also stimulates CTL generation in vitro, in some cases via IL-2 (Alderson 
et al., 1990) and in other cases, in the absence of IL-2 (Kos and MLillbacher, 1992; Kos 
and Mullbacher, 1993; Carini and Essex, 1994 ). Although IL-7 and IL-1 synergise in 
timulating y8+ T lymphocytes in vitro (Skeen and Ziegler, 1993), the in vivo interactions 
of IL-7 with IL-1, as well a with other cytokines, require further investigation. 
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1.3.4 Antiviral cytokines 
Cytokines such as IFN-y and TNF-cx exhibit antiviral activities: indeed, it was 
such activity that led to the discovery of IFN-y (Isaacs and Lindenmann, 1957; Wheelock, 
1965). The role of cytokines in antiviral responses has been more clearly defined with the 
identification and cloning of cytokine genes, the availability of assays to measure cytokine 
expression, and the development of mutant mice lacking genes for cytokine and cytokine 
receptor (reviewed by Biron, 1994; Kaufmann, 1994). 
The importance of the antimicrobial activities of IFN-y was demonstrated in mice 
lacking IFN-yfunctions. Mutant mice deficient for the IFN-y gene (Cooper et al., 1993; 
Flynn et al., 1993) or the receptor for IFN-y (Kamijo et al., 1993a and 1993b) were 
unable to control Mycobacte rium infection. This is probably due to a lack of 
IFN-y-mediated macrophage activation underlying the production of antimicrobial agents, 
such as NO, ROI and TNF-cx, and the lack of IFN-y-induced class II MHC expression 
(Kamijo et al., 1993b). Targeted disruption of the IFN-y gene also renders normally 
resistant mice susceptible to Leishmania infection (Wang et al., 1994a). Infection of 
LCMV was exacerbated in animals depleted of IFN-y by anti-IFN-y antibody treatment 
(Leist et al., 1989a). In addition, antibodies to IFN-y abrogated the control of LCMV 
infection in mice adoptively transferred with immune spleen cells (Klavinskis et al., 1989). 
Further insights into the antiviral functions of IFN-y came from experiments in which 
recombinant VY were constructed to express this factor (Kohonen-Corish et al., 1990). 
Immunodeficient athymic and y-irradiated mice normally succumb to infection with VY 
but are able to rapidly control a recombinant VY expressing IFN-y. The authors 
concluded that virus-encoded IFN-y had a direct antiviral effect. IFN-y can increase the 
virucidal effects of macrophages by up-regulating their production of hypochlorous acid 
(Chase and Klebanoff, 1992), NO synthase (Karupiah et al., 1993) and also by 
up-regulation of MHC expression (Wong et al., 1983). IFN-y may also act indirectly at 
late stages of the replication cycle of human immunodeficiency virus (HIV), by inhibiting 
po t-translational processing of virus structural proteins within infected cells (Yahi et al., 
1992) and virion production (Bis was et al., 1992), or by inhibiting syncytium formation 
l 
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(Wells et al., 1991). In the light of these findings, Ramsay et al. (1993) proposed that 
antiviral effects of CTL may be mediated through focusing potent antiviral cytokines such 
as IFN-y at sites of virus replication, thus controlling virus spread to adjacent cells. 
TNF was first shown to possess tumouricidal activity (Carswell et al., 1975) but 
was later found to exhibit potent antiviral activities against VSV (Mes tan et al., 1986; 
Wong and Goedde!, 1986), adenovirus, HSY and EMCV (Wong and Goeddel, 1986). 
Dramatic antiviral synergy is seen between TNF and IFN-y in inhibiting replication of 
some viruses, such as VSV, EMCV, HSY and adenovirus, and inducing an antiviral state 
in uninfected cells (Wong and Goeddel, 1986; Feduchi et al., 1989). The direct antiviral 
activity of TNF was established in immunodeficient animals infected with a recombinant 
VV expressing this factor (Sambhi et al., 1991). In addition, a ligand for belonging to the 
TNF receptor superfamily and expressed on activated T lymphocytes, CD40L (Armitage, 
1994 ), has been shown to exhibit potent anti viral activity when expressed by a 
recombinant VV (J. Ruby, JCSMR, personal communication). 
Another cytokine with antiviral activity is tumor growth factor ~ (TGF-~), which 
n1ay suppress HIV replication in monocyte-macrophage cell lines in vitro (Poli et al., 
1991). However, a biological antiviral role for TGF-~ remains unclear, as this factor has 
also been shown to overcome the lymphocytotropic restriction seen in many HIV isolates, 
hence increasing pathogenecity of some HIV isolates (Lazdins et al., 1992). 
1.3.5 Role of cytokines in immune class regulation 
Encounter with antigens leads to the stimulation of cell-mediated and antibody 
responses which may be mutually exclusive (Parish, 1972; Bretscher, 1981 ). The role of 
cytokines in the regulation of these responses was clarified when Mosmann and 
colleague ob erved that mouse CD4+ T lymphocyte clones can be divided according to 
two predominant cytokine secretion patterns (Mosmann et al., 1986; reviewed by 
Mo mann and Coffman , 1989b). Th 1 clones produce IL-2, IFN-y and lymphotoxin, and 
promote delayed-type hypersensitivity (DTH) reactions characteristic of cell-mediated 
immunity (Mosmann et al., 1986; Mosmann and Coffn1an, 1989a). Th2 clones, 
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conversely, produce IL-4, IL-5 and IL-10, and direct antibody responses (Mosmann et al., 
1986; Mosmann and Coffman, 1989a; Sher and Coffman, 1992). There is another 
population of Th lymphocytes that produces both Thl and Th2 cytokines, and they are 
referred to as the ThO phenotype (Firestein et al., 1989; Street et al., 1990). Th 1 and Th2 
subsets were also found to cross-regulate: IFN-y secreted by Thl lymphocytes inhibits 
Th2 lymphocyte proliferation (Fernandaz-Botran et al., 1988; Gajewski and Fitch, 1988), 
whereas IL-4 and IL-10 produced by Th2 lymphocytes down-regulate Th 1 responses 
(Powrie and Coffman, 1993a and 1993b). 
The inhibition of Th 1 cytokine synthesis by IL-10 (Fiorentino et al., 1989) is an 
indirect process occurring by suppression of APC/accessory cell function for Th 1 clones 
(de Waal Malefyt et al., 1991; Fiorentino et al., 1991a and 1991b; Ding and Shevach, 
1992) through the down-regulation of expression of IL-12 (D' Andrea et al., 1993) and 
B7 (Ding et al., 1993). In contrast, IL-4 directly inhibits in vivo effector functions of Th 1 
populations, such as production of IFN-y and DTH (Powrie and Coffman, 1993a and 
1993b; Powrie et al., 1994), and the development of Thl lymphocytes from naive 
populations (Hsieh et al., 1992; Seder et al., 1992). The development of Th2 
lymphocytes in vitro is promoted by IL-4 during initial stimulation of resting T 
lymphocytes with either concanavalin A (con A; Swain et al., 1990) or cross-linked 
anti-CD3 antibodies (Le Gros et al., 1990). The role of IL-4 in Th2 response 
development in vitro was also established using immune cells from specific 
TCR-transgenic mice (Hsieh et al., 1992; Seder et al., 1992). The development of in vivo 
Th2-type responses to microbial antigens, such as Leishmania major (Sadick et al., 1990; 
Chatelain et al., 1992) and Candida albicans (Romani et al., 1992) has also been shown 
to be critically dependent on the presence of IL-4. Further evidence that IL-4 is central to 
the development of Th2 responses in vivo came from the demonstration of reduced levels 
of Th2 cytokines following infection of mice lacking the IL-4 gene with the nematode 
Nippostrongylus brasiliensis (Kopf et al., 1993). More recently, the in vivo inhibitory 
effects of IL-4 on the generation of CTL was demonstrated by Sharma et al. ( 1995): a 
recombinant VV encoding IL-4 inhibited generation of CTL, down-regulated expression 
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of mRl"\J"A for IFN-y, IL-2 and IL- 12 in splenocytes. However, the effects of IL-4 in 
promoting Th2 cytokine expression were less convincing in mice expressing the IL-4 as a 
trans gene; these mice have elevated expression of IFN-y (Platzer et al., 1992). 
In contrast to the well-characterised development of the Th2 phenotype, the roles 
of factors involved in Thl subset development remain controversial. One of the dominant 
factors determining Th 1 lymphocyte development, leading to cell-mediated immune 
responsiveness, is IL-12 (Hsieh et al., 1993b; Manetti et al., 1993 and 1994; Seder et al., 
1993; Sieling et al., 1994 ). This factor is produced by monocytes (D' Andrea et al., 1992) 
and B lymphocytes (Stern et al., 1990), and has been shown to suppress the production of 
IL-4 (Manetti et al., 1993). Moreover, IL-12 has been found to promote the development 
of Th 1 responses, as shown by the promotion of CTL activity by IL-12 both in vivo 
(Gately et al., 1994) and in vitro (Chouaib et al., 1994 ), and by the induction of T 
lymphocytes to IFN-y expression (Seder et al., 1993; Sieling et al., 1994). IL-12 has 
been shown to act directly on CD4+ T lymphocytes to stimulate IFN-y production in vitro 
(Seder et al., 1993). IL-12 has even been shown to induce Th2 subsets to transient IFN-y 
production in vitro (Manetti et al., 1994). When given in vivo, IL-12 promotes 
antimicrobial Thl activities against L. major (Heinze! et al., 1993; Sypek et al., 1993) and 
toxoplasma (Gazzinelli et al., 1993) through elevation of IFN-y production by T 
lymphocytes or NK cells. The up-regulation of IFN-y production by IL-12 occurs 
through synergy with IL-2 and results in stabilisation of mRNA transcripts for IFN-y 
(Chan et al., 1992). 
The induction of IFN-y by IL-12 suggests that the activity of IL-12 may be 
mediated through this factor. Indeed, this has been supported by in vitro studies. 
Antibodies against IFN-y, added to cultures of cells from specific TCR transgenic mice, 
inhibit the IL-12-induced production of IFN-y (Macatonia et al., 1993 ). In contrast , 
several studies have demonstrated IL-12 activity occurring independently of IFN-y. 
Studies using IFN-y-GKO mice have revealed an IFN-y independent, IL-12-mediated 
reduction of IL-4 production during Leishmania infection (Wang et al., 1994b ). In 
addition, co-administration of antibodies to IFN-y and recombinant IL-12 did not abrogate 
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activities of IL-12 during immune responses to hemocyanin in normal mice (McKnight 
et al., 1994). 
While IL-12 apparently may act both via IFN-y and independently of this factor, 
the role of IFN-y itself in Thl development is still unclear. The presence of IFN-y during 
priming of T lymphocytes from mice transgenic for the ovalbumin-specific TCR in vitro 
did not enhance subsequent IFN-y production (Seder et al., 1992; Macatonia et al., 1993; 
Seder et al., 1993), while mice with targeted disruption of the IFN-y gene have normal 
levels of CTL responses (Graham et al., 1993). Mice lacking the receptor for IFN-y also 
have normal CTL and Th lymphocyte responses (Huang et al., 1993). In contrast, 
recombinant IFN-y, when given in vivo, favours the production of IFN-y and reduced 
pathogenecity of Leishmania in susceptible mice (Scott, 1991). Together, the requirement 
for IFN-y in promoting Th 1 immune responses has yet to be convincingly demonstrated. 
lFN-y has, however, been shown to inhibit Th2 lymphocyte responses (Femandaz-Botran 
et al., 1988; Gajewski and Fitch, 1988). 
Little is known about the role of IL-2 in the development of different Th subsets 
(Swain, 1991 ). However, it is clear that this cytokine may act as a growth factor for 
lymphocytes (Seder and Paul , 1994 ). Another factor, TGF-~, may play a role in the 
development of Th 1 responses in vitro , as shown by its down-regulation of Th2-type 
cytokine (IL-4 and IL-5) production (Swain et al., 1991; Hsieh et al., 1993a) and 
promotion of Th 1 cytokine (IL-2 and IFN-y) secretion (Swain et al., 1991). However, 
TGF- ~ was also found to inhibit Th 1 effector functions during immune responses to 
Leislzmania (Barral-Netto et al., 1992). 
The nature and quantity of antigen has also influence the development of 
cell-mediated or antibody responses (Parish, 1972; Bretscher, 1981 ). Moreover, the 
genetic background of experimental animal may contribute profoundly to the types of 
immune responses mounted following infection (Bretscher et al., 1992). Nevertheless, the 
vital roles played by cytokines in immune class regulation have been amply shown. Given 
that infections by viruses or parasites are generally controlled by either cell-mediated or 
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antibody responses, the pattern of host cytokine production may determine the outcome of 
the infection. 
1.3.6 Chronic or acute disease: a matter of cytokine dominance 
Pathogens are most effectively controlled by the induction of either a dominant 
cell-mediated (a Thl response) or an antibody (a Th2 response) response (reviewed by 
Scott and Kaufmann, 1991; Sher and Coffman, 1992; Sher et al., 1992; Urban et al., 
1992). Hence, the generation of appropriate Th lymphocyte responses is crucial in the 
resolution of many infections. Dominance of inappropriate Th responses, in some 
chronic diseases, has resulted in the inability to eradicate invading organisms, thereby 
exacerbating the disease. For example, a strong DTH (Th 1) response in mice during 
infection by L. major results in eradication of the organism. In contrast, certain mouse 
strains (for example BALB/c) mount a mostly antibody (Th2) response during L. major 
infection and succumb to disseminated disease (Scott et al., 1988; Heinzel et al., 1989). 
Such dichotomy of immune responses is also seen in human leishmaniasis (Carvalho 
et al., 1985; Sacks et al., 1987). Another example is human tuberculoid and lepromatous 
leprosy that are, respectively, accompanied by a strong Thl response promoting DTH or a 
weak cell-mediated immunity. Strong DTH eventually clears the bacilli, whereas weak 
cell-mediated immune responses result in a more severe and persistent disease (Salgame 
et al., 1991; Yamamura, 1992). IL-12 has now been implicated in the induction of Th 1 
lymphocytes in lesions of tuberculoid leprosy but not in lesions of lepromatous leprosy 
(Sieling et al., 1994 ). In other disease states, such as during helminth infections (Sher 
and Coffman, 1992; Urban et al., 1992), toxoplasma (Sher and Coffman, 1992; Sher 
et al., 1992) and listeriosis (Magee and Wing, 1988; Tripp et al., 1993), similar 
correlations also exist between Th lymphocyte phenotype dominance and di sease 
u ceptibility. 
It has recently been suggested that a Th2 bias may occur during progression to the 
Acquired Immunodeficiency Syndrome (AIDS ) following infection with HIV (Maggi 
et al., 1987; Sher et al., 1992; Clerici and Shearer, 1993; Clerici et al. , 1993a). HIV 
cause a slow progressing infection that, initi ally, is es sentially symptomless. 
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Subsequently, the course of HIV infection leads to a loss of CD4+ T lymphocytes, 
suppressed CTL levels and susceptibility to other pathogens (Rosenberg and Fauci, 
1989). Clerici et al. (1993a and 1994b) have noted that peripheral blood cells from 
HIV-infected individuals secrete reduced levels of IL-2 ( a Th 1 cytokine ), and high levels 
of IL-4 and IL-10 (Th2 factors) after stimulation with recall antigens, allogeneic cells or 
PHA. These observations led Clerici and Shearer (1993) to postulate that the progression 
to AIDS is due to Th2 responses induced in HIV-seropositive individuals. This 
hypothesis was supported by findings of non-lytic CD8+ lymphocytes secreting Th2 
cytokines that provide help to antibody responses (Maggi et al., 1994a) and suppressed 
IL-12 expression (Chehimi et al., 1994) in HIV-seropositive individuals, and high levels 
of cell-mediated immunity in seronegative HIV-infected individuals (Clerici et al., 1992). 
However, studies of secondary lymphoid tissues in HIV-infected individuals have 
not confirmed the Th2-bias in HIV infection during progression to AIDS (reviewed 
recently by Romagnani et al., 1994). There was no demonstrable overall shift towards the 
Th2 responsiveness shown in the abovementioned in vivo studies: expression of IL-4 was 
not detected (Emile et al., 1994; Graziosi et al., 1994) while IL-2 and IFN-y expression 
was found (Emile et al., 1994 ). Instead, Maggi et al. (1994b) have demonstrated a 
predominance of cells of the ThO phenotype. The different lymphoid cells used in the 
abovementioned studies may account for the discrepancies observed. Later, Clerici and 
Shearer (1994) proposed a new classification for grouping according to cytokine 
functions, i.e. type-1 or type-2 cytokines, instead of the former dichotomy of Th l-Th2 
based on the cell-type producing a particular factor. 
An uncontrolled or chronic Th lymphocyte response can also lead to 
immunopathology, for example in vernal conjunctivitis (Maggi et al., 1991 ), exposure to 
allergen (Wierrenga et al., 1990; Parronchi et al., 1991; Y ssel et al., 1992) and in 
infections with respiratory syncytial virus (Alwan et al., 1994) or Borrelia (Y ssel et al., 
1991). Therefore, the ability to manipulate Th lymphocyte phenotypes present following 
expo ure to antigen might not only be advantageous for the development of improved 
prophylactic strategies, but also raises the possibility of inducing an appropriate response 
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for a specific pathogen with minimum pathology. The selective manipulation of immune 
responses with cytokines may have important implications in the design of vaccines for 
prophylaxis and therapy. 
1.3.7 Role of cytokines in antibody production 
A number of cytokines secreted by T lymphocytes, during interactions between T 
and B lymphocytes, may directly affect the development and maturation of B 
lymphocytes. IL-4 acts early in the activation process (reviewed by Coffman et al., 1988; 
Snapper et al., 1988; Mosmann and Coffman, 1989a) while the action of IL-5 is 
apparently restricted to activated B lymphocytes (Beagley et al., 1988; Harriman et al., 
1988), suggesting that IL-4 and IL-5 may act in sequence. As well as its activity on T 
lymphocytes, IL-2 induces proliferation of B lymphocytes (Waldmann et al., 1984) and 
synergises with IL-5 in enhancing antibody responses in vitro (Takatsu et al., 1988). 
IL-6 is a B lymphocyte differentiation factor (Vink et al., 1988) that acts late in the 
differentiation process (Kishimoto and Hirano, 1988; Muraguchi et al., 1988). Given this 
information, it is thought that these cytokines have the following temporal order of activity 
on B lymphocytes: IL-4 ~ IL-5 ~ IL-2 ~ IL-6 (Sanders and Vitetta, 1990). 
Cytokines also contribute to the molecular mechanism of isotype switching 
although the signals that control the switch are not fully understood. IFN-y favours the 
production of IgG2a in mice as illustrated by Snapper and Paul ( 1987), and by Finkelman 
et al. ( 1990). IL-4 is important for the production of IgG 1 and IgE (Snapper et al., 1988; 
Finkelman et al., 1991; Goodman et al., 1993) and may be crucial for the latter 
(Finkeln1an et al., 1991). With the development of IL-4-GKO mutant mice, IL-4 was 
shown to be necessary, but not essential, for the production of IgG 1. Low levels of IgG 1 
were found in these naive mutant mice (Kuhn et al., 1991; Kopf et al., 1993) and in those 
given (4- hydroxy-3-nitrophenyl)acetyl-c hicken y-globulin (Kuhn et al., 1991) or 
N. brasiliensis (Kopf et al., 1993). Very recently, the effect of IL-4 in development of 
n1ucosal antibody respo nses has also been studied (Vajdy et al., 1995; Ramsay et al., 
unpublished). Mice lacking the IL-4 gene have impaired mucosal IgA antibody responses 
with the defect due to a poor development of Th2 lymphocytes at the mucosae. Cytokines 
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such as IL-5 (Beagley et al., 1988; Harriman et al., 1988; Ramsay and Kohonen-Corish, 
1993) and IL-6 (Beagley et al., 1989; Ramsay et al., 1994a and 1994b), which are 
secreted by Th2 lymphocytes and other non-T cells, at the mucosae (Taguchi et al., 1990; 
Mega et al., 1992; Xu-Amano et al:, 1992) are particularly important for differentiation of 
committed IgA B lymphocytes into IgA-secreting cells. Mutant mice lacking IL-6 mount 
negligible antibody responses to virus infection at the mucosae, however, infection with a 
recombinant VV expressing IL-6 restored mucosal antibody responses in these animals 
(Ramsay et al., 1994a). TGF-~, together with IL-4 and IL-5, has also been shown to 
promote IgA class switching of activated B cells in vitro and this activity can be inhibited 
by IFN-y (McIntyre et al., 1995). However, the physiological significance of 
TGF-~-mediated production of IgA remains to be demonstrated, given that IgA secretion 
under these conditions is only associated with a small percentage of cells with surface IgA 
(Lebman et al., 1990; Ehrhardt et al., 1992). Together, these data suggest that the 
manipulation of antibody responses by cytokines may also have important ramifications 
for the development of vaccine strategies for immunisation of mucosal surfaces. 
1.4 THE MUCOSAL IMMUNE SYSTEM 
Antibodies in the systentic circulation neutralise infectivity and promote clearance 
of viruses that have a viremic mode. Indeed, lg prophylaxis has been shown to prevent or 
decrease infection of target organs by measles, hepatitis, rubella and varicella viruses 
(Krugman, 1963). However, the great majority of pathogenic organisms infect the large 
and exposed mucosa! surface area. An in1mune system which is at least partially 
autonomous from the systemic immune system has developed to protect these sites. The 
mucosa! immune system is anatomically and functionally distinct, and is divided into 
inductive and effector tissues (Kiyono et al. , 1992; McGhee et al. , 1992). Recent 
increased understanding of the mucosa-associated lymphoid ti ssues (MALT), reviewed 
recently by Staats et al. ( 1994), has provided a rationale for improved immunoprophylaxis 
at the n1ucosae. 
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1.4.1 Inductive tissues 
The major mucosal inductive sites are the gut-associated lymphoid (GALT) and 
nasal-associated lymphoid tissues (NALT) that are strategically located at the 
gastrointestinal (GI) tract and nasopharyngeal area (tonsils). Other MALT, including that 
of the reproductive tract, will not be reviewed here. Antigenic stimulation of inductive 
tissues of the MALT, particularly the Peyer's patches (PP) of the gut, gives rise to both 
mucosal cell-mediated and antibody responses (reviewed by Mestecky and McGhee, 
1987; McGhee et al., 1992; McGhee and Kiyono, 1993). Nearly 75o/o of T lymphocytes 
in these tissues express a~ TCR, with a small population of y8+ T lymphocytes which 
remain poorly characterised. Among the a~+ T lymphocytes, more than half (50-60%) 
are CD4+ Th lymphocytes and the rest are CDS+ (Hunninghake and Crystal, 1981 ). PP 
also contain APC (phagocytic dendritic cells and macrophages) and B lymphocyte zones 
(follicles) containing the majority of B lymphocytes with surface IgA. Follicle-associated 
epithelium or microfold (M) cells allow transport of intact antigen from the apical 
membrane exposed to the lumen of the GI tract to the basolateral surface and underlying 
lymphoid cells. 
The N ALT and bronchus-associated lymphoid tissues (BALT) are mucosa! 
inductive sites of the upper (URT) and lower respiratory tracts (LRT), respectively (Kuper 
et al., 1992). NALT appears to be the principal inductive site in these tissues, however 
both are structurally organised lymphoid tissues containing B and T lymphocytes, APC 
(phagocytic dendritic cells and macrophages), and M cell-like epithelial cells to facilitate 
antigen processing and induction of immune cells that relocate to distant effector tissues 
(Fig. 1.1). 
Antigen-specific T and B lymphocytes, upon activation, leave inductive sites via 
efferent lymphatics and are transported to the systemic circulation through the thoracic 
duct. These lymphocytes ultimately arrive at mucosa! effector sites consisting of the 
lan1ina propia (LP) of respiratory, GI and reproductive tracts, as well as glandular tissues, 
such as the alivary and mammary glands. This circular pathway for dissemination of T 
24 
NALT 
0 
A. / 
/(. 
•• .f:t< 
,/" 
,-;I' / 
,/ 
/ / 
~ ntlgen\ .;·_/,/ 
~ // Nasal lumen 
lymphoblasts 0 
APC 
specific T lymphocytes 
specific B lymphocytes 
B lymphocyte 
prolif era ti on 
& 
differentiation 
Nasal mucosa 
APC 
Systemic (serum) 
response 
or tolerance 
FIGURE 1.1 Schematic representation of compartments and cellular composition of 
NALT 
The pathways eliciting mucosal and systemic responses via NALT are illustrated 
(Adapted from Kuper et al., 1994) 
B, B lymphocytes; T4, CD4+ T lymphocytes; T8, CD8+ T lymphocytes; M, microfold epithelial 
cell ; APC, antigen-presenting cells (macrophages & dendritic cells); NALT, nasal-associated 
lymphoid ti ue ; PCLN, posterior cervical lymph node; SCLN, superior cervical lymph node 
and B lymphocytes to mucosa! effector sites forms the 'common mucosa! immune 
system' (Mestecky, 1987; Mc Ghee et al., 1989). 
1.4.2 Effector tissues 
The effector site of GI, the LP, consists mainly of T ( 40-60o/o) and B lymphocytes 
(20-40% ), including plasma cells (McGhee et al., 1992). About 60% of the T 
lymphocytes are CD4+ and one-third express the CDS marker. The major activated CD4 
subset comprises Th2-type lymphocytes (Taguchi et al., 1990; Mega et al., 1992; 
Xu-Amano et al., 1992), however significant numbers of Th 1 lymphocytes are also found 
here (Taguchi et al., 1990; Mega et al., 1992). Approximately 70-90% of the local plasma 
cells produce IgA, and are responsible for antigen-specific secretory IgA (S-IgA) found at 
mucosa! surfaces of the gut and intestinal secretions. In the lungs, IgA secretion 
predominates (Merrill et al., 1982) and is thought to be the most important host defense 
along the URT. IgG production is far less evident, but IgG is found more and may 
assume roles in host defense in smaller bronchi (Reynolds, 1991 ). Indeed, the hallmark 
of the mucosa! antibody response is the secretion of antigen-specific S-IgA antibodies 
(Mestecky and McGhee, 1987). 
At the mucosae, S-IgA may bind specific antigen forming immune complexes and 
inhibit the interaction of pathogens with the mucosa! surface (Crowe et al., 1994 ), a 
protective mechanism termed 'immune exclusion' (Michetti et al., 1992). IgA can also 
neutralise pathogens intracellularly in epithelial cells (Mazanec et al., 1992). Furthermore, 
there is evidence to suggest that IgA may be cytophilic and bind to Fe-a receptors of 
alveolar macrophages (Sibille et al., 1986). IgA has also been shown to bind complement 
during the complement-mediated killing of Neisseria (Jarvis and Griffiss, 1989). 
However, the cytophilic activities of IgA remain relatively poorly studied. 
Cytotoxicity by CTL (Kagnoff and Campbell, 1974: Guy-Grand et al., 1978; 
Dav ies and Parrot, 1981; Issekutz, 1984; Klein et al., 1985; Klein and Kagnoff, 1987), 
ADCC (Mac Dermott et al., 1980) and NK cells (Tagliabue et al., 1981) has been 
described at mucosa! effector sites. Antigen-specific CTL activities have been 
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demonstrated at the mucosae following local administration of allogeneic tumour cells 
(Kagnoff and Campbell, 1974; Klein et al., 1985; Klein and Kagnoff, 1987) and are 
mediated by CD8+ T lymphocytes (Ernst et al., 1985; Klein et al., 1985). Infection with 
rota virus (Offit and Dudzik, l 989)"or VV (Issekutz, 1984) at the mucosae generates local 
and also systemic CTL in the spleens or adjacent lymph nodes. 
1.4.3 Immunity to influenza virus 
Immunity to influenza virus infection has been reviewed at length (Potter and 
Oxford, 1979; Askonas et al., 1982; Couch and Kasel, 1983; Murphy and Clements, 
1989). Antibodies mediate immunity to strain- or subtype-specific influenza virus, 
whereas cross-reactive immunity is cell-mediated (Askonas et al., 1982; Ada et al., 1983; 
Ada and Jones, 1986). CTL recognise the nucleoprotein (NP) of the virus as a 
cross-reactive antigen (Yewdell et al., 1985; McMichael et al., 1986; Gotch et al., 1987) 
and thus clear infection with either heterologous (Taylor and Askonas, 1986; 
Montgomery et al., 1993) or homologous (Taylor and Askonas, 1986) virus. 
The major protective antibody against influenza virus infection is S-IgA directed 
against the hemagglutinin (HA) glycoprotein of the virus (Renegar and Small, 1991). IgA 
is most important upon infection of the URT but does not always neutralise the virus 
(Yanagihara and McIntosh, 1980). When infection occurs throughout the respiratory 
tract, local IgA and serum-derived IgG both provide protection (Couch et al., 1979; 
Ramphal et al., 1979; McDermott et al., 1982; Prince et al., 1985; Ada and Jones, 1986). 
Indeed, passive transfer of IgG in the peritoneum affords protection against virus 
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challenge in the lungs (Prince et al., 1985). Despite these findings, a greater 
understanding of the immune response to influenza virus and other respiratory pathogens 
is crucial for the development of more effective immunoprophylaxis. 
1.5 IM1VIUNOLOGICAL MEMORY 
Memory lymphocytes allow the immune system to mount a much stronger 
response, that is both faster and more effective than the primary response, on second 
encounter with antigen (Male and Roitt, 1993). There are two schools of thought 
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regarding the longevity of memory lymphocytes: one, that memory lymphocytes are 
long-lived, and the other, that memory lymphocytes are short-lived in the absence of 
antigen. In support of the first model, Mi.illbacher (1994) using adoptive transfer, showed 
that cytotoxic T memory responses against influenza virus can be maintained for 
25 weeks in the absence of the vin1s. CDS+ (CD44hi) CTL memory against LCMV has 
also been maintained in the absence of the antigen (Lau et al., 1994). 
Others have demonstrated that lymphocytes of memory phenotype are short-lived 
and have a more rapid turnover than naive lymphocytes (Mackay et al., 1990; Michie 
et al., 1992). These short-lived lymphocytes may have been maintained by reversion to 
long-lived naive lymphocytes (Sprent, 1993); this 'naive memory' population may be ready 
to respond to recall antigen. Indeed, lymphocytes of memory phenotype have been shown 
to acquire cell surface markers that are similar to those found on newly activated 
lymphocytes (Budd et al., 1987; Akbar et al., 1988; Cerottini and MacDonald, 1989; 
Powrie and Mason, 1989; Bell and Sparshott, 1990). However, memory-type responses 
have not been detected amongst these 'naive memory' lymphocytes (Merkenschlager et al., 
1988). This may be due to an inability to activate these populations in vitro. 
The long-term maintenance of immunologic memory mediated by short-lived 
memory lymphocytes with rapid turnover would suggest a continuous activation of 
memory lymphocytes with antigens. Recent studies of Gray and Skarvall ( 1988), and 
Gray and Matzinger ( 1991) using adoptive-transfer of memory lymphocytes have indeed 
demonstrated a requirement for antigen persistence in the maintenance of long-term 
memory B and T lyn1phocytes prin1ed with hemocyanin. Maintenance of long-term CTL 
responses to LCMV has also been shown to require antigen persistence (Oehen et al., 
1992). The slow release of antigen-antibody complexes retained in follicular dendritic 
cells (FDC) in B lymphocyte areas may account for the maintenance of memory 
lymphocyte by continuously restimulating and expanding memory B lymphocyte clones 
(Tew et al., 1980; Szakal et al., 1989; Gray, 1992). 
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Other molecules having a significant influence on cell immortality, such as bcl-2 
(Nunez et al., 1991), may contribute to the long-term survival of memory lymphocytes. 
Bcl-2 blocks cell death by apoptosis following a variety of stimuli (Strasser et al., 1991), 
and may be important in saving progenitor and long-lived cells in a variety of cell lineages. 
At the mucosae, antigen-specific IgA responses are short-lived and 
reimmunisation may not always induce higher levels of IgA faster during recall antibody 
responses (Mc Ghee and Kiyono, 1993 ). There is some evidence to show that 
long-lasting immune responses can be generated at the mucosae, for example with cholera 
toxin (Lycke and Holmgren, 1986; Lycke and Holmgren, 1989), however it is possible 
that these responses may have been maintained by memory lymphocytes in the blood 
circulation (Lycke et al., 1987). A continual restimulation of MALT may be required for 
maintenance of mucosa! immune responses. Dendritic cells including FDC in the PP 
may serve an antigen-retaining role in mucosal inductive sites; however, more studies will 
be required to determine roles for antigen persistence and IgA immune complexes in these 
tissues. If antigen persistence is predominantly responsible for the maintenance of 
memory lymphocytes, then mechanisms underlying their persistence are key parameters 
in determining the efficiency and duration of protection afforded by vaccines. 
1.6 THE PRACTICE OF IMMUNISATION 
Vaccination is a deliberate attempt to protect humans against infectious diseases. 
Although vaccination has a long hjstory, it is only in this century that such practices have 
become routine. With the exception of safe water, no other modality - not even 
antibiotics - has had such a major effect on reducing mortality than vaccination. Since 
Edward Jenner introduced vaccination against smallpox, simjlar practices have resulted in 
the control of nine major diseases, at least in certain parts of the world: smallpox, 
diphtheria, tetanus, yellow fever, pertussis, poliomyelitis, measles, mumps and rubella 
(Plotkin and Plotkin, 1994). Indeed, as the result of active immunisation against smallpox, 
the dream of eradicating a virulent pathogen has been fulfilled (World Health 
Organization , 1980). 
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1.6.1 A brief history of vaccination 
The practice of immunisation stems from observations, in early civilisations, that 
individuals who survived a disease seldom suffered a second similar clinical infection. In 
the Roman Empire, the livers of rabies-infected dogs were used for protection against 
rabies (Wigzell, 1993). Protection against smallpox by transmission of smallpox scabs, 
called 'variolation', was practised in China in the sixth century A.D. (Wong and Wu, 1932; 
Hume, 1940; Huard and Wong, 1968). Such efforts were also recorded in the Brahmin 
caste of Indian Hindus in the 16th century (Major, 1954 ). 
However, vaccination procedures employed today have their roots in the mid-18th 
century. It was observed then, in several European countries, that milkmaids acquiring 
infection from cows were protected from smallpox. Edward Jenner, in the late 18th 
century, proved that previous inoculations with harmless cowpox, a practice now known as 
'vaccination', afforded protection against the virulent smallpox (Plotkin and Plotkin, 1994). 
Unfortunately, it was not until 200 years after Jenner's demonstration that this procedure 
was to be used for widespread protection of humans from diseases. An intensified global 
programme of smallpox vaccination was carried out in 1967 and in less than 15 years 
following the beginning of active immunisation, smallpox virus was eradicated. Truly, 
such success represents an illustration of the efficacy of vaccination (World Health 
Organization, 1980). 
Louis Pasteur, in the latter half of the 1870s, introduced the concept of 'attenuation' 
to modify the virulence of a pathogen while retaining its immunogenicity (Plotkin and 
Plotkin, 1994 ), thus enabling the use of attenuated strains to induce protection against the 
virulent pathogen. Attenuation of infectious agents can be achieved in different ways, 
including serial passages in an unrelated host. For example, virulent rabies was passaged 
in rabbits, while poliovirus (Sabin and Bougler, 1973) and hepatitis A virus (Provost et al., 
1983) in primates species. 
Since the contributions of Jenner and Pasteur, numerous vaccines have been 
developed and used successfully despite initial objections or pessimism. Generally, the 
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vaccines used were either live, attenuated or inactivated preparations and are known as 
'conventional' vaccines. Testimonies to the efficacy of such conventional vaccines are the 
eradication of smallpox and the great reduction in morbidity from infection by bacterial 
and viruses, such as tuberculoid bacilli, measles, mumps, polio and n1bella. 
1.6.2 New technologies for making vaccines 
Although conventional vaccines have proved to be most successful for 
prophylactic immunisation, their use has certain inherent limitations. These include the 
limited stability of some vaccines under field conditions and the cost of preparation of 
large quantities of attenuated vaccine strains. The most notorious side-effect is the 
occasional reversion of attenuated strains to virulent phenotypes giving rise to 
vaccine-induced or vaccine-associated complications. For example, immunisation with 
poliovirus (Norrby, 1987) or VV (Lane et al., 1969; Lane et al., 1970; Behbehami, 1983) 
has been noted to cause complications, particularly in immunocompromised individuals 
(see also Section 1.7.4 ). Atypical infections have been related to vaccination with 
inactivated preparations, W-G-A-as atypical measles may arise following vaccination with 
formalin-treated measles virus (Norrby, 1987). 
Conventional vaccines were made available without a comprehensive knowledge of 
crucial properties of the organism or of their effects on the immune system. With the 
advent of recombinant DNA technology and increased understanding of immunology and 
protein chemistry, new candidate vaccines with the potential to overcome many of the 
linutations of conventional vaccines have been developed. Such novel strategies include 
synthetic peptides (Arnon, 1987), subunit vaccines (Zanetti et al., 1987), anti-idiotype 
in1munogens (Dalgeish and Kennedy, 1988), immunostimulating complexes (Morein 
et al., 1987; Lovgren et al., 1990) and vaccines based on replicating recombinant bacterial 
and viral vectors (Cavanagh, 1985; Flexner et al., 1988). Attempts have even been made to 
expre vaccine antigen in tran genie plants with the aim of inducing systemic and 
muco al immunity u ing 'edible' vaccines (Mason et al., 1992; Arntzen et al., 1994 ). 
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1.6.3 Recombinant vaccine vectors 
Hitherto, various replicating viral and bacterial vectors have been explored for their 
potential to generate cell-mediated and antibody responses (Cavanagh, 1985; Flexner 
et al., 1988). There are advantages in using replication-competent bacteria and viruses, 
such as Salmonella, herpesviruses, adenoviruses and poxviruses over other novel 
approaches in vaccine development. Upon replication of the vector, amplification of 
heterologous gene products increases the antigen load. Moreover, such vector-encoded 
antigens are processed and presented to the immune system in a similar manner to that 
which occurs during natural infection. Other advantages of recombinant vaccines include 
the low cost of vaccine preparation and the feasibility of their use in field or clinical 
situations. Despite these advantages, recombinant vaccine vectors may possess inherent 
limitations also associated with the use of conventional vaccines, such as causing 
vaccine-associated complications in immunodeficient recipients as discussed earlier 
(Section 1.6.2). 
1.6.3.1 Recombinant bacterial vectors 
Salmonella typhimurium and mycobacteria are examples of bacteria that have been 
developed as vaccine vectors. Due to the mode of Salmonella infection in the gut, this 
organism has been engineered for delivery of foreign polypeptides of other gut pathogens, 
such as Vibrio cholerae (Tacket et al., 1990) and Escherichia coli. Vaccine antigens from 
Clostridium tetani have also been encoded in Salmonella in efforts to develop an oral 
vaccine (Fairweather et al., 1990). Intracellular infection with mycobacteria, leading to the 
presentation of antigens in association with class I MHC molecules (De Libero et al., 
1988), may be useful in eliciting strong cell-mediated immune responses against the 
encoded vaccine antigen. Indeed, HIV-1 genes expressed by the bacille Calmette-Guerin 
vaccine strain of mycobacteria induced strong specific cell-mediated and antibody 
re pon es for prolonged periods in test animals (Stover et al. , 1991 ). This suggests that 
antigens encoded by mycobacteria can be presented in association with both class I and 
cla s II MHC molecules. 
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1.6.3.2 Recombinant virus vectors 
Adenoviruses, herpesviruses and poxviruses are among those being studied for 
their potential as vaccine vectors. Early adenovin1s vectors, based on human adenovirus 
type 5 (Ad5), were used to demonstrate the expression of hepatitis B virus surface antigen 
(HBsAg; Morin et al., 1987). Adenoviruses are potentially important vectors for 
intranasal (i.n.) immunisation due to the mucosa! tropism of the virus, indeed, i.n. 
immunisation of hamsters with recombinant Ad5 expressing HBsAg has elicited mucosa! 
antibody responses to both vector and HBsAg. In rabbits, others have primed for 
antibody responses upon intravenous (i.v.) inoculation with a similar construct (Ballay 
et al., 1985). Human adenoviruses of the Ad4 and Ad7 strains (Top et al., 1971) have 
also been developed as potential vectors for the expression of the HBsAg and the 
envelope (env) glycoprotein of HIV; intratracheal immunisation with the recombinant 
encoding HBsAg generated specific antibodies against the vaccine antigen (Hung et al., 
1990). 
Potential recombinant herpesvirus vaccine vehicles include HSV-1 and the 
attenuated varicella-zoster virus strain Oka. Recombinant herpesviruses have been 
constructed to express HBsAg (Shih et al., 1984) and Epstein-B arr virus membrane 
glycoprotein (gp) 350/220 (Lowe et al., 1987). The vaccine efficacy of these constructs, 
however, has not been reported in any detail. 
Other recombinant virus vaccines have been constructed from influenza (Li et al., 
1993) and pseudorabies viruses (Thomsen et al., 1987). Recently, RNA picornaviruses , 
uch as poliovirus (Evans et al., 1989; Matti on et al., 1994) and mengovirus (Altmeyer 
et al., 1994), have been developed as potential vaccine vectors. These viruses are incapable 
of reverse transcription and integration into the host DNA genome due to their replication 
exclusively in the form of RNA in the cytoplasm of infected cells. However, poxviruses 
by far are the most studied fami ly of viruses to be developed as candidate vaccine vectors. 
After the eradication of smallpox and the cessation of smallpox vaccination, YV, the 
prototype poxvin1s, was adapted as a vector (Sam and Dumbell, 1981; Mackett et al., 
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1982a; Panicali and Paoletti, 1982) where foreign genes were inserted by homologous 
recombination into the vin1s genome (reviewed by Moss and Flexner, 1987). 
1.7 POXVIRUSES AS VACCINE VECTORS 
Poxviruses or Poxviridae are large double-stranded DNA viruses with cuboid or 
prolate virions of 260-450 nm in length (reviewed by Fenner et al., 1989; Moss, 1990a). 
These viruses multiply in the cytoplasm (Moss, 1990a), display intrageneric genetic 
recombination and participate in non-genetic reactivation (Christopher et al., 1978). 
Fenner and Burnet (1957) reviewed these poxviruses in the Poxvirus Subcommittee at the 
Sixth International Congress for Microbiology (1953). Later, this review formed the 
basis for subsequent classification of poxviruses. Poxviridae are divided into two 
subfamilies: Entomopoxvirinae (poxviruses of insects) and Chordopoxvirinae 
(poxviruses of vertebrates); Table 1.1 shows viruses grouped under the latter category. 
Poxvirus recombinants offer several advantages over other replicating virus 
vectors. These include the ability to accommodate large foreign genes of up to 25 kb 
while maintaining genome stability (Smith and Moss, 1983 ). Hence, a recombinant virus 
can be n1ade to harbour multiple foreign genes of different pathogens, for example surface 
antigen, gpD and HA of hepatitis B virus, HSY and influenza virus, respectively (Perkus 
et al., 1985), or be made to express several genes from the same pathogen (Wild et al., 
1992), for the development of polyvalent vaccines. Other important advantages of 
poxvirus vectors include their ability to stimul ate both cell-mediated and antibody 
immunity (McCarthy et al., 1958; Pincus and Flick, 1963) that is relatively long-lasting 
(Henderson and Fenner, 1994 ), their heat stability, low cost of preparation, ease of 
administration and visible proof of vaccination (scars). With replication of pox viruses 
restricted to the cytoplasm (Moss, 1990a), the risk of viral integration into the host 
genome 1 also minimised. 
Advances in the development of poxvirus-based vectors have been recently 
exte nded to the avian-restricted avipoxviruses, namely fowlpox virus (FPV) and 
33 
Genus 
Orthopoxvirus 
Parapoxvirus 
Capripo.,n,irus 
A vipo.,n,irus 
Leporipoxvirus 
Suipoxvirus 
TABLE 1.1. Poxviruses of the vertebrates 
Type species 
Vaccinia 
Orf 
Sheeppox 
Fowlpox 
Myxoma 
Swinepox 
Species 
Other virus species 
Rabbitpox, variola, cowpox, ectromelia 
Stomatitis papulosa, pseudocowpox 
Goatpox, lumpy skin disease virus 
Canarypox, pigeonpox, turkeypox 
Rabbit fibroma, squirrel fibroma 
Nil 
Adapted from Buller and Palumbo (1991). 
canarypox virus (CPV; Taylor and Paoletti, 1988; Taylor et al., 1992). The development 
of these avipoxviruses as vaccine vectors will be detailed in Section 1.8.1. 
1.7.1 Biology of vaccinia virus 
VV is the type species of Orthopoxvirus. The VV genome, about 200-kb long 
(Coupar et al., 1990; Goebel et al., 1990), consists of a linear double-stranded DNA 
structure and is covalently-linked at the termini (Geshelin and Berns, 1974). The linear 
genome encodes genes essential for transcription, replication and production of progeny 
particles independently of host nuclear functions. These termini contain inverted terminal 
repeats (Garon et al., 1978; Wittek and Moss, 1980), and while genes encoded here are 
non-essential for replication, they are important for cytopathogenicity which include host 
range functions (Gillard et al., 1986) and growth factors for viral virulence (Brown et al., 
1985; Twardzik et al., 1985; Buller et al., 1988). 
Host range. VV has a wide host range that includes humans, primates, rodents 
and rabbits (Fenner et al., 1989). Infection of permissive cells is followed by cytopathic 
effects (CPE) or toxic effects, such as cell rounding, granulation and clumping, and 
progeny virion production. The genetic basis of host restriction of VV was initially 
ascribed to the left terminus of the genome (Drillien et al., 1981), but later, to host range 
genes, such as the KIL gene (Rosel et al., 1986) and C7L (Goebel et al., 1990) located at 
the terminus. 
Virus replication. The expression, replication and packaging of the VV genome 
consists of a series of temporally regulated events. Individual gene products are assigned 
- based on sensitivity to inhibitors of viral DNA and protein synthesis - to either early, 
intermediate or late expression (Moss and Filler, 1970; Drillien et al., 1978). 
Virus-encoded proteins related to VY transcription and the DNA sequences recognised by 
these pecific proteins in early gene expression have been characterised (Moss, 1990b). 
The entire VV genome is transcribed by the onset of DNA replication. 
Early gene products interact with the host during VV replication to ensure 
adequate level of precursors for viral DNA synthesis; these interactions mitigate against 
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the effects of cell cycle control and inhibit host protein synthesis that would lead to cell 
cytopathy (Moss and Filler, 1970; Drillien et al., 1978). Termination of early 
transcription occurs about 50 nucleotides downstream from TTTTTNT sequences, in 
which N can be any nucleotide (Rohrmann and Moss, 1985; Yuen and Moss, 1987). Late 
gene expression requires different promoter sequences (Keck et al., 1990). RN A 
transcripts are modified after transcription (Oda and Joklik, 1967; Sebring and Salzman, 
1967). Expression of early genes ceases with the onset of late gene expression (Moss, 
1990a and 1990b ). Proteins made during this stage are largely structural, as well as 
enzymes essential for the assembly of the structural proteins into progeny virions. Some 
of these proteins are further modified by glycosylation, phosphorylation, acylation or 
cleavage reactions before incorporation into virions (Hiller and Weber, 1985; Franke 
et al., 1989; reviewed by Tower et al., 1988). 
Assembly into uniform, spherical, immature particles appears to be sequential and 
occurs in different stages during virion morphogenesis ( de Harv an and Yohn, 1966). 
During assembly, the DNA genome, enzymes and assorted structural polypeptides enter 
the particle (Gold and Dales, 1968; reviewed by Dales and Pogo, 1981). Following virion 
assembly and maturation , the sequence of events involving virus dissemination, such as 
virus migration to the cell membrane, fusion to the membrane and rupture of the 
membrane to release virions, has been reported to vary depending on the poxvirus strain 
and the nature of the host cells (Ichihashi et al., 1971; Dales and Pogo, 1981). 
1.7.2 Biology of fowlpox virus 
FPV, the type specie of Avipoxvirus, has chicken as its natural host (reviewed by 
Tripathy and Cunningham, 1984 ). FPV is different from other pox viruses in that it 
cannot be grown in established cells lines (Randall et al., 1964 ), has the highest lipid 
content of any pox virus, contains the largest genome among the pox viruses (Coupar et al., 
1990) and does not cause a rapid cessation of cellular DNA synthesis in natural host, for 
example in chicken epithelial cells (Hanafusa, 1960; Joklik and Becker, 1964; Cheevers 
et al., 1968; Jungwirth and Launer, 1968; Chan and Hodges, 1973). 
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Like the VV genome, FPV contains a large and linear double-stranded DNA of 
approximately 300-kb with covalently-linked terminal hairpins (Coupar et al., 1990). 
FPV has many regions similar to those found in VV, for example, between the 10.5-kb 
FPV HindlII fragment of the FPV ·genome and the central portion of the VV HindIII D 
region (Tartaglia et al., 1990). Furthermore, homology of nucleic acid and amino 
sequences has also been noted among their thymidine kinase (TK) proteins (Boyle et al., 
1987; Binns et al., 1988), DNA polymerases (Binns et al., 1987) and 4b core 
polypeptides (Binns et al., 1989). However, the FPV TK gene is located in a different 
region than the TK gene of VV (Boyle et al., 1987; Binns et al., 1988). Similarities 
between FPV and VV were also noted among many open reading frames (ORF) in FPV 
and VV (Drillien et al., 1987; Binns et al., 1988; Tomley et al., 1988). 
Host range. FPV causes similar cellular pathology in avian cells as other 
pox viruses (Christopher et al., 1978). However, in contrast to the wide host range of 
many orthopoxviruses, avipoxviruses are restricted to growth in avian species. While 
infection of non-permissive mammalian cells with FPV at high multiplicity causes CPE, 
there is no evidence to suggest that productive replication of viruses occurs in these cells. 
There has been only one report of the isolation of an avipoxvirus from a mammal: an 
atypical FPV was isolated from a terminally ill and immunosuppressed rhinoceros in a 
zoo (Somogyi et al., 1993). Little is known about the fate of a vi pox viruses in mammalian 
cells. A complex family of host range regulatory genes was initially thought to be 
responsible for host restriction (Perkus et al., 1990). However, Somogyi et al. (1993) 
later showed that the replication 'block' of FPV is due to inefficient expression of late 
genes and poor maturation of virus particles in mammalian cells. 
1.7.3 Strategies for construction of recombinant poxviruses 
There are several factors important in the construction of an infectious 
recombinant VV. First, the inserted foreign DNA should not interfere with expression of 
essential viral genes. Second, appropriate VY regulatory sequences must be juxtaposed at 
the 5' end of the foreign gene for transcription by VY-encoded polymerases. Other 
factor e sential for efficient expression of foreign genes are the absence of intrans within 
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the gene and appropriate codon usage, since VV translational machinery has been found 
to display codon bias or preference (Hruby and Guarino, 1984). Non-essential insertion 
sites are now well defined in VV. A 9-kb segment at the left terminus of the poxvirus 
genome has been identified by the .isolation of spontaneous mutants (Moss et al., 1981; 
Panicali et al., 1981; Paez et al., 1985). Other non-essential genes, such as the TK and 
HA genes, were identified by physical mapping (Weir et al., 1982; Hruby et al., 1983; 
Shida, 1986). Insertional and deletion mutagenesis have also been employed to locate 
regions not essential for virus functions (Perkus et al., 1986). While most methods 
involved attempts to insert genes within non-essential ORF, some investigators have 
begun to place foreign genes in intergenic sites (Spehner et al., 1990; Fathi et al., 1991; 
Duncan and Smith, 1992). 
Foreign genes were initially inserted empirically into non-essential VV regions 
(Panicali and Paoletti, 1982), however expression was dependent on a VV promoter being 
adjacent to sites of insertion. Later, VV promoters and regulatory sequences were 
engineered proximal to foreign genes. Promoter sequences differ with respect to their 
temporal regulation, and include the early and late 7.5-kDa promoter (P7.5; Mackett et al., 
1984; Cochran et al. , 1985), the early A vaIH promoter (Perkus et al., 1985; Wachsman 
et al., 1987) and the late promoter in the 11-kDa gene (Wittek et al., 1984; Cantin et al., 
1987). Because of conserved transcriptional machinery in both VV and FPV (Binns 
et al., 1987 and 1989; Boyle et al. , 1987; Boyle and Coupar, 1988a; Prideaux et al., 1990), 
their transcriptional promoters can function in either virus. The bidirectional early/late and 
late FPV promoter, P.E/L (Kumar and Boyle, 1990; Prideaux et al., 1990), has been used 
successfully for gene expression in VV recombinants (Boyle, 1992). Likewise, gene 
exp re sion driven by the VV H6 promoter (Paoletti and Grady, 1977) in a recombinant 
avipoxvirus has been successful (Tartaglia et al., 1993). 
The iso lation of recombinant poxv1ruses encoding foreign DNA is usually 
achieved by marker rescue techniques. Unlike other animal and bacterial viruses, such as 
the baculoviru -insect cell expression system (Summers and Smith, 1987; Luckow and 
Summers, 1988), co-transfection with purified viral and foreign DNA is not applicable to 
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the VY expression system. VV DNA is not infectious and virus-associated enzymatic 
functions are required during initial stages of the replication cycle. Transfected foreign 
DNA can, therefore, only be 'rescued' using infectious VV particles, the feasibility of this 
approach first being shown in studies using thermosensitive (Sam and Dumbell, 1981) or 
deletion (Nakano et al., 1982) mutants. Since then, a variety of marker rescue techniques 
have been used to isolate recombinant viruses. These include the use of the TK gene 
(Mackett et al., 1982b; Panicali and Paoletti, 1982), DNA polymerase by virtue of 
phosphonoacetic-acid resistant marker (Jones and Moss, 1984; Traktman et al., 1984), 
various temperature-sensitive genetic markers (Condit et al., 1983; Drillien and Spehner, 
1983; Ensinger and Rovinsky, 1983; Thompson and Condit, 1986), rifampicin-resistance 
(Tartaglia and Paoletti, 1985; Bal dick and Moss, 1987) and neomycin-resistance (Franke 
et al., 1985) markers, or using E. coli genes for xanthine-guanine phosphoribosyl 
transferase (Ecogpt; Boyle and Coupar, 1988b; Falkner and Moss, 1988) and 
~-galactosidase (lacZ; Chakrabarti et al., 1985; Panicali et al., 1986). Briefly, the process 
of foreign gene insertion is as follows. The foreign gene is flanked by VV DNA, ranging 
from 0.1-10 kb in length, which serves as the 'homologous arms' to direct insertion into 
desired locations within the VV genome. Upon infection with VV and transfection of the 
engineered insertional plasmid, homologous recombination occurs, and chimeric virus 
genomes are replicated and packaged into infectious progeny virus. 
Other strategies have recently been undertaken in constructing and isolating 
recon1binant vin1ses. Falkner and Moss ( 1990) have introduced an approach called 
'transient dominant selection' for making recombinant viruses without retaining the 
se lectable marker. While all of the abovementioned strategies have been based on 
recombination of homologous sequences in vivo, the insertion of foreign DNA into the 
VV genome by direct in vitro ligation has also been successful (Merchlinsky and Moss, 
1992). 
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1.7.4 Safety and efficacy of vaccinia viruses as vaccine vectors 
The acceptability of VY, or of any virus as a potential vaccine vector, is dependent 
on many factors. The paramount concerns are those of safety and efficacy (Ada, 1991 
and 1994). 
Safety. The success of VY as an immunising agent against smallpox points to the 
potential of poxviruses as effective antigen delivery vehicles (Behbehami, 1983). 
However, the success of smallpox vaccination was also marred by tragic incidents 
resulting from vaccine-associated side-effects in some recipients. In 
immunocompromised individuals, smallpox vaccines cause rare but serious complications, 
such as eczema vaccinatum (Lane et al., 1969; Lane et al., 1970; Behbehami, 1983) and 
rare central nervous system disease (de Vries, 1960; Wilson, 1967; Lane et al., 1969; Lane 
et al., 1970). Vaccination against smallpox has also been reported to cause vaccinal 
osteomyelitis (Sewall, 1949) and malignant skin tumours, such as melanoma in vaccinated 
scars, many years later (Marmelzat, 1968). Furthermore, VY has a broad host range 
(Fenner et al., 1989) which raises the question of species-restriction of the vaccine. 
Hence, there are still concerns over the reintroduction of pox virus-based vaccines. 
Efficacy. The availability of a highly effective vaccine was a major reason for the 
success of the Smallpox Eradication Programme (Fenner et al., 1988). Indeed, 
poxviruses have been shown to elicit long-term immunity in immunised individuals 
(Henderson and Fenner, 1994). Recently, some volunteers for vaccination with a 
recombinant VY expressing gp 160 of HIV were found to possess antibodies to VY 
(Cooney et al., 1991 ), even though they were vaccinated against smallpox many years 
earlier. In this light, one concern pertaining to the use of VY-based vaccines is whether 
prior exposure to the immunising vehicle, or to an encoded antigen, will prevent the 
induction of optimal immune responses upon revaccination. There is evidence for 
successful revaccination using VY recombinants despite previous exposure to the vector 
or vaccine antigen (Perkus et al., 1985; Flexner et al., 1988). Conversely, others have 
found that pre-existing immunity from smallpox vaccination modulated immune 
responses to a novel antigen expressed by a recombinant VY (Rooney et al., 1988; 
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Cooney et al., 1991; Etlinger and Altenburger, 1991). These conflicting results may stem 
from differences in the parameters analysed, however, the use of VY-based vaccines in a 
large population previously immunised against smallpox requires further evaluation. 
Moreover, VY infections may expose many endogenous virus-encoded antigens, besides 
the heterologous vaccine antigen_, that will stimulate the immune system. Antigen 
competition between such proteins may modulate immune responses generated against the 
vaccine antigen (Andrew et al., 1986). 
The efficacy of a vaccine also lies in its ability to generate an appropriate immune 
response given that pathogens are most effectively controlled by the induction of 
cell-mediated or antibody responses (Section 1.3.6). Hence, the ability of vaccines to 
prime for either antibody or cell-mediated immune responses, or both, may not only 
improve prophylaxis, but also offers the potential to alter the course of disease by vaccine 
immunotherapy, as previously suggested by Ioannides and Whiteside (1993). 
1.7.5 Attenuation of vaccinia viruses 
Based on increased understanding of viral virulence factors, efforts have been 
undertaken to modify VY strains for use as improved immunisation vehicles. Three 
general approaches have been investigated: adaptation of existing attenuated VY by serial 
passage in unrelated hosts, selective deletion of specific VY genes and insertion of 
cytokine genes into the VV genome. 
The modified VY Ankara (MV A) is one of the most highly attenuated vaccine 
strains (Moss, 1994 ). After more than 570 passages in chicken embryo fibroblasts, the 
virus was unable to replicate in human and other mammalian cells, and restricted to avian 
cells. MV A is avirulent in normal and immunosuppressed animals: no significant 
side-effect have appeared after inoculation of over 120,000 humans, many of whom were 
at high risk for the conventional smallpox vaccine strai ns. Later, genetic analysis showed 
that the attenuation was due to deletions of more than 30-kb DNA, including at least two 
host range genes, from the genome of MY A (Meyer et al., 1991). The block of MY A 
replication in non-permissive human cells was found to occur during virion assembly 
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(Sutter and Moss, 1992). Nevertheless, even during non-productive infections, MV A 
vectors produce recombinant proteins in a manner similar to wild-type viruses (Sutter and 
Moss, 1992). Furthermore, the immunogenicity of MV A recombinants in mice resembles 
that of virulent strains (Moss, 1994 ), suggesting that MV A may represent a greatly 
improved VV vector. 
Attenuation by specific gene deletions has also been used to modify virulence. 
Deletions include genes for TK (Buller et al., 1985), a growth factor (Buller et al., 1988), 
HA (Flexner et al., 1987; Shida et al., 1988), 13.8-K secreted protein (Kotwal et al., 
1989), ribonucleotide reductase (Child et al., 1990), env proteins (Rodriguez et al., 1992; 
Engelstad and Smith, 1993; Wolffe et al., 1993), steroid dehydrogenase (Moore and 
Smith, 1992), complement control protein (Isaacs et al., 1992) and host range genes (Lee 
et al., 1992). Subsequently, Paoletti and co-workers have developed and tested a 
host-range-restricted mutant with 18-gene deletions, called NYVAC (Konishi et al., 1992; 
Tartaglia et al., 1992). The attenuation of NYV AC was illustrated by the lack of ulceration 
normally induced on rabbit skin and non-lethality in immunodeficient animals (Tartaglia 
et al., 1992). 
1.7.6 Expression of cytokine genes by vaccinia viruses 
Insertion of cytokine genes into the VV genome offers yet another method of 
decreasing virulence without adversely affecting immunogenicity. IL-2 was the first 
cytokine gene to be inserted into VV (Flexner et al., 1987; Rams haw et al., 1987); its 
expression led to the attenuation of the virus in both normal and immunodeficient mice. 
Elevated NK cell activity and secretion of IFN-y by NK and NK-like cells induced by 
IL-2 was responsible for the attenuation this recombinant VV (Karupiah et al., 1990a, 
1990b, 1990c and 1991). Attenuation of the IL-2 recombinant VV in immunocompetent 
monkey a measured by smaller skin lesions , was also noted (Flexner et al., 1990; Ruby 
et al., 1990). The virulence of VV was also attenuated when IFN-y (Kohonen-Cori sh 
et al., 1990) or TNF-cx (Sambhi et al., 1991) was encoded. It is interesting that cytokines 
decrea ing viru virulence are all the Th 1 type. On the other hand, encoding a Th2 
cytokine, IL-4, was hown to greatly enhance viral pathogenicity by suppress ing ant iv iral 
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CD8+ CTL activity and down-regulating IL-2, IFN-y (Thl cytokines) and IL-12 in the 
host (Shanna et al., 1995). 
VY-expressing IL-5 or IL-6, although not attenuating the virus, selectively 
stimulated the production of different lg isotypes against co-expressed vaccine antigens in 
immunised animals. VY-encoded IL-6 enhanced specific systemic antibody responses of 
the IgG 1 subclass (Ramshaw et al., 1992) and, when delivered at the mucosae, enhanced 
specific mucosal IgA and IgG antibodies (Ramsay et al., 1994a). Similarly, mucosal 
infection with recombinant VV encoding IL-5 augmented specific local antibody 
responses to vaccine antigens (Ramsay and Kohonen-Corish, 1993). 
1.8 NOVEL VACCINE VECTORS FOR MAMMALS 
Due to the abovementioned problems associated with replicating vectors as 
vaccines, non-replicating vectors, such as avipoxviruses and nucleic acid vaccine (NA V), 
have emerged as potential alternatives. In animal studies to date, these vectors have proved 
to be both safe and effective in eliciting long-term and protective immunity. 
1.8.1 A vipoxviruses 
Orthopoxviruses have a very broad host range; in contrast, avipoxviruses are 
restricted to avian species for productive replication (Esposito, 1991). Thus, FPV has 
been developed as a vaccine vector for poultry (Taylor et al., 1988a and 1990; Edbauer 
et al., 1990; Nazerian et al., 1992; Heine and Boyle, 1993). FPV infection of mammalian 
cell is non-productive, i.e. no progeny viruses are produced (Taylor and Paoletti, 1988), 
however, early gene expression occurs (Somogyi et al., 1993 ). Indeed, foreign genes 
engineered under the transcriptional control of an early virus promoter (Taylor et al., 
1988b; Cox et al., 1993 b ), as well as a subset of avipoxvirus-encoded early genes, are 
appropriately expressed. 
These findings have raised the prospect of using avipoxviruses as vaccine vectors 
in mammalian hosts and, recently, recombinant FPV and CPV (also known as ALY AC) 
have been studied in non-avian species, such as mice (Cox et al., 1993b ), cats (Tartaglia 
et al., 1993), dogs (Taylor et al., 1991 and 1992) and man (Cadoz et al., 1992). The 
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expression of the foreign gene products is sufficient to induce both antibody (Taylor 
et al., 1988b, 1991 and 1992) and cell-mediated immune responses (Cox et al., 1993b) 
that can afford protective immunity (Taylor et al., 1988b, 1991 and 1992; Tartaglia et al., 
1993). Such reponses were elicited for prolonged periods in vaccinated individuals 
(Taylor et al., 1992; Cox et al., 1993b; Tartaglia et al., 1993). 
The abortive nature of avipoxvirus infection in mammalian cells suggests the 
possible safe use of these viruses as vaccine vectors. Indeed, the safety of AL V AC and its 
derivative recombinants has recently been demonstrated in immunocompromised 
recipients (Paoletti et al., 1994 ). No disseminated infection was observed following 
intracranial infection with more than 107 plaque-forming units (PFU) in newborn mice, 
young adult mice , genetically deficient nude mice or cyclophosphoamide-treated 
immunosuppressed mice. In a further study, no significant local or systemic 
reactogenicity was observed in human volunteers and the recombinant AL V AC was 
well-tolerated (Cadoz et al., 1992). 
1.8.2 Nucleic acid vaccines 
NA V technology had its birth with the demonstration that large quantities 
(> 100 µg ) of DNA expression vectors, when injected into mice intramuscularly (i.m.), 
were taken up by muscle cells (Wolff et al., 1990) that are thought to persistently express 
the encoded genes (Wolff et al., 1992). Muscle may be particularly suited for harbouring 
and expressing NA V; its structural features allow cell regeneration after damage due to 
injection, while the longevity of muscle cells may account for the prolonged expression of 
the encoded gene product in vivo (Wolff et al., 1992). Subsequently, other investigators 
reported gene expression after direct injection of DNA into heart and skeletal muscle cells 
of rat (Lin et al. 1990; Acsadi et al., 1991 b; Kitsis et al., 1991) and dogs (Vonharsdorf 
et al. 1993), and in the diaphragm (Davis and Jasmin, 1993) and neurons (Sahenk et al., 
1993). Expre ion wa al o found following i.m. injection in other animals, including 
fi h (Hansen et al., 1991 ), dog (Vonhar dorf et al., 1993 ), rabbits (Gal et al., 1993; 
gad j anyan et al. 1994) cattle (Cox et al., 1993a) and primate (Jiao et al., 1992; 
Donnelly et al., 1994). 
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Other routes of NA V administration have also been attempted, including 
intraperitoneal (i.p.), i.n., subcutaneous (Fynan et al., 1993) and i.v. injection (Fynan et al., 
1993; Zhu et al., 1993). An 1.v. inoculation of chloramphenicol 
acetyltransferase-encoding NA V, coated with liposomes, transfected virtually all tissues, 
including the lungs, spleen, lymph nodes and bone marrow of recipient mice (Zhu et al., 
1993). Another mode of NA V delivery that has proven highly successful is the particle 
bombardment or 'gene-gun' method (Tang et al., 1992; Fynan et al., 1993; Haynes et al., 
1994). Gene-gun delivery of NAY to the epidermis offers a direct and intracellular 
delivery of very small amounts ( < 1 µg), as well as a practical and easy delivery site. This 
method has been shown to induce protective immunity against lethal challenge with 
influenza virus (Fynan et al., 1993). 
The elicitation of specific-antibodies by NA V was first described in mice 
inoculated with vectors encoding human growth hormone by the gene-gun method (Tang 
et al., 1992). However, the vaccine potential of NA V was first explored by Ulmer et al. 
( 1993), who reported that mice immunised i.m. with NA V expressing a conserved internal 
protein of influenza virus , the NP, mounted both NP-specific CTL and antibody 
responses, and were protected against subsequent challenge with a heterologous strain of 
influenza virus. Protection against a homologous strain of influenza virus was also 
obtained after immunisation of chicken with HA-encoding NA V (Robinson et al., 1993). 
Since these reports, direct injection of NA V has been extended to include numerous other 
genes, including genes encoding env of HIV (Wang et al., 1993) and circumsporozoite 
protein of Plasmodium yoelii (Sedegah et al., 1994). Mice given the NAV-HIV env 
recombinant i.m. developed neutralising antibodies against HIV while CDS+ T 
lymphocyte-dependent protection against malaria was attained in mice immunised with 
NA V expressing the circumsporozoite antigen. 
Immunisation with DNA has been shown to be a more efficient method for 
delivery of antigen into muscle than other vectors, such as adenoviruses and retroviruses 
(Davis et al., 1993). Injection of NA V results in the generation of long term immunity 
(Ulmer et al., 1993; Agadjanyan et al., 1994; Sedegah et al., 1994) and this may be due to 
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prolonged expression of encoded genes, by long-lived muscle cells harbouring the NA V, 
for many months after immunisation (Wolff et al., 1992). In addition, the advantages of 
NA V for revaccination have been amply illustrated in vaccinated individuals (Fynan et al., 
1993; Ulmer et al., 1993). A most desirable feature is that NA V may represent a safe 
approach to vaccination. Despite widespread use, there are, as yet, no reports of 
integration of injected plasmids into the genome of mammalian cells (Wolff et al., 1992). 
Furthermore, immunisation with NA V has not been shown to elicit anti-DNA responses 
(Jiao et al., 1992) that could lead to autoimmunity in vaccinated individuals. Nevertheless, 
these aspects of NA V vaccination should continue to be monitored in experimental 
studies. 
1.9 OBJECTIVES AND SCOPE OF THIS THESIS 
The advent of non-replicating vectors has improved prospects for the development 
of safe and effective vaccines against a variety of diseases. Moreover, the effectiveness of 
vaccines can be further improved by their ability to induce appropriate immune responses. 
Cytokines play critical roles in the development of immune responses. The aims of this 
work are to study the potential of cytokines expressed in recombinant viruses to modify 
antiviral immune responses and to investigate the use of different vaccine strategies in 
attempts to generate augment immune responses against encoded vaccine antigen. 
In Chapter 2, the construction of recombinant FPV expressing the HA gene of 
influenza virus NPuerto Rico/8/34 (NPR/8) together with genes for murine IL-6 or 
IFN-y is described. The use of these recombinants and the influence of the FPV-encoded 
cytokine in generating both systemic and mucosal inunune responses against HA are 
examined in Chapter 3. The safety of recombinant FPV, their long-term express ion of 
encoded genes, and their ability to induce immune respon ses in animals will also be 
tudied. The efficacy of these constructs in affording protection against lethal challenge 
with influenza virus is also documented. 
In Chapter 4 , studies of the use of NA V immuni sation in inducing protective 
immune re ponse are reported. The combinati on of th is s trategy wi th that of 
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recombinant FPV, each expressing the common HA antigen, to generate greatly enhanced 
immune responses will also be investigated. Both systemic and mucosa! antibody 
responses after NA V immunisation i.m. and boosting with recombinant FPV at the 
respective site are studied. The effects of FPV-encoded cytokines on boosting of immune 
responses are also described. 
In Chapter 5, the construction of a recombinant VY expressing murine IL-7 and 
the immune regulatory effects of this cytokine during antiviral immunity are recorded. 
The functional roles of a number of cytokines in the immune responses have been 
previously studied successfully using similar approaches (Ramshaw et al., 1992; Ramsay 
and Kohonen-Corish, 1993; Ramsay et al., 1994a and 1994b). 
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CHAPTER2 
Construction and in vitro testing of 
recombinant f ow/pox viruses expressing cytokine genes 
2.1 INTRODUCTION 
VV is a highly immunogenic virus capable of stimulating long-term cell-mediated 
and antibody immunity (McCarthy et al., 1958; Pincus and Flick, 1963; Henderson and 
Fenner, 1994 ). The availability of a highly effective vaccine was a major reason for the 
success of the Smallpox Eradicatio.n Programme (Fenner et al., 1988). However due to 
rare but serious vaccine-induced complications occurring in immunocompromised 
individuals (Lane et al., 1969; Lane et al., 1970; Behbehami, 1983), there are still concerns 
over the use of VV in humans. The acceptability of a virus vaccine depends on the 
paramount concerns of safety and efficacy (Ada, 1991 and 1994 ). 
Host-restricted poxviruses, such as the avian species-restricted avipoxvirus, have 
been developed as alternative vaccine vehicles. Avipoxviruses, for example FPV, have 
been used as vaccine vectors for immunogens of fowl pathogens in poultry (Taylor et al., 
1988a and 1990; Edbauer et al., 1990; N azerian et al., 1992; Heine and Boy le, 1993 ). In 
mammalian cells, these viruses cause abortive infections (Taylor and Paoletti, 1988; 
Somogyi et al., 1993) and thus cannot produce mature infectious virions. Although 
unable to replicate in mammals, avipoxviruses nevertheless can express appropriately 
engineered foreign genes under the transcriptional control of early poxvirus promoters 
(Taylor et al., 1988b; Cox et al., 1993b). CPV have been shown to be safe and effective 
vectors capable of eliciting prolonged immunity in mammals (Taylor et al., 1991 and 
1992; Cadoz et al., 1992; Cox et al., 1993b; Tartaglia et al., 1993). 
Cytokine gene expression has been used to decrease the virulence of VV vectors 
without adversely affecting the immunogenicity of the virus. For example, attenuation of 
VV expressing mouse or human IL-2 in immunodeficient athymic nude mice has been 
reported by Ramshaw et al. ( 1987) and Flexner et al. ( 1987), and in immunocompetent 
monkey by Flexner et al. ( 1990) and Ruby et al. ( 1990). The growth of recombinant 
VV encoding IFN-y (Kohonen-Corish et al., 1990) or TNF-a (Sambhi et al., 1991 ) was 
al o attenuated to the extent that infection could be rapidly resolved by severely 
immunodeficient mice. Further, local expression of cytokines during VV replication has 
been u ed to electively manipulate the immune response generated against co-expressed 
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heterologous antigens (Ramshaw et al., 1992). Such approaches have allowed studies to 
be undertaken into the immunobiology of several cytokines. For example, IL-6 
expression by recombinant VV at mucosae has revealed the pivotal role of this cytokine in 
the development of mucosal antibody responses (Ramsay et al., 1994a). 
In this chapter, the construction of recombinant FPV vectors expressing the HA 
gene of influenza virus strain A/PR/8 together with murine cytokines IL-6 or IFN-y is 
described. 
.... 
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2.2 MATERIALS AND METHODS 
2.2.1 Culture mediun1 
Fl 5 medium is made of Eagles Minimum Essential Medium (Cytosystems, Castle 
Hill, NSW, Australia) supplemented with NaHC03 (2.2 g/1), L-glutamine (216 mg/1), fetal 
calf serum [5o/o (v/v); FCS; Flow Laboratories, North Ryde, Australia], PSN [penicillin 
(30 mg/1), streptomycin sulphate (50 mg/1) and neomycin sulphate (50 mg/1)] and 
2-mercaptoethanol (50 µM). 
For culturing hybridomas and cytokine-dependent cells, Mixed Lymphocyte 
Mediun1 (MLC) was used. MLC is made of DMEM (GIBCO BRL, Life Technologies, 
MD, USA) supplemented with glucose ( 4 g/1), folic acid ( 6 mg/ml), L-asparagine 
(36 mg/1), L-arginine ( 116 mg/1), sodium pyruvate ( 1 mM), L-glutamine (216 mg/1), 
HEPES (10 mM), 2-mercaptoethanol (50 µM), FCS [lOo/o (v/v)] and PSN. Supernatant 
[10% (v/v)] from con A-stimulated spleen cells was added to MLC during growth of 
cytokine-dependent cell lines as a source of growth factors. 
2.2.2 Cell lines and hybridomas 
Human osteosarcoma 143B cells (Rhim et al., 1975) and CV-1, a cell line derived 
from African green monkey (Jensen et al., 1964), were grown in F 15 medium. Chicken 
embryo skin (CES) cells, a primary epithelial cell line, were obtained from 13-day old 
embryos as described in Section 2.2.3 and maintained in F15 medium, and used before 
three passages. 
The IL-6-dependent cell line, B9 (Aarden et al., 1987), and the rat anti-murine 
IFN-y antibody secreting hybridoma, R4.6A2 (Spitalny and Havell, 1984), were grown in 
MLC. 
2.2.3 Preparation of primary CES cells 
Primary CES cells were prepared using the method of Silim et al. ( 1982) . 
Specific pathogen-free (SPF) eggs were candled after 13 days of incubation, and embryos 
from the e eggs were harvested and washed extensively with Puck's saline A [phenol red 
.... 
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(0.5 mM), NaCl (140 mM), KCl (5.4 mM), glucose (5.6 mM) and NaHC03 (4 mM), 
pH 7 .2-7.4]. After washing, the embryos were transferred to Puck's saline A 
(25 ml/embryo) containing collagenase (100 µg/ml; Sigma Chemical Co., MO, USA) and 
CaCb (5 mM). The mixtures were incubated at 37°C, with gentle and constant stirring, 
for 30 min. The embryos were th~n removed leaving the skin in solution and digestion 
was allowed to proceed for another 10 min at 37°C. The cell suspension was then filtered 
through 4 layers of sterile gauze to remove large debris and cell clumps, and pelleted by 
centrifugation. The cell pellet was resuspended in F 15 medium and seeded in plastic 
roller bottles (850 cm2; Coming, NY, USA) at 150 x 106 cells in 200 ml of F15 medium. 
2.2.4 Viruses 
FPV-M3, a tissue culture passage strain derived from the mild vaccine strain, 
FPV-Web (Arthur Webster Pty Ltd, Northmead, Australia), was grown in CES cell 
monolayers as described (Boyle et al., 1987). VV-HA (TK+), VV-HA-IL6 and 
VV-HA-IFNy used here have been made and described elsewhere by Coupar et al. 
(1988), Rams haw et al. (l 992) and Kohonen-Corish et al. (l 990), respectively. 
FPV and VV stocks were grown in acid-washed 2-1 Schott or plastic rollers 
(850 cm2; Corning) on CES and CV-1 monolayers, respectively. These monolayers were 
infected at a multiplicity of infection (moi) of 0.01 (i.e. 1 o-2 PFU/cell). FPV stocks were 
harvested after 5-7 days while VY stocks were collected at 48 h after infection. The titres 
of stock vin1ses were determined by plaque assay and stored in 1-ml aliquots at -75°C. 
VV stocks were sonicated twice at 50 W for 5 sec using a Branson Sonifier (Branson 
Sonic Power Co., CT, USA), whereas FPV stocks were trypsinised [O.So/o (w/v); Sigma] 
for 30 min at 37°C before neutralisation with FCS [50% (v/v)]. Viruses were diluted in 
gelatin- aline to appropriate titres (usually 5 x 107 PFU/ml) before use. 
2.2.5 DNA manipulation, polymerase chain reactions (PCR), sequencing and 
Southern blotting 
Molecular cloning, re triction enzyme (RE) digestions and other recombinant 
DNA technique were performed using conventional procedures (Sambrook et al. , 1989). 
... 
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RE and other molecular biology reagents were purchased from Boehringer Mannheim, 
GmbH, Germany (BM) and Bethesda Research Laboratory, MD, USA (BRL). 
PCR reactions for producing DNA fragments for subcloning were performed with 
1 ng of CsCl-purified plasmid { total reaction volume of 18 µl containing SuperTaq 
(0.2 units; P.H. Stehelin & CIE AG, Basel) , Tris (10 mM; pH 9.0), KCl (50 mM), gelatin 
[0.01 % (v/v)], MgCb (1.5 mM), Triton X-100 [0.1 % (w/v)], dNTPs (G, A, T and C, each 
at 2.5 mM) and primers ( each at 5 µM)} using a capillary FTS-Thermal Sequencer 
(Corbett Research, Australia). The reactions were carried out as follows - 95°C, 5 min 
(1 cycle): 950c, 5 sec; 53°C, 2 sec; 72°C, 1 min (25 cycles): 72°C, 5 min (1 cycle). PCR 
products were then purified by phenol extraction after agarose gel purification and 
digested with appropriate REs before use for subcloning into phagemid pTZ19U (Mead 
et al., 1986). PCR reaction of FPV DNA was performed using an AmpliTaq kit 
(Perkin-Elmer Cetus, NJ, USA) using PCR machine HYBAID (Hook and Tucker 
Instruments Ltd., UK) as outlined by Heine and Boyle (1993) - 95°C, 1 min; 60°C, 
2 min; 72°C, 5 min (30 cycles), with the elongation time in each cycle extended by 20 sec. 
PCR products were then analysed by agarose gel [ 1-l.5o/o (w/v)] electrophoresis in TBE 
buffer, pH 8.3. 
For sequencing, single-stranded DNA templates were prepared from recombinant 
phagen1id pTZ19U maintained in£. coli DHl lS (Lin and Mattson, 1991) and sequenced 
by the dideoxy-chain termination method of Sanger et al. ( 1977) using the PRISM Ready 
Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., CA, 
USA). Analysis of DNA sequences was performed using Seq Ed version 1.0 (Applied 
Biosystems, Inc.). 
For Southern blotting, DNA fragments were transferred onto a nylon membrane 
(GeneScreen Plus, DuPont, MA, USA), by capillary blotting under alkaline conditions 
(0.4 M NaOH), after agarose gel electrophoresis. The Southern blot was then blocked 
with 1.0% (w/v) skin1 milk in hybridisation buffer { SSPE (2X), SDS [7% (w/v)], herring 
testes DNA (0 .5 mg/ml; Sigma)} for 2-6 h at 65°C. The blot was probed with 
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heat-denatured 32P-labelled DNA probe in hybridisation buffer with gentle mixing at 
68oc (HYBAID Mini Oven MK.II, Hybaid Ltd., UK). After hybridisation for 14-20 h, 
unbound DNA probe was removed under high stringency (68°C) by washing in SSC 
(2X) and SDS [0.1 % (w/v)], and then in SSC (0.2X) and SDS [0.1 o/o (w/v)] for 
20-30 min each before the membrane was air-dried and used for autoradiography. 
2.2.6 Primers 
Primers PHA-1 and PHA-2 (Appendix I) complementary to the 5' and 3' ends, 
respectively, of the ORF of the HA gene of influenza virus A/PR/8 were designed with 
BamHl and Bglll restriction sites for PCR fragment subcloning. PHA-2 also contains 
two overlapping transcriptional termination signals, TTTTTTTT (Boyle, 1992), and an 
in-frame translational stop codon for termination of expression at the 3' end. 
PIL6-1 and PIL6-2 (Appendix I) containing transcriptional and translational stop 
signals, and BamHl restriction sites for subcloning of PCR fragments, were used to 
prepare murine IL-6 DNA for subcloning. For subcloning the murine IFN-y gene, 
primers described in Appendix I, with similar features to the primers for IL-6, were used. 
PCR primers P330 and P348 (Appendices I and II), homologous to the FPV TK 
gene and the Neal site downstream of the TK gene (Heine and Boyle, 1993), respectively, 
were used for PCR analysis of recombinant FPV genome arrangements. 
2.2.7 Construction of recombinant viruses 
FPV recombinants were constructed as described elsewhere (Boyle and Coupar, 
1988a) using the co-expressed Ecogpt gene for recombinant virus amplification and 
selection (Boyle and Coupar, 1988b ). CES were infected with FPV-M3 at moi of 0.0 l 
for 1 h and these monolayers were then transfected with 10 µg of plasmid in 0.2 mg 
DEAE-dextran (molecular weight 2 x 106; Pharmacia, NJ, USA)/ml. After 16-24 h, 
n1onolayers were washed and incubated for 6-7 days in F15 mediun1 containing MXHAT 
[mycophenolic acid (2.5 µg/ml ), xanthine (250 µg/ml), hypoxanthine (0.1 mM), 
aminopterine (0.4 µM) and thymidine (30 µM)]. 
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After three cycles of growth under MXHAT selection, recombinant viruses 
(containing a lacZ gene) were purified by plaguing under non-selective conditions with 
5-bromo-4-chloro-3-indolyl-~-D-galactopyranoside (0.3 mg/ml; BRL) in Fl5 medium. 
Two or three cycles of purification of blue-plaque recombinant viruses were performed 
until the virus population was ho_mogeneous. DNA from recombinant viruses was 
analysed by PCR using primers P330 and P348 (Appendices I and II), as described 
previously (Heine and Boyle, 1993), to confirm both the insertion of heterologous DNA 
and the absence of wild-type FPV-M3 in recombinant FPV stocks. 
2.2.8 Preparation of FPV DNA 
The method described by Heine and Boyle (1993) was used for preparing FPV 
DNA. Aliquots of virus stocks, 100 µl, were digested with proteinase K (500 µg/ml; BM) 
in Tris (10 mM; pH 7.6), 2-mercaptoethanol (50 mM), NaCl (100 mM), EDTA (10 mM), 
sarkosyl (1 o/o (w/v)] and sucrose [26% (w/v)] for 1 hat 58°C, and the lysate was then 
extracted with phenol/chloroform (50%:50%, v/v). DNA was precipitated with ethanol, 
digested with RNase (20 mg/ml) and denatured at 100°C for 10 min before use. 
2.2.9 Cytokine assays 
Supernatants from cell cultures infected with recombinant virus (moi l) were 
passed through 0.1 µm filters to remove virus particles prior to assay. The presence of 
IL-6 was detected by [3H]-thymidine incorporation (78 Ci/mmole; ICN Radiochemicals, 
CA, USA) using the IL-6-dependent cell line , B9 . Cytokine-dependent cells 
(5 x 103 cells/well), in flat-bottomed 96-well plates (Nunc , Roskilde, Denmark), were 
cultured for 48 h at 37°C in MLC containing serially diluted supernatant from infected 
monolayers. Wells were pulsed with [3HJ-thymidine (1 µCi) during the last 4-6 h of 
culture. Cells were then harvested onto filter mats using a Skatron 96 well harvester 
(Pharmacia). Scintillation fluid (LKB Scintillation Products, Leics , UK) was added and 
[3H]-thymidine uptake was measured in a Pharmacia liquid scintillation counter. 
IFN-y in supernatants was detected by indirect ELISA, as described elsewhere 
(Sheehan et al., 1989; Carpenter et al., 1994), using the purified rat anti-murine IFN-y 
.... 
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monoclonal antibody, R4.6A2, as the capture antibody and a polyclonal rabbit anti-murine 
IFN-y (Silenus Laboratories Pty. Ltd., Australia) as the secondary antibody. ELISA 
plates (Titertek, Flow Laboratories, The Netherlands) were coated with the capture 
antibody [1:5000 (v/v)] in carbonate buffer [NaHC03 (35 mM) and Na2C03 (15 mM), 
pH 9.6] at 40c overnight. These plates were then blocked for 2 hat room temperature 
with skim milk [5% (w/v) in PBS]. Two-fold serially diluted samples were added to the 
wells and incubated at 37°C for 2 h. After removal of samples by washing with 
PBS-Tween-20 [0.2o/o (v/v); Sigma], the secondary antibody [ 1: 1000 (v/v)] was added and 
incubated at 37°C for 2 h. The cytokine-antibody complexes were detected using a 
polyclonal anti-mouse IFN-y antisera and alkaline phosphatase-conjugated anti-rabbit Ig 
(Silenus). The assay was then developed at room temperature by application of substrate 
(p-nitrophenyl phosphate, disodium, 5 mg/ml; Sigma) in alkaline buffer 
(2-amino-2-methyl-1-propanol buffer; 1.5 M; pH 10.3 ; Sigma). The enzymatic product 
was read at 430 nm with a THERMOmax microplate reader (Molecular Devices, CA, 
USA). ELISA results were analysed using SOFTmax programme version 2.0.1 
(Molecular Devices). 
Cytokine titres were determined by comparison of the dilution giving half maximal 
proliferation of cytokine-dependent cells, or in the case of ELISAs, by comparison of 
optical density with that of a concurrently performed appropriate standard recombinant 
murine cytokine. 
2.2.10 Immunofluorescence assays 
143B monolayers, grown for 1 day on acid-washed glass cover slips, were 
infected with virus at a moi of 1 for 24 h at 37°C. Monolayers were then washed with 
pre-chilled PBS before incubation with anti-HA antiserum [ 1: 100 (v/v); raised in rabbits] 
for 30 min at room temperature. After washing , membrane-bound antibodies were 
detected by FITC-conjugated anti-rabbit lg antibody (Silenus). Immunofluorescence was 
examined by ultraviolet microscopy. 
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2.2.11 Statistical analysis 
Data were expressed as means + standard error of the mean (SEM) or standard 
deviation (SD) and a two-tailed Student's t test was used to determine the significance of 
the differences between experimental and control groups. The Student's t tests were 
performed using InStat for MacIntosh version 2.1. Statistical significance was set at 
p < 0.05 for all comparisons. Each experiment was repeated at least twice and accepted as 
valid only when similar results were obtained in at least 2 experiments. 
55 
2.3 RESULTS 
2.3.1 Construction of FPV plasmid insertion vectors 
A novel FPV insertion plasmid, pLRB 100, was derived from pAF09 (Heine and 
Boyle, 1993) for the construction of recombinant FPV expressing the influenza virus 
AJPR/8 HA and murine cytokine genes (Fig. 2.1). Plasmid pLRB 100 contains the HA 
gene inserted as a 1.8 kb Bglll fragment proximal to the early promoter of a FPV 
bidirectional promoter, P.E/L (Kumar and Boyle, 1990) and an additional copy of the 
P.E/L promoter at the 3' end of the HA gene. This additional promoter was obtained 
from pAF03 (kindly provided by Dr. D.B. Boyle, Australian Animal Health Laboratory, 
Geelong, Australia) into which the HA gene, derived from pJZ102 (Young et al., 1983) by 
PCR, was initially cloned (Fig. 2.2). In pLRB 100, the ATG initiation codon of HA is 
preceded by four codons in alignment with the ATG initiation codon of the P.E/L 
promoter to ensure in-frame translation. In addition, pLRB 100 contains a BamHI site in 
front of the 3'-end of the second P.E/L promoter for further insertion of cytokine genes. 
Plasnlids pLRB 120 and pLRB 140 contain a copy of PCR-derived IL-6 and IFN-y 
genes, respectively, at the BamHI site of pLRB 100 (Fig. 2.3). Insertion of a PCR-derived 
HA gene directly into pAF09 gave rise to pLRB 130 (Fig. 2.1 ). The initiation codon of 
each heterologous gene is also preceded by four codons in alignment with the initiation 
codon of the P.E/L promoter. Nucleotide sequences of the PCR-derived HA, IL-6 and 
IFN-y genes were confirmed by sequencing. 
2.3.2 Expression of HA and cytokine genes by recombinant FPV s in vitro 
Transfection of FPV-M3-infected CES cells with plasmid insertion vectors 
pLRB 130, pLRB 120 and pLRB 140 resulted in isolation of recombinants FPV-HA , 
FPV-HA-IL6 and FPV-HA-IFNy, respectively. The genomic arrangements of the 
recombinant FPV are illustrated in Fig. 2.4. The purity of recombinant FPV virus stocks 
wa confirmed by PCR analysis with primers P330 and P348: PCR of FPV-M3 DNA 
gave ri e to a - 0.4-kb fragment unlike the other recombinant FPV (Fig . 2.5) . PCR of 
recombinant DNA, in theory, hould produce fragments of> 3 kb , however, these large 
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FIGURE 2.1 
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FIGURE 2.1. Construction of insertion plasmids pLRBlOO and pLRB130 
The HA gene and an inverted repeat P.E/L promoter at the 3' end flanking a BamHI site 
were recovered as a 1.8-kb BglII fragment (see Fig. 2.2). This fragment was subcloned 
into pAF09 (Heine and Boyle, 1993) to produce pLRBlOO, a novel FPV insertion plasmid 
vector into which a BamHI fragment of murine IL-6 or IFN-y was subcloned. A control 
plasmid, pLRB 130, used for the construction of a control recombinant FPV expressing 
only HA but no cytokine genes was constructed by insertion of a PCR-derived HA gene 
into pAF09. 
AcR, ampicilin-resistance gene; FPV tk, thymidine kinase gene of FPV; Ecogpt, xanthine-guanine 
phosphoribosyl transferase gene of Escherichia coli; /3-gal , ~-galactosidase gene of E. coli; HA, 
hemagglutinin gene of influenza virus A/PR/8; P7 .5, vaccinia early/late promoter; P.E/L, 
bidirectional early/late promoter of FPV; T 8, two overlapping transcriptional stop signals 
Bglll 
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HA-P.E/L complex 
l __ 
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FIGURE 2.2. Construction of plasmid pAF03-HA 
PCR from pJZ102 
BamHI 
Bg!IT 
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The HA gene was amplified by PCR from pJZ 102 (Young et al. , 1983) using PCR primers 
PHA-1 and PHA-2, and subcloned into pAF03 (kindly provided by Dr. B.B. Boyle, 
AAHL). The HA gene and an inverted repeat P .E/L promoter at the 3' end fl anking a 
BamHI ite were recovered a a 1.8-kb BglII fragment. 
Abbreviation are as for Fig. 2.1. 
cytokine 
BamHI gene 
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(11.5 kb) 
BamHI 
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cytokine gene PCR from: 
IL-6 pCD-mu-IL-6 
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Cytokine co-expressed: 
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FIGURE 2.3. Construction of insertion plasmids pLRB120 and pLRB140 
Plasmid pLRB 120 contains a copy of the IL-6 gene, derived from pCD-muIL6 (Chiu 
et al., 1988) by PCR using primers PIL6-1 and PIL6-2, at the BamHI site of 
pLRB 100. Plasmid pLRB 140 was constructed similarly with the IFN-y gene derived 
from pCD-muIFNy (Gray and Goeddel , 1983) by PCR. 
Abbreviation are as for Fig. 2.1 . 
1 kb FPV-M3 FPV tk I I 
FPV-HA ~~;~~  HA 
P7.S PEIL ) 
FPV-HA-IL6 ~ . c~~*'  HA IL-6 ,,, ~ ~
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FIGURE 2.4. Genomic arrangements of FPV 
Foreign genes were inserted at a single site downstream of the tk gene. Ecogpt (under the control of the VV P7.5 promoter) and lacZ (under the control of 
the late P.E/L promoter) genes were used for selection and purification, respectively, of recombinant FPV. For the control virus FPV-HA, the HA gene of 
influenza virus was subcloned proximal to the early/late P.E/L promoter. FPV-HA-IL6 and FPV-HA-IFNy contain the murine IL-6 and IFN-y genes, 
respectively, each under the transcriptional control of early/late P.E/L promoters. The HA, IL-6 and IFN-y genes contain transcriptional stop signals at the 3' 
ends. The use of inverted repeats of the promoter, in this case P.E/L, ensures the stability of recombinants (Spehner et al., 1990). To achieve this, HA and 
cytokine genes were expressed in opposite directions and independently of each other by inclusion of transcriptional terminator signals at the 3' end of each 
gene. 
Abbreviations are as for Fig. 2.1, except for the following: IL-6 and IFN-y refer to murine interleukin-6 and gamma-interferon genes, respectively. 
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FIGURE 2.5. Detection of recombinant and wild-type FPV by PCR 
FPV DNA was prepared as described in Section 2.2.8 and 10 ng of DNA was used for PCR 
with primers P330 and P348. PCR products were analysed on a 1.0 % (w/v) agarose gel. 
Lanes: 
1 - FPV-HA 
2 - FPV-HA-IL6 
3 - FPV-HA-IFNy 
4- FPV-M3 
5 - A-Hindlll digests 
fragments were not obtained in this study. Insufficient primer elongation time during 
PCR may account for the inability to amplify for long PCR products. 
Expression of HA on the surface of human 143B cells infected with recombinant 
FPV was shown by immunofluore_scence using a rabbit antibody against influenza virus 
A/PR/8 (Fig. 2.6). Secretion of biologically active IL-6 from monolayers infected with 
FPV-HA-IL6 was confirmed by bioassay (Table 2.1). Secretion of IFN-y by cells 
infected with FPV-HA-IFN-ywas shown by ELISA (Table 2.1). The biological activity 
of secreted IFN-y was confirmed by bioassay using WEHI-279 cells (Reynolds et al., 
1987; data not included). 
Table 2.1 shows daily production of IL-6 and IFN-y from 143B cells infected 
with either recombinant FPV or VV. Expression of these factors was more protracted in 
cultures infected with recombinant FPV than VV. Microscopic examination at day 3 after 
inoculation revealed that the VY-infected cells had undergone cytopathy, while 
FPV-infected cells, which are abortively infected, were still viable. 
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A B 
FIGURE 2.6. Immunofluorescence of FPV-infected 143B cells 
143B cell monolayers were infected with FPV-HA (A) or FPV-M3 (B) at a 
multiplicity of infection of 1 for 24 h and were stained with rabbit anti-HA (influenza 
virus A/PR/8) antisera. Antibodies binding HA were detected using an anti-rabbit 
immunoglobulin-flourescein conjugate. The monolayers were then mounted on 
microscope glass slides and examined by ultraviolet microscopy. 
[magnification x400] 
TABLE 2.1. Daily in vitro production of cytokinesa 
24-h periods Units of cytokine/ml (mean+ SEM)b supernatant from cells infected with: 
FPV-HA-IL6C VV-HA-IL6C FPV-HA-IFN'f VV-HA-IFN'f 
24 65 301 + 3 853 31 512 + 216 650 + 27 1 175 + 59 
48 21541+528 9 360 + 421 370 + 8 126 + 5 
72 9 057 + 418 348 + 13 117 + 6 < 5e 
144 4 374 + 267 < 1ooe 68 +2 < 5e 
asupernatants fron1 143B n1onolayers infected at a n1oi of l were passed through 0.1 µm filters to remove virus particles 
(see Section 2.2.9). 
bData shown are the n1eans + SEM of triplicate supernatant san1ples. These results were reproduced with another 3 samples. 
CIL-6 was assayed using the IL-6-dependent cell line, B9 (Aarden et al., 1987). IL-6 was detected at very low background 
levels fron1 143B cells infected with control viruses, FPV-HA or VV-HA (Coupar et al., 1988). 
dJFN-y activity was assayed by ELISA (Carpenter et al., 1994). No IFN-y was detected in supernatants overlying cells infected 
with control viruses. 
eLimit of detection of the cytokine assay. 
2.4 DISCUSSION 
Different techniques for construction of recombinant VV are now well-established 
and widely used. Recombinant viruses are selected using markers, such as the HSY TK 
(Mackett et al., 1982b; Panicali and Paoletti, 1982), neomycin-resistance (Franke et al., 
1985), Ecogpt (Boyle and Coupar, 1988b; Falkner and Moss, 1988) or lacZ (Chakrabarti 
et al., 1985; Panicali et al., 1986) gene. These techniques have now been extended to the 
construction of other recombinant poxviruses that may be useful as vaccine vectors in 
mammals, namely a vi pox viruses (Taylor and Paoletti, 1988; Cox et al., 1993b ). In this 
chapter, the construction of recombinant avipoxviruses, FPV, for delivery of HA and 
murine cytokines was described. 
The FPV genome has not been extensively studied and there are only a few 
non-essential regions identified for insertion of heterologous genes. The isolation of the 
TK gene of FPV (Boyle et al., 1987; Binns et al., 1988) and the demonstration that this 
gene is non-essential for virus replication (Boyle and Coupar, 1988a) has allowed the 
insertion of foreign genes into this site. In this study, heterologous DNA was inserted in 
the FPV genome downstream of the TK gene. The presence of repeated sequences, such 
as P.E/L promoters driving different genes, could contribute to the instability of 
recombinant viruses as a result of homologous recombination among identical sequences. 
In order to minimise the occurrence of these recombination events, the viruses were 
engineered so that similar sequences were placed in opposite directions of each other 
(Spehner et al., 1990). In this way, homologous recombination is unlikely, thus ensuring 
the stability of resultant recombinant viruses. 
Although infection of FPV in mammalian cells is abortive (Taylor and Paoletti , 
1988; Somogyi et al., 1993), genes under the transcriptional control of early virus 
promoters are expressed (Taylor et al., 1988b; Cox et al., 1993b). Thus, genes for both 
HA and murine cytokines IL-6 or IFN-y proximal to the P.E/L FPV promoter were 
ex pre sect early after infection of a human cell line. Two factors important for optimal 
ex pres ion of heterologous genes in the recombinant viruses were alignment of initiation 
codons and inclusion of transcriptional termination signals . Kumar and Boyle ( 1990) 
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have shown that transcription initiates at the ATG sequences of the P.E/L promoter. 
Hence, to allow in-frame translation of the inserted gene, the ATG initiation codons of the 
heterologous gene and the P.E/L promoter were aligned. The utility of the P.E/L 
promoter would be enhanced if the ATG sequences of the promoter are mutated, thus 
abolishing the need for initiation codon alignment. However, this could not be achieved as 
the ATG sequences of the P.E/L promoter are necessary for optimal promoter activity 
(Boyle, 1992). Expression of both cytokine and HA genes, positioned in opposite 
directions to each other, was also optimised by inclusion of two overlapping 
transcriptional termination signals for early expression, i.e. TTTTTTTT (Rohrmann and 
Moss, 1985; Yuen and Moss, 1987), at the end of each gene. These termination signals 
reduced the possible modulation of gene expression through the transcription of 
anti-sense mRNA. 
While VY caused destruction of the infected cells, little or no cytopathic effect due 
to FPV infection was observed. The abortive nature of FPV infection in mammalian cells 
may be important for the prolonged expression of foreign genes. In this regard, 
recombinant FPV secreted the encoded cytokines for longer periods than the 
corresponding recombinant VY. Furthermore, the majority of FPV proteins are not 
expressed in abortive infections. Therefore, antigenic competition between viral and 
heterologous proteins is reduced, and the immune response may be directed towards the 
encoded antigens. The lack of immune responses directed against FPV antigens may also 
allow persistence of the vin1s resulting in more prolonged expression of the vaccine 
antigens in recipient animals. Given that long-lived immune cells may be maintained by 
persistence of antigen (Gray and Skarvall, 1988; Gray and Matzinger, 1991; Oehen et al., 
1992), the prolonged expression of foreign antigens due to persistence of virus may 
account for the protracted immune responses reported after immunisation with 
recombinant avipoxviruses (Taylor et al., 1991 and 1992; Cadoz et al., 1992; Cox et al., 
1993b; Tartaglia et al., 1993). Furthermore, multiple immunisations are likely to be more 
effective in situations where there is a reduced primary immune response to the vector 
itself. Indeed, prior exposure to the vector did not inhibit boosting of antibodies against 
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rabies virus glycoprotein by recombinant CPV in humans (Cadoz et al., 1992). Moreover, 
cytokine expression by recombinant VV has markedly altered immune responses 
generated against the co-expressed heterologous antigen (Ramshaw et al., 1992). 
However, the adjuvant effect of VY-encoded factors was short-lived (Ramsay et al., 
1994a). Taken together, the nature of the abortive infection of FPV and the likelihood of 
protracted expression of encoded genes point to the potential of recombinant FPV as safe 
alternative vectors for the induction of protracted immune responses, and prolonged 
effects of FPV-encoded cytokines on these responses. These possibilities will be 
examined in Chapter 3. 
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CHAPTER3 
Selective induction of immune responses by 
recombinant fowlpox viruses expressing cytokine genes 
3.1 INTRODUCTION 
FPV, the type species of Avipoxvirus, causes abortive infections in mammalian 
cells (Taylor and Paoletti, 1988; Somogyi et al., 1993). Although unable to replicate in 
mammals, avipoxviruses can express appropriately engineered foreign genes under the 
transcriptional control of early virus promoters (Taylor et al., 1988b; Cox et al., 1993b ). 
FPV has recently been developed as a potential vector for the delivery of antigens to 
mammalian hosts (Taylor and Paoletti, 1988). FPV and another avipoxvirus, CPV (Taylor 
et al., 1991; Tartaglia et al., 1993), have been used for vaccination of mice (Cox et al., 
1993b ), cats (Tartaglia et al., 1993) and dogs (Taylor et al., 1991 and 1992). Recently, 
successful immunisation of humans with recombinant CPV vectors has also been reported 
(Cadoz et al., 1992). 
Effective vaccination lies in the development and maintenance of long-term 
protective immunity. For many diseases, protection is determined by the type of immune 
response induced. Whether the immune response is driven towards antibody or 
cell-mediated responsiveness is critically influenced by the profile of cytokines produced 
by Th lymphocytes and other immune cells. For example, in helminth (Pearce et al., 
1989; Sher and Coffman, 1992; Urban et al., 1992) or toxoplasma infestation (Sher and 
Coffman, 1992; Sher et al., 1992), or infection with HIV (Maggi et al., 1987; Clerici et al., 
1991 and 1993a; Sher et al., 1992; Clerici and Shearer, 1993) or Listeria (Magee and 
Wing, 1988; Bancroft et al., 1989; Tripp et al., 1993 ), there are strong correlations 
between Th phenotype dominance and disease susceptibility as outlined in Chapter 1. 
In order to modify the immune responses elicited by vaccine antigens, 
recornbinant VV have been engineered to express cytokine genes (Ramshaw et al., 1992; 
Ramsay and Kohonen-Corish, 1993; Ramsay et al., 1994a and 1994b). Results from 
studies with these recombinants suggested that the encoded cytokines can either alter the 
pathogenicity of the vector virus (Karupiah et al., 1990b; Ramshaw et al., 1992) or 
selectively augment immune responses generated against co-expressed heterologous 
antigen (Ramsay and Kohonen-Corish, 1993; Ramsay et al., 1994a and 1994b). 
61 
In this chapter, the safety of avipoxvirus vectors encoding cytokine genes and their 
ability to selectively induce immune responses were studied. In particular, the ability of 
encoded IL-6 and IFN-y to stimulate antibody and cell-mediated immune responses to 
co-expressed vaccine antigen was examined. 
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3.2 MATERIALS AND METHODS 
3.2.1 Mice 
CBA/H and severe-combined immunodeficient (SCID) mice were obtained from 
the Animal Breeding Establishment of the John Curtin School of Medical Research. 
Mice were raised under SPF conditions and were used at 6-8 weeks of age unless stated 
otherwise. 
3.2.2 Culture medium 
As described in Section 2.2.1. 
3.2.3 Cells 
Murine L929 cells, a continuous fibroblast line from the C3H mouse (Sanford 
et al., 1948), were grown in Fl5 medium. The human 143B cell line is described in 
Section 2.2.2. 
3.2.4 Viruses 
The construction of recombinant FPV was illustrated in Chapter 2. Recombinant 
FPV and VY were prepared as described in Section 2.2.4. An L929 cell-adapted strain of 
VV, VY-WR (Wokatsch, 1972), was grown in 143B cells. 
Influenza virus strain A/PR/8 was grown and purified according to standard 
techniques (Jones and Ada, 1986). Briefly , embryonated eggs, 8-10 days old, were 
infected at 5 hemagglutining units (HAU) of influenza virus/egg for 3 days in a 
humidified incubator (37°C) with gentle rocking. Allantoic fluid was harvested and titres 
of viru stocks were determined by hemagglutination. Virus was purified by elution with 
chicken red blood cell and followed by centrifugation on a sucrose [ l 0-40 o/o (w/v)] 
gradient before freezing at -7 5°C. 
Lethal challenge with influenza 1ru was given by i.n. inoculation of 100-fold the 
median lethal dose (LDso) of mouse-adapted viru { in cold PBS supplemented with FCS 
[5% ( I )]· PBS-FCS} into the lungs of mice anaesthetised i.p. with avertin [2o/o (v/v) 
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2-methyl-2-butanol, 2o/o (w/v) 2,2,2-tribromoethanol; 10 µl/g of mouse]. Intravenous 
inocula of influenza virus comprised 1 x 103 HAU in 200 µl of cold PBS-FCS. 
3.2.5 Isolation of spleen and lung cells 
Lymphoid cells were prepared from spleens as described elsewhere (Karupiah 
et al., 1990b ). Single cell suspensions from pooled spleens were obtained by gently 
pressing minced spleens through stainless steel mesh with syringe plungers. These cells 
were washed once in F15 medium, erythrocytes were removed by water lysis and the cells 
were washed twice. After the final wash, cells were resuspended at the required 
concentration in F15 medium. 
Lung lymphoid cells were prepared as previously outlined (Ramsay and 
Kohonen-Corish, 1993). Lungs were minced gently into a paste and suspended in F15 
medium. Collagenase A (EC 3.4.24.3; BM), dispase II (EC 3.4.24.4; BM) and DNase 
type II (EC 3.1.22.1; CALBIOCHEM Corporation, CA, USA) were added at 
concentrations of 2 mg/ml, 1.2 U/ml, and 5 U/ml , respectively, in a final volume of 
2 ml/pair of lungs. After incubation at 37°C for 90 min, the lysates were passed gently 
through an 18-G needle attached to a 20-ml syringe. The resulting suspension was 
filtered through sterile gauze and washed once with HANKS buffer. Erythrocytes were 
removed by water lysis and cells were filtered through mesh nybolt nylon filters (pore 
size, 60 µm; Ure Pacific Pty. Ltd., Vic., Australia). After the final wash, cells were 
suspended at an appropriate concentration in Fl5 medium. 
3.2.6 CTL assays 
Cytotoxic activity was measured in Ster release assays (Karupiah et al., 1990b). 
Target cells were labelled with Ster (10 µCi/106 cells) at 370c in a humidified 
atmosphere containing CO2 [5% (v/v)] in air. After incubation for 90 min, cells were 
washed three times in F 15 medium without FCS and resuspended at 2 x 1 os cells/ml of 
F 15 medium for use as targets. For virus-infected target cells, L929 cells were infected 
with wild-type FPV-M3, VV-WR or recombinant FPV at a moi of 10, or with 
5 x 1 o-3 HAU of influenza virus/cell during 5 I Cr labelling. 
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CTL assays were performed in triplicate in 96-well U-bottom microtiter plates 
(Linbro, Virginia, USA) for 6 hat 37°C in a humidified atmosphere of CO2 [5% (v/v)] in 
air. 51 Cr released from targets was measured in a Packard Auto-Gamma counter and 
specific lysis was calculated using the following formula: 
experimental release - spontaneous release 
% specific lysis = ----------------
maximal release - spontaneous release 
X lOOo/o 
For secondary CTL assays, 1 os splenocytes or lung lymphoid cells were isolated. 
One-fifth of these cells were used as stimulator cells and were infected with 5 x 103 HAU 
of influenza virus, or at a moi of 10 for VV or FPV, for 90 min at 37°C in a volume of 
0.5 ml of F15 medium. Infected cells were washed six times in F15 medium before 
exposure toy-radiation (2000 rads; 60Co source) and two further washes, prior to use as 
stimulator cells. The remaining four-fifths of the cells were then cultured with the 
stimulator cells in a volume of 50 ml MLC for 5 days at 37°C. At the end of this period, 
cells were harvested and used as effectors in CTL assays. 
3.2.7 Antibody assays 
Specific anti-HA antibody titres in sera were determined by ELISA (Andrew et al., 
1989). ELISA plates (Titertek, Flow Laboratories, The Netherlands) were coated with 
sucrose-density gradient purified influenza virus (5 HAU/ml) in carbonate buffer (Section 
2.2.9) at 4°C overnight. After coating, plates were blocked with skim milk [5% (w/v) in 
PBS] for 1 h at room temperature. Two-fold serially diluted samples were added to the 
wells and incubated at 37°C for 90 min. Bound antibody was detected with biotinylated 
anti-murine lg antibody followed by incubation with streptavidin-conjugated alkaline 
phosphatase at 37°C for l h in PBS-Tween-20 [0.2o/o (v/v); Sigma]. The assay was then 
developed and analysed as described in Section 2.2.9, and results were expressed as the 
reciprocal of the endpoint dilution of sera. The endpoint was defined as the highest 
dilution that gave optical density readings above background levels in preimmune sera + 
(3 SD of background levels). 
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Antibody-secreting cells (ASC) among lung and spleen lymphoid cell isolates 
were enumerated using an ELISPOT assay described elsewhere (Sedgwick and Holt, 
1986; Ramsay et al., 1994a). Wells of ELISPOT plates (Milli titer HA 96-well filtration 
plate; Millipore Corporation, MA, USA) were coated with sucrose-density gradient 
purified influenza virus (5 HAU/ml) in carbonate buffer. After blocking with skim milk, 
as described above, each well was filled with cells in F15 medium and plates were 
incubated at 37°C for 6 h in a humidified atmosphere of CO2 [5% (v/v)] in air. After 
washing cells out of the wells, ELISPOTS were next detected by application of 
anti-murine lg antibodies as described above for ELISA assays. The numbers of ASC 
were enumerated after reaction with the substrate BCIP-NBT 
(5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium at concentrations of 
150 and 300 µg/ml, respectively; Sigma) in carbonate buffer. 
3.2.8 Isolation and PCR-detection of viral DNA in organs of mice 
Total DNA from organs or tissues of mice was obtained using a modified 
proteinase K digestion method (Strauss, 1994 ). Approximately 100 mg of frozen tissue 
was homogenised using a mortar in an 1.5-ml Eppendorf tube and digested at 580C using 
freshly prepared proteinase K ( 10 mg/ml; Boehringer Mannheim) in 500 µl of digestion 
buffer {Tris (100 mM; pH 7.5), EDTA (5 mM), NaCl (200 mM) and SDS 
[0.2o/o (w/v)]}. After incubation for 12-18 h, the lysate was extracted with an equal 
volume of Tris (pH 8.0)-buffered phenol-chloroform (50%:50%, v/v) followed by 
chloroform. DNA was precipitated in ammonium acetate (2 M) and two volumes of 
isopropanol, and washed with ethanol [70% (v/v)]. After drying, the pellet was dissolved 
in 100 µl H20. 
For PCR analysis, 2-µl aliquots of DNA were used. Detection of recombinant 
FPV-HA was performed by PCR using primers P 100 
(S'G GAG AT TT CAT CG ACT AT GAGG AG C 3') and P200 
(5'CGTGTT ACACTCATGCATTGATGCG3'; see Appendix III) which are homologous 
to nucleotides 328-352 and 858-882 of the influenza virus HA ORF, respectively. PCR 
reaction were performed in PCR buffer (Section 2.2.5) using a capillary FTS-Thermal 
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Sequencer (Corbett Research). The PCR conditions were as follows - 95°C, 5 min 
(1 cycle): 950c, 5 sec; 54°C, 2 sec; 72°C, 1 min (45 cycles): 72°C, 5 min (1 cycle). PCR 
products were analysed by agarose gel electrophoresis. 
Southern blotting and pro_bing of DNA fragments were performed under high 
stringency (Section 2.2.5). 
3.2.9 Histology 
Organs were fixed in 10% (v/v) neutral buffered formalin before embedding in 
paraffin. Sections of tissues ( 4 µm thick) were then stained with haematoxylin and eosin, 
and mounted in mounting fluid. 
3.2.10 Statistical analysis 
As described in Section 2.2.11. 
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3.3 RESULTS 
3.3.1 Immunodeficient mice survive infection with recombinant FPV 
SCID mice lack functional B and T lymphocytes and are, therefore, highly 
susceptible to virus infections. These mice were used to test the safety of recombinant 
FPV. SCID mice were inoculated with 108 PFU of FPV-HA i.v. and were monitored for 
up to 3 months post-immunisation. No mortality occurred in mice given recombinant 
FPV (Table 3.1). Histological examination of tissues from spleens, ovaries, lungs and 
livers obtained from infected mice, at 3 weeks post-immunisation, revealed no obvious 
pathological changes (Fig. 3.1). These results were not affected by the co-expression of 
cytokine genes: no deaths were recorded following administration of i.v. inocula of either 
108 PFU of FPV-HA-IL6 or FPV-HA-IFNy. In contrast, SCID mice died within 
5-8 days after infection with 107 PFU of VY-HA i.v. 
Neonatal CBA/H mice (3-day old) are also highly susceptible to virus infection; 
however, there was no mortality or morbidity found among neonates immunised i.p. with 
107 PFU of recombinant FPV (Table 3.1). Furthermore, systemic anti-HA antibodies 
(i.e. reciprocal end-point titres of 400) were elicited by 3 weeks post-immunisation with 
107 PFU of FPV-HA i.p. Co-expression of IL-6 or IFN-y genes had no effect on either 
the n1ortality or morbidity, or the levels of antibody responses induced in neonates. In 
contrast, neonates given 107 PFU of VV-HA i.p., all died within 2-4 days from 
disseminated vaccinal infection. 
The use of recombinant FPV in SCID and neonatal mice without mortality 
demonstrates the safety of these constructs. 
3.3.2 Prolonged infection of recombinant FPV in vivo 
The abortive nature of FPV infection of mammalian cells may allow for the 
prolonged expression of the heterologous genes. Indeed, it was shown in Chapter 2 that 
FPV-encoded cytokines were secreted from infected cells for extended periods in culture. 
However, infectious progeny virus could not be recovered from infected cells, although the 
presence of viral DNA could be detected by PCR with specific primers. In order to 
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TABLE 3.1. Mortality of mice infected with recombinant virusesa 
Mice Mortality of mice after infection with virus [time of death (days)]: 
Recombinant FPVb VV-HA 
scmc 0/6 6/ 6 [ 5, 5, 6, 7, 7, 8] 
Neonatal CBAJH<l 0/6 6/6 [2, 3, 3, 3, 4, 4] 
aGroups of 6 mice were given the appropriate recombinant viruses and results are 
representative of 2 experiments. 
bEach group of mice was given FPV-HA, FPV-HA-IL6 or FPV-HA-IFNy. 
cRecombinant FPV and VV-HA were given at 108 and 107 PFU i.v., respectively, and 
animals were observed for mortality for 3 months. 
<lRecon1binant FPV and VV-HA were given at 107 PFU i.p. and animals were 
observed for mortality for 3 wk. 
FIGURE 3.1 
Uninfected FPV-HA 
A 
B 
FIGURE 3.1 
Uninfected FPV-HA 
C 
D 
FIGURE 3.1. Histological changes in organs of SCID mice immunised with FPV-HA 
Mice were given 108 PFU of FPV-HA i.v. and at 3 wk post-immunisation, organs were 
collected. Haematoxylin and eosin-stained histological sections were prepared. The 
organs examined were (A) liver, (B) spleen, (C) lungs and (D) ovary. 
[magnification xlOO for (A), (B) and (C), and x40 for (D)] 
examine the persistence of recombinant FPV in vivo, CBA/H mice were immunised with 
107 PFU of FPV-HA i.v., and DNA was prepared from livers, spleens, ovaries and lungs. 
After PCR with primers P 100 and P200, a PCR product of - 0.5-kb long was found 
using DNA extracted from lungs, and to a lesser extent, from spleens and liver (Fig. 3.2). 
As expected, the 0.5-kb PCR fragment was not found after PCR with DNA prepared from 
unimmunised mice. Thus, recombinant FPV-encoded viral DNA was detected for at least 
5 weeks post-immunisation, indicating that FPV can persist in vivo for prolonged periods. 
3.3.3 Induction of systemic CTL responses 
Next, the ability of recombinant FPV to elicit immune responses was studied. No 
significant primary splenic CTL responses against the FPV vector or co-expressed HA 
were found at either 1 week (Table 3.2) or 4 weeks (data not shown) after i.v. inoculation 
with FPV-HA, FPV-HA-IL6 or FPV-HA-IFNy. Secondary in vitro stimulation with 
influenza virus of splenocytes from immunised mice induced strong CTL responses, 
however co-expression of cytokines had little effect on the levels of CTL generated. For 
clarity, only data obtained from mice given control virus, FPV-HA, are shown (Table 3.3). 
Marked CTL responses against HA and FPV antigens were also found after in vitro 
restimulation of primed splenocytes with the corresponding recombinant FPV used for 
priming. Again, there were no observable differences in the levels of secondary CTL 
responses induced in splenocytes taken from mice given recombinant FPV expressing 
IL-6 or IFN-y. Interestingly, although secondary CTL could be generated against FPV 
antigens, these effectors could not lyse VY-infected target cells, showing the lack of CTL 
cross reactivity between these viruses in vivo. 
Modest anti-HA and anti-FPV CTL responses were found in mice boosted at 
week 3 with recombinant FPV. Boosting with VV-HA after priming with FPV-HA also 
induced anti-HA CTL responses (Table 3.3). Again, no effect due to the co-expression of 
IL-6 or IFN-y was observed. 
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FIGURE 3.2. Detection of recombinant FPV DNA by PCR and Southern blotting 
Groups of 4 CBA/H mice were given 107 PFU of FPV-HA i.v. and organs were collected 
at time intervals indicated. DNA from these FPV-infected tissues (100 mg) were prepared 
according to Section 3.2.8. Tissues from uninfected mice were used as negative controls. 
After PCR of 10 ng of tissue DNA with primers PlOO and P200, PCR products were 
resolved on a 1.5 % (w/v) agarose gel and followed by Southern blotting of PCR products. 
Hybridisation was next performed with 32P-labelled HA gene of influenza virus A/PR/8 
under high stringency. 
Lanes: 1 - uninfected spleen 
2 - uninfected liver 
3 - uninfected lungs 
4 - uninfected lungs + pJZ 102 ( 1 ng) 
5 - spleen (wk 1 post-immunisation) 
6 - liver (wk 1) 
7 - lungs (wk 1) 
8 - spleen (wk 3) 
9 - lungs (wk 3) 
10 - liver (wk 3) 
11 - spleen (wk 5) 
12 - liver (wk 5) 
13 - lungs (wk 5) 
14 - pJZ102 (10 ng) 
CTLb 
Anti-FPV 
Anti-influenza virus 
TABLE 3.2. Prinzary splenic CTL responses in ,nice given reconzbinant F pya 
Effector: target ratio 
60: l 
20: 1 
6: 1 
3: 1 
60: 1 
20: 1 
6: 1 
3: 1 
% specific lysisc by splenocytes obtained from mice immunised with viruses: 
FPV-HA 
11.13 
7.09 
4.52 
4.58 
1.85 
-3 .26 
-3.00 
-1.57 
FPV-HA-IL6 
15.63 
9.46 
9.33 
6.22 
2.44 
-2.04 
0.67 
-0.72 
FPV-HA-IFNy 
11.68 
10.61 
6.18 
6.88 
4.21 
-2.00 
-3.14 
-0.27 
aGroups of 4 CBA/H n1ice were given 107 PFU of recombinant FPV i.v. Spleens were removed at 1 wk post-immunisation and pooled, 
and antigen-specific CTL assays were performed as described in Section 3.2.6. 
bL929 target cells were infected with different viruses, as described in Section 3.2.6, for use in antigen-specific CTL assays. 
cuninfected L929 cells, used as negative controls, gave low levels of lysis (< 2o/o). Data shown are means of triplicate wells. SEM for all 
CTL assays were< 5% and are omitted for clarity. Results are representative of 3 experiments. 
TABLE 3.3. Secondary systemic CTL responsesa 
% specific lysisb of L929 cells infected with: 
Uninfected FPV-M3 influenza VV(WR) 
In vitro restimulationc 
nil 4.9 5.6 15.6 2.7 
FPV-HA 14.1 86.1 82.0 18.6 
influenza virus 4.6 26.0 73.7 16.0 
In vivo boostd 
nil 8 .1 14. l 5.0 
FPV-HA 4.1 22.6 12.0 ND 
VV-HA 5.1 8.8 26.3 ND 
aGroups of 4 CBNH mice were given 107 PFU of FPV-HA i.v. The spleens were 
collected at times indicated and pooled. 
bEach point represents the mean of triplicate wells. SEM for all CTL assays were< 5o/a 
(omitted for clarity) and re ults are representative of 3 experiments. 
cspleen cell taken from mice at wk 3 post-immuni ation were restimulated in vitro for 
,, 
- da . 33% of the re timu1ated ,rlfeetor cell cultures were used (see Section 3.2.6). 
dMice immuni ed \ ith 107 PF of recombinant FPV 3 wk earlier were given a booster 
imilar to the priming do e or 107 PFU of VY-HA i.v. CTL activity was determined 1 
week after boo ting. Effector to target ratio were 60: 1. 
e ·D. not determined. 
3.3.4 Induction of systemic antibody responses 
Mice were given 107 PFU of recombinant FPV i.v. and primary anti-HA antibody 
responses were monitored for 12 weeks. At 1 week after priming, responses mounted in 
mice given FPV-HA-IL6 were approximately 2-fold higher than those measured in 
animals given FPV-HA, however, little difference in the levels of antibody responses was 
noted at later times (Table 3.4). Anti-FPV antibody titres were low. Both anti-HA and 
anti-FPV IgG titres were enhanced after boosting with recombinant FPV, while recall 
anti-HA antibody titres were markedly elevated upon challenge with wild-type influenza 
virus. The high anti-HA antibody titres were not sustained and by 9 weeks after boosting 
had fallen to the maximal levels attained following primary immunisation. Anti-HA 
antibody levels were higher at this time in mice given FPV-HA-IL6 compared to those 
receiving FPV-HA. 
Following subclass analysis of these responses, it was found that the 
IL-6-expressing recombinant FPV stimulated heightened IgG 1 responses which were 
maintained for at least 4 weeks (Table 3.5). However, boosting with recombinant FPV or 
challenge with wild-type influenza virus induced high levels of IgG2a antibody that 
accounted for the great majority of the IgG response at this stage. 
Greatly reduced levels of anti-HA antibody were induced in mice immunised with 
FPV-HA-IFNy compared to those found in mice primed with control virus (Table 3.6). 
E en after boosting, pecific antibody levels in mice given FPV encoding IFN-y were 
markedly uppres ed. 
De pite the aborti e nature of infection, the results presented here point to the 
effectivene of recombinant FPV in priming for protracted immune responses. 
Moreo er, antibod respon e , but not CTL re ponses were markedly altered by 
co-expre ed c tokine : expres ion of IL-6 enhanced systemic antibody responses 
\ herea IF - ( do\ n-regulated the e re ponse . 
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TABLE 3.4. Systenzic antigen-specific lgG responsesa 
Time Immunisation 
Primary Seconct·ary 
Prin1ary responses: 
wk 1 FPV-HA nil 
FPV-HA-IL6 nil 
wk4 FPV-HA nil 
FPV-HA-IL6 nil 
wk 12 FPV-HA nil 
FPV-HA-IL6 nil 
Boosting at 3 wk after immunisation: 
wk 1 FPV-HA 
FPV-HA-IL6 
wk 9 FPV-HA 
FPV-HA-IL6 
FPV-HA 
FPV-HA-IL6 
FPV-HA 
FPV-HA-IL6 
Challenge at 3 wk after immunisation: 
wk 1 FPV-HA influenza 
FPV-HA-IL6 influenza 
wk 9 FPV-HA influenza 
FPV-HA-IL6 influenza 
Reciprocal of end-point IgG titres 
(mean + SEM)b 
anti-HA 
17 067 + 4 267 
29 867 + 11 289 
42 667 + 8 533 
34133+8533 
10067+2133 
17 067 + 4 267 
273 067 + 68 267 
341 333 + 68 267 
10 667 + 2 133 
51 200C 
238 933 + 90 308d 
307 200 + 102 400d 
34 133 + 8 533 e 
59 733 + 22 577e 
anti-FPV 
2 133 + 533 
3 733 + 1 411 
2 133 + 533 
5 333 + 1 067 
2 133 + 533 
1 067 + 267 
68 267 + 17 067 
68 267 + 1 7 067 
17 067 + 4 267 
25 600C 
5 120 + 1 067 
5 120 + 2 822 
3 200 + 1 600 
2 133 + 533 
TABLE 3.4 ( continued) 
aoroups of 4 CBA/H mice were given 107 PFU of recombinant FPV i.v. and 
antigen-specific antibody responses were determined at time intervals as indicated. At 
wk 3 post-immunisation, mice were given a booster, similar to the priming dose, or 
challenged with 103 HAU wild-type influenza virus i.v. Recall antibody responses 
were determined 1 or 9 wk later. 
bResults shown are the mean+ SEM of reciprocal end-point titres for sera taken from 4 
individual mice. Results are representative of 2 experiments. 
cThe titres for 4 sera were the same and hence there were no SEM. 
dTitre in control groups that were not given recombinant FPV prior to challenge was 
25 600. 
cTitre in control groups that were not given recombinant FPV prior to challenge was 
6 667. 
TABLE 3.5. Systemic anti-HA IgG subclass responsesa 
Time Immunisation 
Primary Secondary 
Primary responses: 
wkl FPV-HA nil 
FPV-HA-IL6 nil 
wk4 FPV-HA nil 
FPV-HA-IL6 nil 
wk 12 FPV-HA nil 
FPV-HA-IL6 nil 
Boosting at 3 wk after immunisation: 
wk 1 FPV-HA 
FPV-HA-IL6 
wk 9 FPV-HA 
FPV-HA-IL6 
FPV-HA 
FPV-HA-IL6 
FPV-HA 
FPV-HA-IL6 
Challenge at 3 wk after immunisation: 
wk 1 FPV-HA influenza 
FPV-HA-IL6 influenza 
wk 9 FPV-HA influenza 
FPV-HA-IL6 influenza 
Reciprocal of end-point IgG titre 
(mean+ SEM)b 
IgGl 
2 133 + 533 
17 067 + 4 627C 
5 333 + 1 067 
10 667 + 2 133 
1 867 + 706 
2133+533 
34 133 + 8 533 
IgG2a 
10 667 + 2 133 
10067+2133 
25 600d 
25 600d 
10667+2133 
10 667 + 2 133 
204 800d 
59 733 + 22 577 273 067 + 68 267 
5 333 + 1 067 
5 333 +1 067 
10667+2133 
34 133 + 8 533 
34133+8533C 170667+34133f 
29 867 + 11 289C 204 soodJ 
3733+1-i11g 25 600d,h 
10 667 + 2 133g 42 667 + 8533h 
TABLE 3.5 ( continued) 
aGroups of 4 CBA/H mice were given 107 PFU of recombinant FPV i. v. and 
antigen-specific antibody responses were determined at time intervals as indicated. At 
wk 3 post-immunisation, mice were given a booster, similar to the priming dose, or 
challenged with 103 HAU wild-type influenza virus i.v. Recall antibody responses 
were determined 1 or 9 wk later. 
bEach result represents the mean + SEM of reciprocal end-point titres for sera taken 
from 4 individual mice. Similar results were obtained in a duplicate experiment. 
csignificantly different in comparison to mice immunised with FPV-HA (p < 0.02 by 
Student's t test). 
dThe titres for 4 sera were the same and hence there were no SEM. 
cTitre in control groups that were not given recombinant FPV prior to challenge was 
<400. 
!°Titre in control groups that were not given recombinant FPV prior to challenge was 
25 600. 
gTitre in control groups that were not given recombinant FPV prior to challenge was 
<400. 
hTitre in control groups that were not given recombinant FPV prior to challenge was 
6 667. 
Virus 
FPV-HA 
FPV-HA-IFNy 
TABLE 3.6. Systenzic anti-HA antibody responses after i1n1nunisation with FPV-HA-IFNy 
IgG 
6 400d 
450 + 126e 
Reciprocal of anti-HA end-point antibody titres (mean+ SEM)a 
Experiment 1 b 
IgGl 
600 + 115 
1 ()()d,e 
IgG2a 
153 600 + 29 560 
2 800 + 4ooe 
Experiment 2c 
IgG IgGl IgG2a 
38 400 + 7 390 2 600 + 1 200 179 200 + 25 600 
8 000 + 1 6ooe 1 500 + 200 12 800d,e 
aThe mean + SEM of reciprocal end-point titres for sera taken from 4 individual mice are shown. These results are representative of 
3 experiments. 
bGroups of 4 CBA/H mice were given 2 x 107 PFU of recombinant FPV i.v. and anti-HA antibody titres were determined at 1 wk 
post-in1n1Lmisation. 
cGroups of 4 CBA/H n1ice were given 2 x 107 PFU of recombinant FPV i.v. and a booster similar to the priming dose 1 wk later. 
Anti-HA antibody titres were determined 1 wk after boosting. 
c.lThe titres for 4 sera were the same and hence there were no SEM. 
eThe suppression of antibody responses in n1ice given FPV-HA-IFNy was significant in comparison to n1ice immunised with control virus 
(p < 0.002 by Student's t test). 
3.3.5 Induction of mucosal immune responses 
The induction of mucosa! antibody responses by recombinant FPV was 
investigated in mice given local inocula of these constructs. For measurements of 
antibody responses in the lungs, the numbers of lung ASC were enumerated. IgG and 
IgA ASC numbers have been correlated closely with secreted antibody titres (Berthon 
et al., 1990). 
While no significant antibody responses were detected in spleens of mice given 
FPV-HA i.n., elevated levels of ASC were found in the lungs. Both IgA and IgG 
responses were found in the lungs of mice by 1 week after immunisation with FPV-HA. 
These responses were significantly higher in mice given virus expressing IL-6 
(Table 3.7). The IgA responses were 2-6-fold higher in mice given FPV-HA-IL6 than in 
controls while the increase in IgG responses was less pronounced. As was the case with 
systemic responses, co-expression of IFN-y markedly suppressed antibody responses in 
the lungs. 
Mucosal antibody responses were greatly augmented following boosting with 
FPV-HA-IL6 but, again, were suppressed in mice rechallenged with FPV-HA-IFNy 
(Table 3.8). Mucosal anti-HA antibody responses in mice primed with FPV-HA-IL6 
were also greatly enhanced following challenge with wild-type influenza virus (Table 3.9). 
Mice primed with the IFN-y recombinant FPV produced lower mucosal antibody 
responses when challenged with influenza virus than those primed with the control virus. 
CTL responses induced in the lungs were similar in mice given recombinant FPV 
(Table 3.10). Thus , expression of IFN-y selectively suppressed the mucosa! antibody 
response but not the CTL responses. 
These results therefore show that recombinant FPV is an effective vector for 
priming mucosal immune responses when given locally. The effects of FPV-encoded 
cytokines in modulating immune responses at the mucosae were similar to those observed 
sy temically after i.v. administration of these constructs. 
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TABLE 3.7. Primary mucosal anti-HA antibody responsesa 
Time Immunisation .. Numbers of anti-HA ASC/106 cells (mean+ SD)b 
I G Jo-A 
wk 1 FPV-HA 50.4 + 17.3 21.0 + 6.0 
FPV-HA-IL6 > 200 122.0 + 18.0C 
FPV-HA-IFNy < 1oct 7.0+ 2.6 
wk2 FPV-HA 20.0 + 1.7 13.3+ 1.2 
FPV-HA-IL6 20.0 + 1.0 33.3 + 2.3c 
FPV-HA-IFNy < 10 < 10 
wk3 FPV-HA 32.3 + 2.4 10.2 + 2.9 
FPV-HA-IL6 41.2+3.lC 21.4 + 4.2c 
FPV-HA-IFNy < 10 < 10 
aGroups of 4 CBNH mice were given 107 PFU of recon1binant FPV i.n. Lungs were 
collected at times indicated, pooled and anti-HA ASC were enumerated. 
bResults shown are the mean of ASC + SD for triplicate samples. The data shown are 
from a single experiment representative of 3 such experirnents. 
csignificantly different from mice given FPV-HA (p < 0.01 by Student's t test). 
dLimit of detection due to limited number of lung cells tested. 
Virus 
Ex12eriment l c 
FPV-HA 
FPV-HA-IL6 
FPY-HA-IFNy 
Experiment 2g 
FPV-HA 
FPV-HA-IL6 
FPV-HA-IFNy 
IgG 
93.3 + 14.0 
486.7 + 11.9d 
< 2or 
34.3 + 6.2 
262.3 + 52.1 cl 
ND 
1 
TABLE 3.8. Recall ,nucosal anti-HA antibody responsesa 
Numbers of anti-HA ASC/106 cells at wk post-boosting (mean+ SD)b: 
IgA 
40.0 + 12.0 
1 320.0 + 52.9d 
< 20 
33.3 + 4.5 
496.7 + 70.1 ct 
ND 
IgG 
85.0 + 30.0 
180.0 + 47_5cl 
< 20 
ND 
· ND 
ND 
2 
IgA 
30.0 + 17.0 
163.7 + 55_5ct 
< 20 
ND 
ND 
ND 
IgG 
NDC 
ND 
ND 
9.3 +2.2 
100.3 + 13.2d 
ND 
3 
IgA 
ND 
ND 
ND 
37.3 + 3.6 
142.0 + 9.1 ct 
ND 
TAilLE 3.8 (continued) 
aGroups of 4 CBA/H mice were given 107 PFU of reco111binant FPV i.n. and an i.n. booster simi lar to the priming dose at the tin1es 
indicated. The lungs were collected at times indicated, pooled and anti-HA ASC were determined. 
bData shown are 111ean + SD of ASC for triplicate wells. In each case, data are from a single experiment representative of 3 such 
experin1ents. 
CMice were boosted at 1 wk post-in1n1unisation and recall antibody responses in the lungs were determined at 1 and 2 wk after 
boosting. 
dSignificantly different in comparison to mice given FPV-HA (p < 0.002 by Student's t test). 
CND, not determined. 
fLimit of detection due to limited nun1bers of lung cells tested. 
gMicc were boosted at 3 wk post-in1munisation, and recall antibody responses in the lungs were detern1ined at 1 and 3 wk after 
boosting. 
TABLE 3.9. Mucosa[ recall antibody responses after i.n. challenge 
with influenza virusa 
Numbers of anti-HA ASC/106 cells 
Time post-challenge Immunisation (mean+ SD)b 
IoG IoA 
wk 1c FPV-HA 59.0 + 15.6 95.7 + 47.9 
FPV-HA-IL6 312.2 + 23.4d 569.7 + 72.6d 
FPV-HA-IFNy < 2oe < 20 
wk 3f FPV-HA 11.0 + 4.1 28.8 + 9.2 
FPV-HA-IL6 58.3 + 17.2d 97.3 + 5.5d 
FPV-HA-IFNy < 20 < 20 
aGroups of 4 CBA/H mice were immunised with 107 PFU of recombinant FPV i.n. 
and at 3 wk post-immunisation, were challenged with a sublethal dose (l0-3 HAU) of 
wild-type influenza virus i.n. Recall antibody responses in lungs pooled frorn 4 mice 
were determined at 1 and 3 wk later. 
bEach figure represents the mean number of ASC + SD in triplicate wells. The data 
shown are from a single experiment representative of 3 such experiments. 
c Anti-HA IgG and lgA ASC nmnbers in control mice that were not primed with 
recombinant FPV before challenge were 5.4/106 and 9.7/106 lung cells, respectively. 
dThe differences when compared with mice given FPV-HA are highly significant 
(p < 0.0001 by Student's t test). 
cLin1it of detection due to limited numbers of lung cells tested. 
f Anti-HA IgG and IgA ASC numbers in control mice that were not primed with 
recon1binant FPV before challenge were 12.3/106 and 27.2/106 lung cells, 
respectively. 
TABLE 3.10. Primary antigen-specific CTL responses in lungs of mic& 
% specific lysisb by 
Time Virus 
effectors against target L929 cells infected with: 
uninfected FPV-M3 FPV-HA influenza 
wk 1 FPV-HA 11.2 8.3 23.6 31.5 
FPV-HA-IL6 12.7 11.1 22.8 36.2 
FPV-HA-IFNy 15.0 13.4 26.5 37.7 
wk 2 FPV-HA 9.7 8.4 28.4 46.1 
FPV-HA-IL6 14.8 22.9 39.0 49.7 
FPV-HA-IFNy 6.9 10.5 28.7 42.5 
aGroups of 4 CBA/H mice were given 107 PFU of recombinant FPV i.n. The lungs 
were collected at times indicated and pooled. CTL responses in these lungs were 
determined as described in Section 3.2.6. 
bData shown are means of triplicate wells and SEM for all CTL assays were < 5o/o. For 
clarity, the SEM were not included. Effector to target ratios were 15: 1 and results are 
representative of 3 experiments. 
3.3.6 Protection against influenza virus challenge 
To test the effectiveness of recombinant FPV vaccination, immunised mice were 
challenged with a lethal infection of influenza virus. Mice were immunised with wild-type 
or recombinant FPV i.v. or i.n. and tested for their ability to withstand i.n. challenge with 
100 LDso of influenza virus. With the exception of priming with FPV-M3, all other 
recombinant FPV afforded protection. Mice vaccinated with recombinants FPV-HA or 
FPV-HA-IL6 were fully protected from lethal virus challenge (Fig. 3.3), however, only 
SOo/o of mice immunised with IFN-y recombinant FPV were protected. 
Although immunisation with FPV-HA i.n. and i.v. resulted in protection against 
mortality following challenge with influenza virus, there was some evidence of morbidity, 
as measured by transient loss of body mass (Fig. 3.4; Andrew and Coupar, 1988; Ulmer 
et al., 1993). This phenomenon was also observed in mice primed with FPV-HA-IL6 by 
the i.n. route, however, mice given this construct i.v. developed no symptoms of morbidity 
after challenge. 
These findings demonstrate the efficacy of recombinant FPV 1n inducing 
protective immunity against lethal virus challenge in mice. 
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FIGURE 3.3. Mortality of mice after challenge with influenza virus 
Groups of 6 CBA/H mice were immunised with 107 PFU of recombinant FPV i.v. (A) or i.n. (B). At 3 wk post-immunisation, mice were challenged with 
100 LD50 of influenza virus i.n. and monitored for mortality. 
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FIGURE 3.4. Morbidity of mice after challenge with influenza virus 
Groups of 6 CBA/H mice were immunised with 107 PFU of recombinant FPV i.v. (A) or i.n. (B). After 3 wk post-immunisation, mice were 
challenged with 100 LD50 of influenza virus i.n. and monitored for morbidity. This was taken as the mean + SD of differences in percentage of body 
mass post-challenge to the original body mass at different times indicated. Results are representative of 2 experiments. *p < 0.05, detemined by 
Student's t test in comparison with mice given FPV-HA. 
3.4 DISCUSSION 
Recombinant VV expressing cytokines have been used firstly, to study the role of 
these factors in antiviral immunity in vivo, and secondly, to modulate immune responses to 
co-expressed vaccine antigens (Karupiah et al., l 990b; Ramshaw et al., 1992; Ramsay 
and Kohonen-Corish, 1993; Ramsay et al., 1994a and 1994b). In the present study, the 
influence of cytokine expression on immune responses to FPV, a non-replicating viral 
vector, was investigated. Recombinant FPV vectors expressing HA were not able to 
induce a primary splenic CTL response, although strong secondary responses could be 
generated following restimulation of splenocytes in vitro. This indicates that anti-HA 
CTL precursors were generated following the primary infection. Levels of secondary 
CTL responses were not influenced by virus-encoded IL-6 or IFN-y however, suggesting 
that optimum levels of these cytokines, if required, are already provided by the host 
immune system. 
Although CTL responses were not apparently influenced by virus-encoded 
cytokines, antibody responses against the heterologous antigen were markedly and 
selectively augmented by IL-6, and were suppressed by IFN-y. The IL-6 encoding virus 
induced a heightened IgG response that was predominantly of the IgG 1 subclass. The 
preferential induction of this antibody subclass is consistent with previous findings 
(Ramshaw et al., 1992) and with other reported in vivo actions of this cytokine (Suematsu 
et al., 1989). Interestingly, on subsequent boosting or challenge with wild-type influenza 
virus, the majority of the HA-specific IgG response was of the IgG2a subclass, which is 
typically elicited by virus infection (Hocart et al., 1989). Although virus-encoded IL-6 did 
not alter peak levels of HA-antibody, the response declined much more slowly in mice 
given FPV-HA-IL6 than in those given control virus. Thus, 9 weeks after the last boost, 
antibody titres against the HA antigen were 2-3-fold higher in mice given FPV-HA-IL6. 
It is not clear how IL-6 might influence the longevity of the response, given that thi s 
molecule is thought to act on terminally differentiated plasma cells (Kishimoto and 
Hirano, 1988). A possible explanation is that there is low but prolonged expression of the 
heterologous genes encoded in recombinant FPV during clearance of the virus. This 
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notion is supported by the finding that FPV-encoded genes were detected for at least 
5 weeks in immunised mice, far longer than is the case for recombinant VY-encoded 
genes. It should be noted that the adjuvant effect of recombinant VY-encoded IL-6 was 
relatively short-lived (Ramsay et al., 1994a). 
More dramatic enhancement of antibody responses was demonstrated when the 
recombinant IL-6 FPV was administered i.n. Anti-HA ASC appeared earlier at mucosae 
and at significantly elevated levels in mice given FPV-HA-IL-6. Antibody responses at 
mucosae have been shown to be critically dependent on IL-6, as mice with targeted 
disruption of the IL-6 gene mount negligible such responses following antigenic 
challenge (Ramsay et al., 1994a). These responses are fully restored, however, following 
challenge with recombinant VV expressing IL-6. In the experiments reported here, the 
supplementation of host IL-6 by FPV-encoded cytokine clearly enhances the mucosa! 
antibody response in normal mice. Antibody responses peaked early and were sustained 
at higher levels in mice boosted with FPV-HA-IL6 rather than control virus. 
FPV-encoded IL-6 also primed for enhanced local antibody responses to co-expressed 
HA antigen upon subsequent i.n. challenge with wild-type influenza virus, a finding of 
potential importance for resistance to infection. Together, these results suggest an 
important role for IL-6 in the expansion of immune cells during the development of the 
immune response. Strategies for the delivery of IL-6, such as those described in this 
thesis, may have major benefits in the development of improved mucosa! 
immunoprophy laxis. 
Local IgA antibodies, as well as serum-derived IgG (in the lower tract) , are 
important for protection against infection throughout the respiratory tract, particularly with 
influenza virus (Ada and Jones, 1986). Findings reported here support an important role 
for serum IgG antibodies in such protection at mucosae (Couch et al., 1979; Ramphal 
et al., 1979; McDermott et al., 1982; Prince et al., 1985). Influenza virus challenge 
locates deep in lungs when deli vered to mice under anaesthesia (Yetter et al., 1980). In the 
pre ent study, mice challenged in this manner were protected against morbidity after 
priming with IL-6 recombinants given systemically rather than at the mucosae. 
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Vector-encoded IL-6 markedly augmented specific serum IgG antibody levels when given 
via systemic routes. The enhanced mucosa! IgA responses which did not confer such 
protection against morbidity in these experiments may, however, be of paramount 
importance when virus challenge occurs in the URT by means of aerosol (Yetter et al., 
1980). Thus, the degree to which serum-derived IgG and local IgA antibodies contribute 
to prevention of infection may vary according to the site of virus challenge. Nevertheless, 
both types of antibody responses are clearly elevated by recombinant FPV-encoded IL-6. 
Results presented in this study clearly show that expression of virus-encoded 
IFN-y suppressed both systemic and mucosal antibody responses. Moreover, IFN-y 
recombinant FPV failed to prime mice for recall antibody responses, even after challenge 
with influenza virus. Previous results show that systemic anti-VY antibody titres were 
significantly lower in mice infected with IFN-y-expressing recombinant VY rather than 
with control VY (Kohonen-Corish et al., 1990). Accordingly, immunisation with 
FPV-HA-IFNy afforded poor protection against influenza virus challenge. This result 
highlights the importance of specific antibody in conferring immunity against 
homologous influenza virus as reported elsewhere (Askonas et al., 1982). While 
antibody responses were markedly suppressed in the present study, CTL responses to 
FPV-HA-IFNy were as high as those generated by control virus. In general, the ability to 
selectively generate a strong cell-mediated immune response, as described in this thesis, 
may have important implications in the developn1ent of vaccines against other intracellular 
pathogens. For example, it has been suggested that the preferential induction of such 
responses may be of paramount importance for successful vaccination against HIV (Salk 
et al., 1993). 
The safety of recombinant FPV was established in immunodeficient mice and 
neonates, and expression of cytokine genes did not produce any obvious side effects. 
Host-restricted FPV abortively infects mammalian cells and is unable to cause 
dissemjnated infection in immunodeficient host incapable of controlling virus infection. 
Intere tingly recombinant FPV also primed for pecific antibody responses in normal 
neonatal mice, although the levels of antibody produced were not affected by 
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vector-encoded IL-6 or IFN-y. The lack of effect by these cytokines may have been due 
to the immaturity of lymphoid cells in neonatal mice (Adkins and Hamilton, 1992). 
Together, these findings have important implications for the development of safe and 
effective vaccine vectors, including the development of immunisation protocols for infants 
and immunodeficient individuals. 
The nature of the abortive infection may be an important element in promoting 
immune responses towards the heterologous antigen. Failure to produce FPV proteins 
would be expected to reduce antigenic competition between viral and heterologous protein, 
and the immune response would, therefore, be directed towards the encoded antigens 
driven by early promoters. The poor immune response mounted against FPV may also 
retard clearance of the virus, allowing more prolonged expression of the vaccine antigens. 
Furthermore, booster immunisations are likely to be more effective in situations where 
there is a reduced primary immune response to the vector itself. Indeed, prior exposure to 
CPV did not inhibit boosting of antibodies against rabies virus glycoprotein by 
recombinant CPV expressing this antigen in humans (Cadoz et al., 1992). 
The finding that there was no immunological cross-reactivity between FPV and 
VY may have important practical applications. A major problem in utilising VY as a 
vaccine vector is that a proportion of the population has already been immunised with the 
virus during the Smallpox Eradication campaign (Fenner et al., 1988). In consequence, 
these individuals mount lower antibody responses to co-expressed vaccine antigens when 
given recombinant VY than their non-vaccinated counterparts (Cooney et al., 1991; 
Etlinger and Al ten burger, 1991 ). The results reported here suggest that this would not be 
a problem if FPV is used a a vaccine vector. Furthermore, it may be possible to utilise 
these different vectors encoding the same vaccine antigen to enhance the efficacy of 
multiple immunisations. Other vectors have been combined successfully in this respect 
(Li et al., 1993). In the next chapter, the potential of combining immunisation with 
recombinant FPV and another vector, naked plasmids (Fynan et al., 1993; Montgomery 
et al., 1993; Ulmer et al., 1993), to increase the efficacy of vaccination will be explored. 
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I 
In summary, the results presented here demonstrate not only the efficacy and 
safety of FPV vectors, but also the use of co-expressed cytokines to selectively manipulate 
the immune response. 
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CHAPTER4 
Induction of immune responses by 
consecutive immunisation with 
nucleic acid vaccine and f ow/pox virus vectors 
4.1 INTRODUCTION 
Various replicating viral and bacterial vectors have been developed for delivery of 
heterologous vaccine antigen (Cavanagh, 1985; Flexner et al., 1988), and the questions of 
safety and ability to elicit prolonged immunity remain the most important factors 
governing their use. Replicating viruses that give rise to productive infections in 
mammalian cells may be harmful when given inadvertently to immunocompromised 
recipients (Lane et al., 1969; Behbehami, 1983). Moreover, the expression of many vector 
antigens during infection may lead to the induction of strong immune responses against 
the vector itself, which may compromise responses against the heterologous antigen. 
Upon reimmunisation, immune responses against vaccine antigens may be diminished as 
a result of existing immune responses to the vector (Cooney et al., 1991; Etlinger and 
Altenburger, 1991). Significant advances have been made towards overcoming these 
problems, with the development of non-replicating vaccine vectors, namely NA V and 
. . 
av1poxv1rUses. 
Immunisation with NA V has been made feasible with the demonstration that direct 
gene transfer into mouse muscle in vivo resulted in the protracted expression of encoded 
foreign antigens (Wolff et al., 1990; Wolff et al., 1992; Raz et al., 1993). The vaccine 
potential of NA V has recently been explored, notably in attempts to develop vaccines 
against influenza virus (Robinson et al., 1993; Ulmer et al., 1993), HIV (Wang et al., 
1993) and malaria (Sedegah et al., 1994). NAV induce low but prolonged specific 
antibody levels and multiple immunisations are often required to obtain good responses 
(Fynan et al., 1993; Ulmer et al., 1993 ). To date, there is no evidence for integration of 
NAV into the genome of muscle cells (Wolff et al., 1992), or for induction of anti-DNA 
antibodies that could lead to autoimmunity (Jiao et al., 1992). 
In Chapter 3, the development of recombinant FPV encoding cytokine genes as 
effective vectors for the induction of long-lasting immune responses to heterologous 
vaccine antigen was described. IL-6 co-expressed by these recombinants augmented 
antibody responses while IFN-y inhibited these responses without affecting the generation 
of cell-mediated immunity. In this chapter, the generation of protective immunity by NAV 
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immunisation was investigated. This ·approach was then combined with subsequent 
immunisation with recombinant FPV in an attempt to enhance immune responses 
generated by the NA V. The effects of cytokines expressed by recombinant FPV in 
boosting immune responses were also studied. 
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4.2 lVIATERIALS AND METHODS· 
4.2.1 Mice 
As described in Section 3.2.1. 
4.2.2 Culture medium 
As described in Section 2.2.1. 
4.2.3 Cells 
As described in Section 3.2.3. 
4.2.4 NAV 
The plasmid pCMVIA/control (5.5 kb; kindly provided by Dr. H.L. Robinson, 
University of Massachusetts, MA, USA), constructed from pUC19, contains a CMV IE1 
promoter/enhancer with intron A and bovine growth hormone polyadenylation (poly A) 
signals (Appendix IV). This plasmid has features similar to those of a plasmid vaccine 
described earlier (Montgomery et al., 1993) and contains a human tissue plasminogen 
activator (t-PA) signal peptide inserted between the promoter and poly A. Replacement of 
the t-PA leader with the HA gene of influenza virus A/PR/8 gave rise to pCMVIA/H 1. 
Plasmids were maintained in E. coli strain DH5a and purified on CsCl density gradients 
by standard procedures (Sambrook et al., 1989). 
Plasmids, dissolved in sterile saline [0.9o/o (w/v) NaCl], were injected i.m. into the 
quadriceps of both hind legs (each quadriceps received one-half of the quantity of NA V 
specified). 
4.2.5 Viruses 
As described in Section 3.2.4. 
4.2.6 Preparation of splenic and lung lymphoid cells 
As described in Section 3.2.5. 
4.2.7 Cytotoxicity assays 
A described in Section 3.2.6. 
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4.2.8 Antibody assays 
Anti-HA antibody titres were obtained using techniques described in 
Section 3.2.7. HA-specific antibody was quantified by comparison of the dilution of 
serum giving half maximal optical density reading with that of a purified mouse lg 
standard. The standards used were MOPC 3 lC (IgG 1), UPC 10 (IgG2a), MOPC 141 
(IgG2b) and TEPC 183 (IgM; Sigma), and these were applied to ELISA plates coated 
with the respective sheep anti-mouse lg subclass antibodies (Southern Biotechnology 
Associates, Inc., AL, USA). After development with substrate (Section 2.2.9), ELISA 
results were analysed using the SOFfmax programme version 2.0.1 (Molecular Devices, 
CA, USA). 
4.2.9 Titration of VV 
Ovaries from mice were collected and stored in pairs at -70°C. For titration of 
VY, these tissues were homogenised in 1 ml of cold PBS and an aliquot of 100 µl was 
incubated with an equal volume of trypsin (1 mg/ml; Sigma) at 37°C for 30 min prior to 
neutralisation with 800 µl of PBS containing FCS [5% (v/v)]. The digests were then 
diluted in serials of 10-fold dilution and VY was titrated as plaques on l43B cell 
monolayers in 6-well plates (Linbro). The monolayers were infected with diluted digests 
for 1 h before being overlaid with FIS medium. After incubation at 37°C for 2 days in a 
humidified atmosphere containing CO2 [So/o (v/v) ] in air, the monolayers were stained 
with crystal violet [0.1 % (w/v)] in ethanol [20% (v/v)] for 5 min, dried and plaques were 
counted. 
4.2.10 Statistical analysis 
As described in Section 2.2.11. 
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4.3 RESULTS 
4.3.1 Induction of primary immune responses after NA V immunisation 
The ability of NA V to stimulate specific immune responses was examined by 
immunisation of mice with an i.m.- dose of either 100, 10 or 1 µg of pCMVINHl, or 
100 µg of the control NA V, pCMVIA/control. Primary systemic anti-HA antibody 
responses were detected at low levels as early as 1 week post-immunisation with 100 µg 
pCMVIA/Hl (Table 4.1). Higher antibody titres were detected at week 2 and were 
sustained for at least 19 weeks post-immunisation. Immunisation with 100 µg induced 
higher antibody responses than with 10 µg; while at 1 µg, no antibody responses were 
detected. Only anti-HA antibodies of the IgG2 subclasses were found. Despite these 
findings of anti-HA antibodies in sera, anti-HA ASC were not found in the spleens after 
NA V priming (below limit of detection; data not shown). 
Primary splenic anti-HA CTL responses could not be detected at either 2 
(Table 4.2) or 4 weeks (data not shown) after i.m. inoculation with 100 µg of 
pCMVINH 1 or pCMVIA/control. However, upon restimulation with influenza virus 
in vitro, moderate CTL responses against HA were generated among splenocytes taken 
from mice primed with pCMVIA/Hl (Table 4.3). 
These findings demonstrate the ability of NA V to evoke both CTL and antibody 
responses in mice and confirm the induction of sustained but low levels of systemic 
antibody as reported by others (Fynan et al., 1993; Ulmer et al., 1993). 
4.3.2 Systemic immune responses after NA V immunisation and i.v. boosting with 
recombinant FPV 
In attempts to augment the systemic immune responses generated by NA V, a 
consecutive immunisation strategy was devised involving priming with NA V i.m. and 
boosting with recombinant FPV i.v. Four weeks following immunisation with NAV i.m. , 
mice were given a booster inoculum of 107 PFU of FPV-HA i.v. High levels of anti-HA 
antibody were found 1 week after boo ting in mice that had been primed with 
pCMVIA/Hl but not in those given control NA V (Table 4.4). Titres peaked by 3 weeks 
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Time 
wk 1 
wk2 
wk4 
wk5 
wk 13 
wk 19 
TABLE 4.1. Primary systemic antibody responses in mice given NA V i.m.a 
Subclass 
IgG2a 
IgG2b 
Ia-Gl b 
Ia-M b 
IgG2a 
IgG2b 
Ia-G 1 C, 
la-M 0 
IgG2a 
1°G 1 0 
IgG2a 
Ia-G l 0 
IgG2a 
lgG2a 
...... 
Ia-G 1 
Anti-HA antibody levels (mean+ SD of µg/ml)b in mice given: 
~rontrol 
100 µg 
< 0.05C 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.5 
< 0.05 
100 µg 
0.13 + 0.01 
0.15+0.0l 
< 0.05 
< 0.05 
4.38 + 1.10d 
9.26 + 2.26 
< 0.05 
< 0.05 
4.75 + 1.92 
< 0.05 
7.26+ 1.43 
< 0.05 
15.2+3.5 
< 0.05 
3.4 + 0.8 
< 0.05 
pCMVIA/Hl 
10 µg 
< 0.05 
NDe 
< 0.05 
< 0.05 
1.18+1.62 
ND 
< 0.05 
< 0.05 
2.25 + 2.06 
< 0.05 
5.70 + 4.65 
< 0.05 
9.4+5.l 
< 0.05 
2.9 + 0.5 
< 0.05 
1 µg 
< 0.05 
ND 
< 0.05 
< 0.05 
< 0.05 
ND 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.5 
< 0.05 
TABLE 4.1 (continued) 
aoroups of 5 CBA/H mice were given the indicated quantity of NA V i.m. (each hind leg 
receiving half the amount) under anaesthesia. At the times indicated, mice were bled and 
anti-HA antibody responses were measured by ELISA as outlined in Section 4.2.8. 
bEach result represents the n1ean + SD in µg of anti-HA antibodies/ml for each group of 
mice. Results are representative of 2 experiments. 
cLimit of detection. 
dSignificantly different from mice given 10 µg of plasmids (p < 0.007 by Student 's t test). 
eND, not determined . 
L929 targets infected with: 
Influenza virus 
Uninfected 
TABLE 4.2. Prilnary syste,nic CTL responses in ,nice given NA V i.m.a 
Effector: target ratios 
60:1 
20:1 
6: 1 
2: 1 
60: l 
20:1 
6: 1 
2: 1 
o/o specific lysisb of target cells by splenocytes taken from mice infected with: 
Uninfected 
7.93 
3.20 
0.07 
-0.12 
6 .04 
0.88 
-0.13 
-0.75 
pCMVIA/control 
5.66 
2.44 
7.33 
0.02 
8.92 
6.02 
-0.13 
-0.75 
pCMVIA/Hl 
8.99 
5.84 
4 .' 18 
1.54 
6.29 
8.08 
2.65 
0.81 
aoroups of 4 CBA/H n1ice were given 100 µg of NA V i.n1., and spleens were harvested 1 wk later and pooled. CTL responses were 
determined as described in Section 4.2.7. 
bData shown are n1ean values from triplicate wells. SEM were< 5% and are onlitted for clarity. Data are representative of 3 experiments. 
TABLE 4.3. Secondary syste,nic antigen-specific CTL responses after NA V i1n1nunisationa 
o/o of restimulated culture o/o specific lysisb of L929 target cells infected with: 
uninfected influenza FPV-M3 FPV-HA 
100 25.85 59.17 27.00 48.87 
33 9.47 49.94 22.11 29.73 
10 3.39 28.80 15.47 10.74 
3 0.85 13.14 7.98 6.53 
aGroups of 4 CBA/H 1nice were given 100 ~Lg of pCMYIA/H 1 i.n1., and 4 wk later, spleens were harvested and pooled. Splenocytes were 
then restin1ulated in culture with influenza virus-infected syngeneic stimulator cells for 5 days. 
bLevels of specific lysis of L929 targets by splenocytes taken fron1 nlice in1munised with the control NA V and restimulated in vitro with 
influenza virus were 3-1 Oo/o. Data shown are n1ean values fron1 triplicate wells . SEM were < 5% and are omitted for clarity. The data 
shown are fron1 a single experiment representative of 3 such experiments. 
TABLE 4.4. Recall systenzic anti-HA antibody responses after consecutive im,nunisation with 
NA V and FPV-HAa 
Tin1e Anti-HA antibody (n1ean + SD of µg/mJ)b elicited after boosting with FPV-HA: 
post-boosting 
Subclass 2CM V IA/controlc CMVIA/I-Il 
(wk) 
100 µgd 10 µgd 100 µg 1 µgc 
l IgG2a 16.0 + 3.5 533.6 + 151.9 433.5 + 400.4 19.1+6.6 
Io-Gl b < o.o5e < 0.05 < 0.05 < 0.05 
3 IgG2a 18.3 + 1.4 1 061.4 + 347.5 r 510.8 + 42.5 22.9 + 2.0 
I oG I b 2.4 + 0.7 5.9 + 1.3 3.2 + 1.0 4.4 + 2.1 
6 IgG2a 8.3 + 2.9 559.5 + 217 .8 373.9 + 31.2 17.5+5.4 
Io-G l 0 2.8 + 1.1 8.1 + 3.7 5.9 + 1.3 1.7 + 0.4 
15 IgG2a 13.2+1.4 235.2 + 122.2 197.0 + 16.9 9.3 + 4.6 
IgGl 6.9 + 1.4 6.6 + 0.2 5.1+2.4 5.9 + 1.2 
TABLE 4.4 (continued) 
HGroups of 5 CBA/H n1ice were given the appropriate NA V i.m. At wk 4 post-immunisation, mice were boosted with 107 PFU 
or FPV-HA i.v. and anti-HA antibody responses were determined at tin1e intervals as indicated. 
bEach result shown is representative of the mean+ SD in ~Lg of anti-HA antibodies/rnl in sera of 5 individual mice. 
cTitres in control groups that were boosted with control virus not expressing HA, FPV-M3, were < 0.05 µg/ml (limit of 
detection). 
dTitrcs in contro l groups that were boosted with control virus not expressing HA, FPV-M3, were 2.2-18.2 µg/n1l. 
CLimit of detection. 
!'Significantly different when compared with mice given 10 ~tg of pCMVIA/Hl (p < 0.008 by Student's t test). 
post-boosting and high levels were maintained for up to 15 weeks. Doses of 100 µg 
pCMVIA/Hl primed for a greater recall response than 10 µg whilst l µg of HA-encoding 
NAY failed to prime the mice. The antibody subclass elicited was mostly IgG2a and 
levels of antibodies of the IgG 1 subclass were not augmented. Antibody responses in 
mice primed with pCMYIA/H 1 and boosted with recombinant FPY were 30-120-fold 
higher than in mice vaccinated sequentially with HA-encoding NAY and FPY-M3 
wild-type, or control NAY and FPY-HA. Accordingly, augmented numbers of 
antigen-specific ASC were detected in spleens of mice consecutively immunised with 
NAY and FPY (Table 4.5). 
Again, primary splenic anti-HA CTL responses were not detected in mice given 
both pCMYIA/Hl (100 µg) and 107 PFU of FPY-HA i.v. (data not shown). Data similar 
to those in Table 4.2 were obtained. 
These findings reveal the success of the consecutive immunisation protocol in 
markedly elevating antibody responses induced by NAY given i.m., however this 
combined strategy had no effects in enhancing the levels of primary CTL responses 
generated. 
4.3.3 Mucosa} immune responses after NA V immunisation and i.n. boosting with 
recombinant FPV 
Previous reports have suggested that NAY given systemically may prime for 
protective immunity at the mucosae (Fynan et al., 1993; Montgomery et al., 1993; Ulmer 
et al., 1993). In order to investigate this effect further, mice primed with NAY i.m. 
4 weeks earlier were given i.n. inocula of 107 PFU of recombinant FPY. Although ASC 
were not found in the lungs after immunisation with 100 µg of pCMYIA/H l (below limit 
of detection; data not hown), both mucosa! anti-HA IgG (particularly IgG2a) and IgA 
antibody responses were markedly enhanced in pCMYIA/H I-immunised mice after 
boo ting with recombinant FPY (Table 4.6). These responses were still present at 
3 weeks post-boosting. Immunisation with 10 µg of pCMYIA/H 1 failed to prime for 
sub equent boosting with recombinant FPY i.n. and only data obtained from 
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TABLE 4.5. Recall syste,nic anti-HA antibody responses after consecutive 
ininiunisation with NA V and FPV-HAa 
Primary Secondary 
100 µg control FPV-HA 
1 µg pCMVIA/Hl FPV-HA 
10 µg pCMVIA/H 1 FPV-HA 
Anti-HA ASC/106 cells (mean+ SD)b 
IgGl 
14.0 + 3.5 
15.0 + 5.2 
13·2 + 1.7c 
IgG2a 
105.0 + 26.0 
93.0 + 5.2 
216.0 + 32.5C,d 
aGroups of 4 CBA/H mice were given NA V i.m. At 4 wk post-immunisation, mice 
were boosted with 107PFU ofFPV-HA i.v. and anti-HA ASC in the pooled spleens 
were enumerated 1 wk later. 
bData shown are means + SD of ASC numbers from triplicate wells. The results are 
representative of 2 experirnents. 
c Anti-HA ASC numbered < 2/106 (linlit of detection) cells in mice immunised only 
with NA V i.m. 
dThe ASC numbers obtained using mice immunised with 10 µg of pCMVIA/H 1 were 
significantly different when compared with those from mice given control NA V 
(p < 0.002 by Student's t test). 
TABLE 4.6. Mucosa! anti-HA antibody responses after consecutive iln,nunisation with NA V and recombinant FPva 
Time post-boosting 
wkl 
wk 3 
Immunisation 
pCMVIA/Hl 
pCMVWHl 
pCMYWHl 
pCMVIA/control 
pCMVIA/control 
pCMVIA/control 
pCMVIA/Hl 
pCMVIA/Hl 
pC11VIA/Hl 
pCMVIA/control 
pCMVIA/control 
pCMVWcontrol 
Boosting 
FPV-HA 
FPV-HA-IL6 
FPV-HA-IFNy 
FPV-HA 
FPV-HA-IL6 
FPV-HA-IFNy 
FPV-HA 
FPV-HA-1L6 
FPV-HA-IFNy 
FPV-HA 
FPV-HA-IL6 
FPV-HA-IFNy 
Numbers of anti-HA ASC/106 cells (mean+ SD)b 
IgG 1 c IgG2ac IgAc 
< 2 382.2 + 46.8d 195.6 + 53.9d 
93.9 + 13.3 
<2 
<2 
<2 
<2 
<2 
25.0 + 5.0 
<2 
<2 
8.3 + 3.6 
<2 
1 324.4 + 93.7e 
850.0 + 87 .2r 
145.5 + 10.5 
359.8 + 111.5 
28.6 + 9.0 
135.0 + 15.0 
540.0 + 63.8C 
155.0 + 27.8g 
<2 
63.3 + 20.8 
<2 
768.9 + 46.8e 
350.0 + 30.0f 
60.6 + 21.0 
189.0 + 40.2 
15.6 + 7.8 
282.5 + 23.3 
793 .8 + 63 .4e 
327 .5 + 23.3h 
<2 
87.5 + 18.5 
<2 
TABLE 4.6 (co ntinued) 
aGroups of 5 CBA/H mice were given 100 µg of NA V i.m. At wk 4 post-in1munisation, mice were boosted with 107 PFU of recombinant FPV 
i.n. and anti-HA antibody responses in the pooled lungs were detennined. 
bData shown represent the n1ean + SD of triplicate wells. Sin1ilar results were obtained in another 2 experiments. 
cNumbers of anti-HA ASC in control groups that were boosted with control virus not expressing HA, FPV-M3, were< 2/106 cells (limit of' 
detection). 
dSigniCicant differences when compared with mice in1n1Lrniscd with pCMVIA/control and boosted with FPV-HA (p < 0.02 by Student's t test). 
CThc differences in ASC nun1bers were highly significant when co1npared with groups that were in1n1unised with pCMVIA/H 1 and FPV-HA 
(boost), or pCMVIA/control ;_md FPV-HA-1L6 (boost) (p < 0.0003 by Student's t test). 
1the differences in ASC nun1bers were highly significant when compared with groups that were iffilnunised with pCMVIA/H 1 and FPV-HA 
(boost), or pCMVlA/control and FPV-HA-JFN)' (boost) (p < 0.0001 by Student's t test). 
gp > 0.05 , detern1ined by Student's t test in con1parison to mice boosted with FPV-HA. 
hp< 0.02, determined by Student's t test in con1parison to 1nice boosted with FPV-HA. 
immunisation with 100 µg of NAY are shown. The major subclasses of specific anti-HA 
antibody found in the lungs were IgG2a and IgA. 
Interestingly, FPV-HA-IFNythat primed mice poorly for antibody responses in 
the lungs (Sections 3.3.4 and 3.3.5; Tables 3.6-3.9), boosted recall responses when given 
to mice that had been primed with pCMVIA/Hl (Table 4.6). The augmented recall 
responses found after boosting with recombinant FPV were further elevated when 
recombinant FPV expressing IL-6 was used. Boosting with FPV-HA-IL6 also induced 
an IgG 1 antibody response. 
Priming with FPV-HA i.n. usually resulted in specific local immunity in the lungs 
(Section 3.3.5). Interestingly, boosting at the mucosae with recombinant FPV after 
pCMVIA/Hl immunisation also induced systemic antibody responses. Higher anti-HA 
IgG2a antibodies were found in sera of mice immunised with pCMVIA/Hl i.m. and 
boosted with an i.n. dose of recombinant FPV (Table 4.7) compared to mice given control 
NA V and recombinant FPV. In addition, systemic anti-HA IgG 1 antibodies were also 
detected after boosting with i.n. immunisations of recombinant FPV. The IL-6-encoding 
recombinant FPV, when given i.n., primed for systemic IgG 1 antibodies and this finding 
confirms the induction of IgG 1 antibody by vector-encoded IL-6 (Section 3.3.4; 
Ramshaw et al., 1992). However, immunisation with pCMVIA/H 1 before boosting did 
not further elevate this response. Recall systemic antibody responses diminished at 
week 3 post-boosting (below limit of detection; data not shown). 
Primary anti-HA CTL responses in the lungs were generated after i.n. inoculation 
with recombinant FPV, as previously shown (Section 3.3.5; Table 3.10), however these 
responses were not enhanced in mice immunised consecutively with pCMVIA/H 1 
(100 µg) and i.n. boosting with FPV-HA (Table 4.8). 
The data presented in this section point to the ability of systemic immunisation 
with NA V to prime for specific mucosa! antibody responses. The responses were 
augmen ted following local boosting with recombinant FPV. Further enhancement of 
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TABLE 4.7. Systeniic anti-HA antibody titres after consecutive inununisation with NA V and recombinant FPV i.n.a 
1Inn1unisation 
pCMVWHl 
pCMVWHl 
pCMVIA/Hl 
pCMVIA/Hl 
pCMVWcontrol 
pCMVIA/control 
pCMVIAJcontrol 
pCMVWcontrol 
Boosting 
FPV-M3 
FPV-HA 
FPV-HA-IL6 
FPV-HA-IFN')' 
FPV-M3 
FPV-HA 
FPV-HA-IL6 
FPV -HA-IFN')' 
Anti-HA antibody titers (µg/ml + SD)b 
I Gl 
< 0.1 C 
0.2 + 0.1 
5.3 + 2.4e 
< 0.1 
< 0.1 
< 0.1 
3.2 + 0.2 
< 0.1 
I G2a 
2.1 + 0.3 
19.5 + 8.ld 
22.0 + 9_5d,f 
13.9 + 9.ld,f 
< 0.1 
2.1+1.8 
4.0 + 1.0 
0.3 + 0.1 
TABLE 4.7 (continued) 
HGroups of 5 CBA/H n1ice were given 100 µg of NA V i.111. At wk 4 post-imn1unisation, n1ice were boosted with 107 PFU of recombinant FPV 
i.n. and anti-HA antibody levels in serum were detern1ined l wk later. 
bEach point represents the n1ean + SD of anti-HA antibodies titres for 5 individual 1nice. Results are typical of 2 experiments. 
CLirni t of detection. 
dSignificantly different in comparison to groups prin1ed with control NA V and boosted with respective recon1binant FPV (p < 0.01 by Student's t 
test). 
cThe levels of lgG l after i111n1Lmisation with pCMVIA/H 1 and FPV-HA-IL6 were not significantly different to the control group given NA V 
control and FPV-HA-IL6 (p > 0.05 by Student's t test). 
fNot significant in comparison to nlice boosted with FPV-HA (p > 0.5 by Student's t test). 
TABLE 4.8. Antigen-specific CTL responses in lungs of ,nice i1n1nunised with 
NA V and reconibinant FPV i.11.a 
o/o specific l ysisb by 
ln1munisation Boosting effectors against target L929 cells infected with: 
uninfected FPV-M3 FPV-HA influenza 
pCMV IA/control FPV-HA 6.5 5. 1 33.6 27.6 
FPV-HA-IL6 2.8 8.2 29.3 30.1 
FPV-HA-IFNy 5.2 2.1 31.9 28.2 
pCMVIA/HJ FPV-HA 9.2 7.7 35.1 30.5 
FPV-HA-IL6 11.5 9.1 27 . l 34.5 
FPV-HA-IFNy 7.0 10.2 29.5 38. l 
aGroups of 4 CBA/H rnice were given 100 ~lg of NA V i.m. and at 4 wk post-immunisation, were boosted with 
l 07 PFU of recon1binant FPV i.n. The lungs were collected l wk post-boosting and pooled. CTL responses in 
these lungs were clctern1ined. 
bData shown are n1eans of triplicate wells and SEM for all CTL assays were< 5%. For clarity, the SEM were 
not included. Effector to target ratios were 15: 1 and results are representative of 2 experiments. 
mucosal responses was achieved when ·JL-6 was encoded by the boosting vector. Again, 
with this sequential vaccination strategy, pulmonary CTL responses were not augmented. 
4.3.4 Protection against influenza virus challenge 
The ability of NA V to protect against lethal challenge with influenza virus when 
used alone or in combination with recombinant FPV was examined. Mice immunised 
with 100 µg ofpCMVIA/Hl alone or in combination with 107 PFU of recombinant FPV 
were tested for their ability to withstand i.n. challenge with 100 LDso of influenza virus. 
All mice given pCMVIA/Hl alone were protected from mortality upon lethal challenge 
with influenza virus unlike those given control NA V (Fig. 4.1). Although mice given 
1 ~ 
pCMVINH! i.m.f r control NAV followed with FPV-HA (either i.n. or i.v.), were 
protected from mortality, these mice developed transient symptoms of influenza as 
determined by loss of body mass (Fig. 4.2). In contrast, no significant loss of body mass 
or other obvious signs of morbidity were observed in mice immunised with pCMVIA/H 1 
and boosted with FPV-HA (either i.n. or i.v.). 
4.3.5 Protection against challenge with VV-HA 
Mice immunised with influenza virus are able to control infections with a 
recon1binant VY expressing certain genes of influenza virus, with protection mediated by 
T lymphocytes (Doherty et al., 1989). Mice immunised with 100 µg of pCMVIA/H 1 
were tested for their ability to control infection with a recombinant VY expressing the 
common HA antigen. Table 4.9 shows that challenge VY encoding HA (Coupar et al., 
1988) was recovered at much lower titres from mice that had been immunised with 
pCMVINHl than from those that had not been given NA V. On the contrary, challenge 
virus was recovered from both pCMVINH 1-primed and unprimed mice at similar titres 
when the wild-type VV strain , VV-WR (Wokatsc h, 1972), which does not express HA, 
was used. These results suggest that the protective immunity was HA-specific. 
Taken together, the findings in Sections 4.3.4 and 4.3.5 demonstrate the efficacy 
of NA V in generating protective an ti-HA immune responses to control infections with 
virulent pathogens. 
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FIGURE 4.1. Mortality of mice after challenge with influenza virus 
Groups of 6 CBA/H mice were immunised with 100 µg of NA V i.m. At 4 wk post-immunisation, mice were challenged with 100 LD50 of influenza virus 
i.n. and were observed for mortality for 14 days. Similar findings were obtained in a duplicate experiment. 
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FIGURE 4.2. Morbidity of mice after challenge with influenza virus 
Groups of 6 CBA/H mice were immunised with (0) 100 µg of pCMVIA/control and 107 PFU of FPV-HA i.v., Ce ) 100 µg of pCMVIA/Hl and 107 PFU of 
FPV-HA i.v., (D ) 100 µg of pCMVIA/control and 107 PFU ofFPV-HA i.n., and( . ) 100 µg of pCMVIA/Hl and 107 PFU of FPV-HA i.n. Boosting with 
FPV-HA was performed after 4 wk immunisation with NAV i.m. Mice were challenged with 100 LD50 of mouse-adapted influenza virus 1 wk after 
boosting. Mice immunised with(.&) 100 µg of pCMVIA/Hl alone were challenged at 4 wk post-immunisation. Morbidity was recorded as differences in 
percentage of body mass (Andrew and Coupar, 1988; Ulmer et al., 1993) on different days post-challenge compared to original body mass on day 0. Data 
shown are the mean+ SEM of percentage of mass lost for 6 mice after challenge. The results are representative of 2 experiments. *p < 0.05, detemined by 
Student's t test in comparison with mice given pCMVIA/control before boosting. 
TABLE 4.9. Titres of VV recovered from mLce immunised with 
pCMVIA/HJa 
Primary immunisation 
pCMVIA/Hl 
pCMVIA/Hl 
nil 
nil 
Challenge Virus titres (log10 + SEM)b 
VY-HA 4.92 + 0.65C 
VV(WR) 7.99 + 0.13 
VY-HA 7.94+0.16 
VY(WR) 8.20 + 0.06 
aGroups of 5 CBA/H mice were given 100 µg of pCMVIA/Hl i.m. At 2 wk 
post-imn1unisation, mice were challenged with 107 PFU of VY i.v. Ovaries were removed 
for determination of vin1s titre 4 days later. 
bData shown are geometric means+ SEM of virus titres in ovaries of 5 individual mice. The 
data are representative of 2 such experiments. 
cThe reduction in VY titres is significantly different in comparison to unprimed mice 
challenged with VY-HA (p < 0.002 by Student' s t test). 
4.4 DISCUSSION 
In Chapter 3, recombinant FPV encoding cytokine genes were studied as potential 
vaccine vectors. Cytokines co-expressed by these recombinants were used to selectively 
manipulate the immune responses generated towards co-expressed vaccine antigen. NA V 
has also been reported to be an effective and potentially safe vaccine, evoking prolonged 
but low level immune responses (Fynan et al., 1993; Ulmer et al., 1993). In this chapter, 
the generation of protective immunity by i.m. inocula of NA V and the enhancement of 
these responses by subsequent immunisation with recombinant FPV was investigated. 
The strategy was based on the premise that immunisation with NA V produces low 
amounts of antigen, and in theory, should induce high affinity specific immune responses. 
On the other hand, recombinant FPV expresses higher levels of vaccine antigen that might 
be expected to considerably expand these responses. A consecutive vaccination strategy 
was designed to test this proposition. 
This strategy proved highly successful, in that following sequential immunisation, 
both systemic and mucosa} antibody responses were greatly elevated after boosting at the 
relevant site. Antibody responses induced by consecutive immunisation were higher than 
those elicited by either HA-encoding NA V or recombinant FPV vector alone. Levels of 
systemic antibody achieved using this strategy were not only higher than anamnestic 
antibody responses generated by immunisation with recombinant FPV (Chapter 3) but 
also higher than those found in convalescent sera (Kavaler et al., 1991; Dr. H.L. 
Robinson , personal communication). These elevated antibody levels afforded enhanced 
protection against mortality and morbidity upon lethal challenge with influenza virus. As 
was the case in Chapter 3, these findings illustrate the importance of specific antibody in 
conferring immunity against homologous influenza virus strains as reported elsewhere 
(A konas et al., 1982). The capacity to prime for mucosal immunity via a systemic route, 
demonstrated here and by others (Fynan et al., 1993; Montgomery et al., 1993; Ulmer 
et al., 1993), i a particularly attractive feature of NA V immunisation. Examples of 
mucosal immunity induced via systemic routes are scarce (Liang et al., 1988), indeed 
mucosal immunity is usually generated by local vaccination (McGhee and Kiyono, 1993). 
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The demonstration that immunisation with NA V primes for mucosal immunity may offer 
an alternative strategy, besides recombinant FPV (Chapter 3), for immunoprophylaxis at 
mucosae. The capacity to boost local immune responses by the consecutive immunisation 
strategy described using NA V and recombinant FPV offers prospects for enhanced 
mucosal immunoprophylaxis. 
The effects of cytokines encoded in recombinant FPV on boosting the mucosal 
antibody responses generated by this consecutive immunisation strategy were also 
examined. Interestingly, the suppression of antibody responses generated against the 
co-expressed HA antigen by FPV-expressed IFN-y, as described in Chapter 3, was not 
observed in this experiment. Instead, boosting with FPV-HA-IFNy augmented antibody 
responses generated by NA V. The effects of IFN-y in inhibiting Th2 responses during 
the early development of immune responses (Belosevic et al., 1989; Scott, 1991) may 
provide an explanation for this finding. During recall antibody responses, FPV-deri ved 
IFN-y may have promoted IgG2a production established by NA V priming. This would 
be consistent with the induction of the IgG2a isotype by IFN-y reported elsewhere 
(Snapper and Paul, 1987; Finkelman et al., 1990). 
Greater levels of recall mucosa! antibody responses were elicited when IL-6 was 
co-expressed in recombinant FPV used for boosting after priming with NA V. The 
development of mucosal antibody responses has been shown to be critically dependent on 
IL-6 , as mice lacking the IL-6 gene mount negligible mucosa! responses following 
challenge with certain antigens (Ramsay et al., 1994a). These responses are restored in 
deficient mice , however, following infection with recombinant VV expressing IL-6. In 
normal mice, IL-6 delivered to the mucosae by recombinant FPV elicited markedly higher 
antibody responses and primed for elevated recall antibody responses (Chapter 3). The 
present finding is a further demonstration of the role that IL-6 can play in the expansion 
of immune cells, particularly at the mucosae, during primary and secondary antibody 
re ponses. Again, strategies for the delivery of IL-6 could have major benefits in the 
development of improved local immunoprophylaxis. 
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An interesting finding was the selective induction of antibodies of the IgG2a 
subclass, a Thl cytokine-driven immune response, after i.m. immunisation with NA V. A 
dramatic increase in the amount of IgG2a antibody usually follows infection of mice with 
replicating viruses, whereas infec~ion with killed or inactivated viruses usually induces 
IgGl antibodies (Nguyen et al., 1994). It is unclear how i.m. immunisation with NAY 
selectively induced IgG2a antibodies, given that there is no evidence to suggest that these 
plasmids replicate in mammalian cells (Wolff et al., 1992). A possible explanation is that 
IFN-y produced by activated macrophages plays an important role in promoting IgG2a 
differentiation (Snapper and Paul, 1987; Finkelman et al., 1990). When plasmid vectors 
are delivered by gene-gun through the skin, as opposed to the i.m. route used here, the 
predominant antibody response is of IgG 1 subclass, a Th2 cytokine-driven response 
(Dr. H.L. Robinson, personal communication). Why this should differ from the response 
induced by i.m. inoculation is unclear. Activation of APC in the skin, such as Langerhans 
cells and keratinocytes (Moll, 1993; Nickoloff and Turka, 1994; Tapia et al., 1994 ), to 
secrete IL-4 , which in tum, promotes IgG 1 production (Snapper et al., 1988; Kuhn et al., 
1991; Goodman et al., 1993) may be a possible explanation. However, a comparison of 
CTL responses between intradermal (i.d.) and i.m. inoculations revealed similar levels of 
CTL induction, suggesting that i.d. inoculation did not totally switch the response to a Th2 
type with concomitant down-regulation of cell-mediated immunity (Dr. H.L. Robinson, 
personal communication). To date, it appears that the major isotype of specific antibodies 
elicited by NA Vis governed by the site of inoculation. The selective induction of IgG2a 
antibodies following i.m. injection of NA V may be beneficial to the host, as this subclass 
i more effective than IgG l at fixing complement and Fe receptor binding, and thus in 
promoting destruction of virus-infected cells by cell lysis and ADCC (Reusser et al., 
1977; Klaus et al., 1979; Fanger et al., 1989). 
Although antibody respon es were elicited after immunisation with NA V and were 
markedly augmented by boosting with recombinant FPV, these approaches were 
ineffective for the induction of specific primary CTL activity. However, strong secondary 
re pon e could be generated following restimulation of splenocytes in vitro, indicating 
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that anti-HA CTL precursors were generated after primary NA V immunisation. The 
induction of CTL responses in mice immunised with NA V encoding the influenza virus 
NP has also been shown after in vitro restimulation of splenocytes with class I 
MHC-restricted peptide epitopes of the NP (Ulmer et al., 1993 ). In the present study, in 
order to demonstrate that CTL activity was generated in vivo, a model system was 
developed in which NA V-immunised mice were challenged with a recombinant VV 
expressing the common HA. A similar model was previously described by Doherty et al. 
( 1989), in which it was shown that mice primed with influenza virus were protected from 
intracerebral challenge with a recombinant VV expressing the influenza virus NP. In this 
case, protective immunity was mediated by T lymphocytes. Data presented from the 
VY-challenge model, described in this chapter, reveal that NA V primes HA-specific 
immune responses sufficiently to afford good protection against VV-HA. Although T 
lymphocytes were not shown to be the effector cells involved in protection, the 
abovementioned experiments by Doherty et al. ( 1989) have shown that protection against 
NP-expressing VV was mediated by T lymphocytes. Nevertheless, specific antibodies 
induced by NA V immunisation may also be involved in mediating antiviral protection 
through ADCC. Given that CTL precursors were produced after NA V immunisation, it is 
unclear why boosting with recombinant FPV did not augment secondary CTL responses 
in vivo. It is possible that the extremely high antibody responses generated following 
consecutive immunisation with HA-expressing NA V and recombinant FPV may have 
inhibited the development of cell-mediated responses (Parish, 1972; Ramshaw et al., 
1976). In any case, when taken together, these findings not only verify the generation of 
CTL activity after NA V vaccination but also the efficacy of NA Vin conferring immunity 
against infection with a virulent pathogen. 
The aim of vaccination is to establish a safe and effective method of immunisation 
that will provide long-lasting immunity (Ada, 1991 ). The data presented here emphasise 
the effectiveness of NA Vas a delivery vehicle for vaccine antigens to generate protective 
immunity. The immune response is directed towards the encoded antigens in the absence 
of antigenic competition with the vector, as was the case with recombinant FPV 
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(Chapter 3). The absence of a significant immune response to the NA V, together with the 
longevity of muscle cells, may provide an explanation for the persistence of NA V 
following inoculation and for the prolonged immune responses that are induced. In 
addition, multiple immunisations ~e likely to be more effective where there is a lack of 
primary immune responsiveness to the vector itself; indeed, successful revaccination with 
NA V (Flynn et al., 1993; Ulmer et al., 1993) as well as recombinant FPV (Chapter 3) has 
been demonstrated. Different vectors encoding the same vaccine antigen may also be 
used to enhance the efficacy of multiple immunisations, a strategy successfully illustrated 
in this chapter. 
In summary, these results demonstrate the ability of NA V to induce both CTL and 
antibody responses. The levels of antibody were augmented by subsequent 
immunisations with recombinant FPV. The consecutive strategy illustrated here has 
implications for the development of vaccines, notably in situations in which other 
strategies have given poor immune responses. 
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CHAPTERS 
The effects of virus-encoded interleukin 7 
on antiviral immunity 
5.1 INTRODUCTION 
IL-7, a stromal cell-derived cytokine, has pleiotropic effects on lymphoid cells of 
both B and T lineage, NK cells and monocytes. This cytokine was first described as a 
growth factor for precursor B lyrpphocytes in vitro (Namen et al., 1988a and 1988b) 
while subsequent studies have shown that it may play important roles in the development 
of pre-T as well as mature T-lineage cells (Morrissey et al., 1989; Murray et al., 1989; 
Welch et al., 1989; Varma et al., 1990; Tushinski et al., 1991). IL-7 also enhances the 
induction of CTL (Alderson et al., 1990; Hickman et al., 1990; Kos and Mtillbacher, 
1992), LAK cell (Alderson et al., 1990; Hickman et al., 1990; Lynch and Miller, 1990; 
Naume and Espevik, 1991; Stotter et al., 1991; Kos and Mi.illbacher, 1992) and NK cell 
(N aume and Espevik, 1991) activities in vitro. In addition, IL-7 induces monocytes to 
secretion of IL-1 a, IL-1 ~, IL-6 and TNF-a, and to tumouricidal activity (Alderson et al., 
1991). 
Most of this information was obtained from in vitro investigations and relatively 
little is known about the in vivo activities of IL-7. Studies using mice in which IL-7 is 
expressed as a trans gene (Samaridis et al., 1991) and in mice lacking the IL-7 receptor 
gene (Maraskovsky et al., 1993) have shown IL-7 to be an important regulatory factor in 
the development of B lymphocyte precursors, mature B lymphocytes, thymocytes and 
peripheral T lymphocytes. Administration of recombinant IL-7 to mice increases the 
numbers of precursor B lymphocytes in the bone marrow as well as mature B 
lymphocytes, and to a lesser extent, T lymphocytes, in the spleen and lymph nodes 
(Morri ey et al., 1991 b ). Such treatment also accelerated the rate of recovery of 
lyn1phocytes in mice pretreated with cyclophosphamide (Morrissey et al., 1991 a) and 
increased the number of immature cells of the myeloid lineage (Faltynek et al., 1992). 
The numbers of CD8+ lymphocytes were elevated in the spleens of recombinant 
IL-7-treated mice, thus altering CD4+/CD8+ ratios (Faltynek et al., 1992; Komschlies 
et al., 1994). 
The interaction of IL-7 with other cytokines has not been extensively studied. 
In vitro proliferation of LAK cells induced by IL-7 has been reported both to be 
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dependent on IL-2 (Morrissey et al., 1989; Okazaki et al., 1989) and to occur 
independently of this factor (Naume and Espevik, 1991). IL-7-induced LAK activity 
could be inhibited with IL-4 in vitro (Stotter and Lotze, 1991 ), although others have failed 
to reproduce this finding (Alders~:>n et al., 1990). Moreover, IL-7 has been shown to 
promote the generation of primary and secondary CTL in vitro in the absence of IL-2 
(Kos and Miillbacher, 1992; Kos and Mlillbacher, 1993; Carini and Essex, 1994) 
although antibodies against IL-2 substantially, but not completely, inhibited the 
stimulatory effect of IL-7 on alloreactive CTL generation (Alderson et al., 1990). These 
findings suggest that IL-7 may act both through IL-2 and independently of this factor in 
stimulating cell-mediated immunity. 
Cytokines expressed by recombinant VV have been found to have profound 
effects on host immune responses to the vector or to co-expressed antigen. This approach 
has been used to elucidate functional roles of a number of different cytokines during 
antiviral immune responses in vivo (Ramshaw et al., 1992; Ramsay and Kohonen-Corish, 
1993; Ramsay et al., 1994a and 1994b ). In this chapter, in vivo effects of IL-7 expression 
on antiviral immune responses and the interactions of this factor with host-derived 
cytolcines were studied. 
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5.2 MATERIALS AND METHODS 
5.2.1 Mice 
Female 6-8-week old athymic nude Swiss outbred mice, bred under SPF 
conditions, were obtained from the Animal Breeding Establishment of the John Curtin 
School of Medical Research. Mice lacking the IFN-y-receptor (IFN-yR) were kindly 
provided by Prof. M. Aguet, University of Zurich, and maintained under SPF conditions. 
Euthymic CBNH mice are described in Section 3.2.1. 
5.2.2 Culture medium 
As described in Section 2.2.1. 
5.2.3 Cell lines 
Murine L929 (H-2k) and human 143B cell lines are described in Section 3.2.3. 
The Y AC-1 (H-2a) cell line, derived from the Moloney leukemia virus-induced lymphoma 
in the A/Sn mouse (Kiessling et al., 1975), and P815 (H-2d) cells, a mastocytoma line 
derived from the DBA/2 mouse (Dunn and Potter, 1957), were grown in Fl5 medium. 
The HT-2 (Watson, 1979), B9 (Aarden et al., 1987) and clone K cells (kindly 
provided by Dr. Phil Hodgkin, JCS MR), used for detection of IL-2, IL-6 and IL-7, 
respectively, were grown in ~C. 
5.2.4 Viruses 
VY were grown and purified according to standard techniques (Boyle and Coupar, 
1986). VV-HA-TK- (Andrew et al., 1986) was used for the construction of the IL-7 
recombinant VY while VY-HA (TK+; Coupar et al., 1988) was used as the control vin1s. 
VY stocks were prepared as described in Section 2.2.4. 
5.2.5 Virus titration 
As described in Section 4.2.9 . 
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5.2.6 DNA manipulation and Southern blotting 
As described in Section 2.2.5. 
5.2. 7 Construction of recombinant VV 
VY recombinants were constructed by marker rescue of the TK gene as previously 
described (Boyle and Coupar, 1986) and plaque-purified under methotrexate selection 
(Panicali and Paoletti, 1982). Monolayers of 143B cells were infected with VV-HA-TK-
at a moi of 0.01 for 1 h and then transfected with plasmids (20 µg/ml) in 
HEPES-buffered saline [HEPES (20 mM; pH 7.0)-saline, CaCb (0.13 M) and calf 
thymus DNA (20 µg/ml)]. Recombinant VV (TK+), which grows under methotrexate 
selection, was identified by dot-blot analysis and probing with 32P-labelled DNA 
containing foreign genes. Plaque purification was repeated until the virus population was 
homogeneous, after which virus stocks were prepared in CV-1 cells. The presence of 
DNA inserts was further analysed by RE analysis and Southern blotting of viral DNA. 
Southern blotting and probing of DNA fragments were performed under high stringency 
(Section 2.2.5). 
5.2.8 Preparation of VV DNA 
VV DNA was prepared from stock grown in 143B cell monolayers for RE and 
Southern blot analyses. VY-infected cells ( 48 h) were suspended in hypotonic buffer 
[Tris (10 mM; pH 7.8) and KCl (12 mM)], frozen and thawed thrice, and the supernatant 
was harvested. Virus particles in supernatant were collected by centrifugation on a 
sucrose gradient [36% (w/v)] and digested with proteinase K (50 µg/ml; BM) in sarkosyl 
[ 1 o/o (w/v); Sigma]. The digests were purified by phenol-chloroform (50 o/o :50%, v/v) 
extraction and precipitated with ethanol. 
5.2.9 Preparation of spleen cells 
A described in Section 3.2.5. 
5.2.10 Cytotoxicity assays 
CTL assays were performed as described in Section 3.2 .6. For LAK assays, the 
K-re i tant and LAK- en itive cell line , P8 15, wa used. Y AC-1 cells that are sensitive 
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to NK-mediated cytotoxicity were used for NK assays. The incubation time for NK 
assays was 4 h. 
CTL, NK and LAK activity is expressed as total lytic units per spleen (Coligan 
et al., 1992). One lytic unit is defined as the fraction of initial culture giving rise to 30o/o 
specific lysis of the target cell population. 
5.2.11 Antibody assays 
As described in Section 3.2.7. 
5.2.12 In vivo and in vitro antibody treatment 
The monoclonal rat antibodies S4B6 (anti-IL-2; Mosmann et al., 1986), 
D9 (anti-CDS; de St. Groth et al., 1986), GKl.5 (anti-CD4; Dialynas et al., 1983), 
XMG-1.2 (anti-IFN-y; Cherwinski et al., 1987) and GL 113 (anti-~-galactosidase; kindly 
provided by Dr. John Abrams, DNAX Research Institute) were prepared as ascites. For 
in vivo depletion of cell subsets or cytokines, ascites were injected i.p., 0.5 mg of 
antibody/mouse, l day before virus infection, on the day of virus infection, and o_n days 1, 
2, 3 and 5 post-infection. 
For in vitro depletion of B lymphocytes , the tissue culture supernatant of the rat 
hybridoma Jl ld (Bruce et al., 1981) was used as follows. Splenocytes (107/ml) were 
incubated in Jl ld (1:5, v/v in Fl5 medium) on ice for 30 min. Rabbit serum 
( 1 nu; Low-Tox®-M Rabbit Complement, Cedarlane Laboratories Ltd., Canada) was then 
added as a source of complen1ent and the mixture was incubated at 37°C for a further 
30 min . Viable cells were recovered on a Histopaque (Sigma Diagnostics, MO, USA) 
density gradient. The antibody depletion process was then repeated and the cells were 
finally washed twice in MLC medium. The B lymphocyte-depleted population was 
ad justed to appropriate concentrations for assay_ 
5.2.13 Proliferation assays 
T lymphocyte proliferation was measured after stimulation of spleen cells with 
anti-CD3 antibody (145-2Cl l; Leo et al., 1987) . 96-well U-bottom microtitre plates 
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(Linbro) were coated with antibody at 125 ng/well. Spleen cells were then cultured at 
2 x 1 os cells/well in 200 µl of MLC for 72 h at 37°C. Each well was pulsed with 1 ~LCi 
of [3H]-thymidine (78 Ci/mmole; ICN Radiochemicals) for the last 6 h of culture. Cells 
were then harvested onto filter ~ats using a Skatron 96 well harvester (Pharmacia). 
Scintillation fluid (LKB Scintillation Products) was added and the [3H]-thymidine uptake 
was measured in a Pharmacia liquid scintillation counter. 
5.2.14 Cytokine assays 
Spleen cells were stimulated with immobilised anti-CD3 antibody, as described for 
the proliferation assay in Section 5.2.13, however, these cells were cultured for only 24 h 
prior to harvest of supernatants for assay for cytokines. Supematants of virus-infected 
cell cultures were prepared as described in Section 2.2.9. 
IL-2, IL-6 and IL-7 were detected by [3H]-thymidine incorporation, as outlined in 
Section 2.2.9, using the IL-2-dependent HT-2, IL-6-dependent B9 and IL-7-dependent 
clone K cell lines, respectively. Due to the slight responsiveness of HT-2 cells to IL-4, 
IL-2-specific proliferation was determined after neutralisation of IL-4 using rat 
anti-murine IL-4 antibodies ( 1 lB 11; kindly provided by Dr. P. Hodgkin, JCSMR). As 
described in Section 2.2.9, IFN-y, TNF-a and IL-4 were assayed by indirect ELISA using 
rat anti-murine IFN-y (R4.6A2; Spitalny and Havel 1, 1984 ), hamster anti-murine TNF 
(TN3-19.12; Sheehan et al., 1989) and anti-murine IL-4 (1 lBl 1), respectively, as capture 
antibodies. Bound IFN-y and TNF-a were detected using polyclonal rabbit anti-murine 
IFN-y and TNF-a antisera, respectively, and alkaline phosphatase-conjugated anti-rabbit 
immunoglobulin (Silenus). Captured IL-4 was assayed using biotinylated anti-IL-4 
antibody (B VD6) followed by streptavidin-conjugated alkaline phosphatase. The ELISA 
assays were developed and analysed as described (Section 2.2.9). 
5.2.15 Flow cytometry 
Cells were labelled with flourochrome-conju gated antibody, and/or biotinylated 
antibody followed by flourochrome-conjugated streptavidin, using standard procedures 
(Loken, 1986). Splenocytes ( 106 cells), depleted of erythrocytes by water lysis, were 
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pelleted by gentle centrifugation at 4°C and were resuspended in 50 µl of a diluted 
flourochrome-conjugated antibody (Silenus) in cold PBS. After 30 min on ice, the 
staining mixtures were diluted 50-fold with cold PBS and cells were harvested by 
centrifugation at 4°C. For double s~aining of cells with a second antibody, the procedure 
outlined above was repeated with a secondary antibody. Biotinylated antibodies were 
detected using flourochrome-conjugated streptavidin (Amersham International Plc., UK). 
Antibody and flourochrome-conjugated streptavidin were used at dilutions of 1 :20 (v/v) 
and 1 :400 (v/v), respectively. Cell samples were resuspended in 0.5 ml of cold PBS for 
flow cytometry. 
Labelled samples were analysed on a FACS 440 Flow Cytometer (Becton 
Dickson Inununocytometry System, CA, USA). For each sample, 10,000 cells/event were 
collected. Gating of dead cells was performed using forward light scatter. Analysis of 
data was performed using the PC-L YSYS software version 1.0 (Becton Dickson 
Immunocytometry System). The percentage of positively stained cells was calculated by 
subtracting control cells not stained with flourochrome-conjugated antibodies fr_om those 
stained with flourochrome-conjugated antibodies. 
5.2.16 Cell composition in the spleens 
Cell types and numbers were determined by light microscopy after 
cytocentrifugation [500 rpm for 10 min in a cytospin centrifuge (Shandon Southern, 
England)] of 1 x 1 os spleen cells and differential staining with May-Grtinwald-Giemsa 
stain as described (Dacie and Lewis, 1984; Gulbenkian et al., 1990). About 
400 leukocytes were counted on each slide_ The cell types were identified according to 
Diggs et al. 
5.2.17 Statistical analysis 
As described in Section 2.2_ l l _ 
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5.3 RESULTS 
5.3.1 Construction of insertion vectors for VV 
A recombinant VY insertion plasmid, pLRO 1, containing a murine IL-7 gene under 
the transcriptional control of an early/late VY promoter was constructed for insertion of 
the cytokine gene into the Hindill F region of the recombinant VY (Fig. 5.1). The murine 
IL-7 cDNA contained in plasmid pSRa296-muIL 7 was kindly provided by Dr. N. 
Wrighton (DNAX Research Institute of Molecular and Cellular Biology Inc.). A PstI 
fragment of pSRa296-muIL 7, containing the IL-7 gene, was generated and subcloned 
into Pstl-digested pGEM-3Z (Promega Corporation, WI, USA) with BamHI and HindIII 
at the 5' and 3' ends of the IL-7 DNA, respectively (data not shown). This BamHI and 
HindIII IL-7 gene fragment was then force-cloned into BamHI and HindIII-digested 
pPS7.5A (Coupar et al., 1988), in front of the early/late P7.5 VY promoter, giving rise to 
pLROl. 
5.3.2 Construction and testing of VV-HA-IL 7 
In vitro homologous recombination of pLROl with VV-HA-TK- gave rise to 
VY-HA-IL 7, which contained the genes for IL-7 and HSY TK in the HindIII F region 
and the HA gene of influenza virus A/PR/8 gene in the J region. The genome 
arrangements of wild-type and recombinant VY are shown in Fig. 5.2. 
The presence of the IL-7 insert was confirmed by RE analysis and Southern 
blotting. When digested with HindIII, VV-HA-TK- releases an F-fragment of -13 kb 
(Panicali and Paoletti, 1982; Goebel et al., 1990). Due to an HindIIT site present in the 
recombinant F-fragment (Figs. 5.1 and 5.2), HindIII digestion of this fragment from 
VV-HA-IL7 gives rise to 2 fragments of -9 kb and - 5 kb (Fig. 5.3). Next, the 
ex pre sion of biologically active IL-7 was tested by assay of supernatants from IL-7 
VY-infected 143B monolayers using clone K cells. The resultant dose-dependent 
proliferation of clone K cells confirmed the production of IL-7 by cells infected with 
VV-HA-IL7 (Fig. 5.4). 
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FIGURE 5.1. Construction of insertion plasmid pLROl 
A Pstl fragment containing the IL-7 gene was obtained from pSRa296-muIL 7. The 5' 
and 3' ends of this fragment were then modified to have BamHI and HindIII, 
respectively (see Section 5.3.1). Plasmid pLROl was constructed after insertion of the 
BamHI and HindIII IL-7 gene fragment in front of a P7 .5 promoter in pPS7 .SA (Coupar 
et al., 1988). 
AcR, ampicilin-resistance gene; Pp, vaccinia promoter; HSV tk, thymidine kinase gene of 
herpes simplex virus; P7.5, vaccinia early/late promoter; VV J region, J-fragment of the 
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FIGURE 5.2. Schematic representation of the genomic arrangements of vaccinia viruses 
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The HA gene of influenza virus, under the control of the P7.5 promoter was inserted into the tk gene of vaccinia virus in the HindIII I-fragment, yielding 
VV-HA-TK-. The disruption of the tk phenotype was compensated for by insertion of an HSV tk gene in the F-fragment under the Pp promoter. This give 
rise to VV-HA (TK+) which is used as the control virus. Marker rescue of VV-HA-TK- with pLROl containing HA and IL-7 genes produced VV-HA-IL7. 
~F , vaccinia promoter Pp; VV tk, thymidine kinase gene of vaccinia virus; HSY tk, thymidine kinase gene of herpes simplex virus; HA, hemagglutinin gene of 
influenza virus A/PR/8; IL-7, murine interleukin-7 gene; P7 .5, vaccinia early/late promoter 
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FIGURE 5.3. Southern blotting of VV DNA 
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VV DNA was prepared as in Section 5.2.8 and digested with HindIII. The digests were 
resolved on a 0.7o/o (w/v) agarose gel and transferred onto nylon membranes (GeneScreen 
Plus, DuPont, MA) by capillary alkaline transfer (Sambrook et al., 1989). Hybridisation 
was performed using either 32P-labelled IL-7 gene or 'A DNA probe (for 'A Hindlll digests 
only) under high stringency. 
Lanes: 
1 - undigested DNA of VV-HA 
2- Hindlll-digested DNA of VV-HA 
3 - undigested DNA of VV-HA-IL7 
4 - Hindlll-digested DNA of VV-HA-IL 7 
5 -Hindlll digests of 'A DNA (probed with 32P-labelled 'A DNA) 
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FIGURE 5.4. Production of murine IL-7 from recombinant VV-infected 143B cells 
Supernatants were taken from VY-HA-infected cells ( D ) and from those infected with 
VV-HA-IL 7 for 8 h ( A ) or 24 h ( e ), and diluted in microtiter before addition of 5 x 103 
clone K cells per well. Results were expressed as mean of [3H]-thymidine incorporation 
for triplicate supernatant samples over the last 6 h of a 48-h culture period. SEM were < 
10% and are omitted for clarity. 
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5.3.3 Survival of immunodeficient mice 
Immunodeficient athymic nude mice, lacking thymus-derived T lymphocytes, are 
highly susceptible to infection with VY. These mice were used to examine the effects of 
cytokine expression on virus attenu_ation (Ramshaw et al., 1987; Karupiah et al., 1990a 
and 1991; Ramshaw et al., 1992). When given VV-HA-IL7 at 107 PFU i.v., only 13o/o of 
mice (n=23) had succumbed to virus infection by 16 days post-infection whereas all mice 
(n=lO) given a similarly constructed control virus lacking IL-7, VY-HA, had died at this 
time from disseminated vaccinal disease (Fig. 5.5). While nude mice given VY-HA 
control virus died rapidly, mice given VV-HA-IL7 died at a slower rate. About 33% of the 
initial population of mice given the IL-7-encoding recombinant VY had survived virus 
infection at 60 days post-infection and no further mortality was observed thereafter. 
5.3.4 Recombinant virus growth in vivo 
The in vivo growth patterns of VY-HA-IL 7 and the control virus VY-HA were 
compared, given the reduced virulence of the former in nude mice. Control virus grew to 
high titres in nude mice (109.0 PFU/ovary) within 3 days of infection and remain_ed at this 
level until death (Table 5.1 ). However, the growth patterns of VY-HA-IL 7 differed, 
reaching a peak titre of 109.0 PFU/ovary at day 8 post-infection and declining thereafter 
(significantly different, p < 0.05 by Student's t test). These observations reveal that some 
immunodeficient mice began to resolve infection with recombinant VY expressing IL-7. 
The attenuating effect of IL-7 expression was also seen in euthymic CBA/H mice. 
IL-7 expression induced an accelerated clearance of the virus. After reaching similar titres 
as the control virus at day 4 post-infection, VY-HA-IL 7 was cleared by day 8 
post-infection at which time the control virus could still be detected (104.85 PFU/ovary; 
Table 5.1). 
Taken together, the findings in Sections 5.3.3 and 5.3.4 suggest that local 
production of vector-ex pre sed IL-7 attenuated the growth of VY in vivo, probably 
through the induction of host responses. Possible mechanisms of this attenuation are 
studied below. 
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FIGURE 5.5. Survival of athymic Swiss outbred nude mice infected with VV 
recombinants 
Groups of 23 and 10 ffilce were given 107 PFU of VV-HA-IL7 and VV-HA i.v., 
respectively, and were observed for mortality for up to 80 days. Similar results were 
obtained in another experiment with 10 mice per group. 
TABLE 5.1. Growth kinetics of recornbinant VV in micea 
Log10 v_irus titers (mean of PFU/ovary + SEM)b 
Days Swiss outbred athlmic nudes CBA/H 
post-infection 
VV-HA VV-HA-IL7 VV-HA VV-HA-IL7 
1 5.87 + 0.17 5.16 + 0.32 4.64 + 0.13 4.73 + 0.09 
2 7.56 + 0.36 6.94 + 0.17 7.10 + 0.42 7.58 + 0.21 
3 8.98 + 0.08 7.84 + 0.17 8.10+0.25 7.77 + 0.16 
4 9.07 + 0.04 8.46 + 0.04 8.07 + 0.17 7.31 + 0.23 
6 9.31 + 0.04 8.44+0.11 6.92 + 0.25 5.42 + O. l9C 
8 9.19+0.12 9.03 + 0.57 4.85 + 0.14 < 2c 
10 9.24 + 0.06 7.99 + O. l8C <2 <2 
14 8.19 + 0.32d 7.07 + 0.31 C NDe ND 
17 5.65 + 0.91 ND ND 
20 5.12 + 0.62 ND ND 
aGroups of 4 mice were given 107 PFU of recombinant VV i.v. and their ovaries were 
harvested on the days indicated. The virus load was estimated by plaque assay as 
described in Section 5.2.5. The limit of sensitivity of these assays was 
> 102 PFU/ovary. 
bEach result represents the geometric mean + SEM of virus titres 1n ovaries for 
4 individual mice. These titres are representative of 2 experiments. 
csignificantly different from mice infected with VV-HA (p < 0.05 by Student's t test). 
dA]l nude mice given VY-HA eventually succumbed to virus infection. 
eND, not determined. 
5.3.5 Induction of immune responses "in mice given virus expressing IL-7 
Next, the effects of recombinant VY-expressed IL-7 on antiviral immune 
responses were examined. After infection with 107 PFU of VV, there was an increase in 
splenic cellularity in mice given VV-HA-IL 7 compared to those given control virus. 
Normal CBA/H mice infected with VV-HA-IL7 showed a 2-fold increase in their splenic 
leukocyte counts by 6 days post-infection (Table 5.2). The increased cellularity was even 
more pronounced in nude mice given VV-HA-IL7. Microscopic examination revealed a 
general increase in the proportion of different cell types in the spleens of CBA/H mice 
given VV-HA-IL7 (Table 5.3). 
Spleen cells from infected mice were next tested for their cytolytic effector activity 
against different target cells. Using spleen effectors from CBA/H mice infected with 
either recombinant VV, there was no apparent difference in CTL lytic activity against 
VY-infected target cells (Table 5.4 ). However, when the considerable increase in 
splenocyte numbers in mice infected with VY-HA-IL 7 was taken into account, peak CTL 
levels were 2-fold higher than in control virus-infected mice at 6 days after infection. 
Table 5.5 gives the CTL lytic activity per spleen in mice given either VV-HA-IL 7 or 
control virus. 
IL-7 is known to induce LAK (Alderson et al., 1990; Hickman et al., 1990; Lynch 
and Miller, 1990; N aume and Espevik, 1991; Stotter et al., 1991; Kos and Mlillbacher, 
1992) and NK (Naume and Espevik, 1991) cell activities in vitro. For this reason, the NK 
and LAK lytic activity of splenocytes from mice given recombinant VV encoding IL-7 
were also investigated. For this purpose, Y AC-1 and P8 l 5 target cells, which have 
different sensitivities to NK lysis were used. Y AC-1 cells are sensitive to NK lysis 
whereas P815 cells are NK-resistant. NK cells would, therefore, lyse only Y AC-1 targets 
(Biron et al., 1990). The induction of LAK activity would be revealed by lysis of both 
target cell (Li et al., 199 1). 
Table 5.6 show the lytic activity of spleen cells from euthymic mice against 
Y AC-1 and P815 target cells. Splenocytes taken 3 days post-infection with VV-HA lysed 
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TABLE 5.2. Splenic cellularity zn rnzce gzven recombinant vva 
Mice Days post-infection Vin1s Leukocytes ( 107)/spleen (mean+ SEM)b 
CBA/H 3 VV-HA 5.8 + 0.5 
VV-HA-IL7 4.5 + 1.4 
6 VV-HA 9.2 + 0.3 
VV-HA-IL7 16.5 + 0.6C 
9 VV-HA 13.1+2.3 
VV-HA-IL7 13.8 + 2.7 
Nude 3 VV-HA 7.5 + 0.4 
VV-HA-IL7 14.8 + 1.oc 
6 VV-HA 6.5 + 0.3 
VV-HA-IL7 12.0 + 1.2c 
9 VV-HA 3.9 + 0.2 
VV-HA-IL7 16.5 + 0.7c 
3 Groups of 4 mice were given 107 PFU of recombinant VY i.v. At the days indicated, 
spleens were harvested and splenocytes pooled. The number of leukocytes among the 
spleen cells were enumerated. 
bData hown are the mean+ SEM of leukocyte counts from 3 experiments. 
cp < 0.0006 by Student's t test in comparison to n1ice given VY-HA. 
TABLE 5.3. Cell composition zn spleens of mice given recombinant vva 
Leukocytes Numbers of cells per spleen ( 1 Q7)b 
VY-HA VV-HA-IL7 
Lymphocytes 6.9 11.8 
Basophils 0.4 0.9 
Neutrophils 0.4 0.9 
Eosinophils 0.2 0.5 
Monocytes 1.2 2.4 
aGroups of 4 CBA/H n1ice were given 107 PFU of recombinant VY i.v. and spleens 
were removed 6 days after infection. The spleens were pooled and the cell composition 
among 1 x 1 as spleen cells was determined as described in Section 5.2.16. 
bA total of 400 spleen cells was enumerated and the proportion of different cells were 
determined following cytocentrifugation and staining by May-Griinwald-Giemsa. The 
total numbers of each cell type in the spleen was then calculated using the cell ratios 
obtained. Results are representative of 2 experiments. 
TABLE 5.4. CTL activity of effectors from mzce infected with 
recombinant vva 
Days post-infection Effector:target ratios 
3 60:1 
20:1 
6: 1 
2:1 
6 60: 1 
20:1 
6: 1 
2: 1 
9 60: 1 
20:1 
6: 1 
2: 1 
o/o specific 1 ysis by effectors from mice 
infected withb: 
VV-HA VV-HA-IL7 
24.14 32.86 
16.20 21.89 
8.64 5.54 
4.49 2.55 
62.81 66.89 
49.68 58.97 
27.79 27.49 
8.58 9.23 
38.89 47.61 
28.89 36.75 
11.54 17.95 
1.44 9.63 
aGroups of 4 CBA/H mice were given 107 PFU of recombinant VY i.v. At the times 
indicated, spleens were removed and splenocytes pooled. 
bA ays were performed using L929 target cells infected with VY (see Section 5.2.10). 
Data shown are means of triplicate wells and SEM were < 5% . Specific lysis of 
uninfected L929 cell was< l Oo/a. These result are representative of 3 experiments. 
TABLE 5.5. Kinetics of CTL responses in spleens of mice given recombinant vva 
Days 
post-infection 
3 
6 
9 
Total lytic units per spleen in mice given (mean+ SEM)b: 
VV-HA VV-HA-IL7 
89 + 8 186 + 53c 
532 + 17 1 145 + 42C 
198 + 35 184 + 36d 
3 Groups of 4 CBA/H mice were given 107 PFU of recombinant VV i.v. and spleens 
were removed at time points indicated. Antiviral CTL responses in pooled spleens 
against VY-infected L929 target cells were determined as described in Section 5.2.10. 
bEach result represents the mean+ SEM of total lytic units at 30% specific lysis in 
triplicate wells. These results are representative of 3 experiments. 
cp < 0.05 and dp > 0.05 by Student's t test. The differences of total lytic units 
detected in mice given VY-HA-IL 7 on days 3 and 6 post-infection were significant 
when compared with mice infected with the control virus. 
TABLE 5.6. Kinetics of NK and UK activity in spleens of mice given recombinant vva 
Mice Targets Days Total lytic units per spleen in mice given (mean± SEM)b: 
CBA/H YAC-1 
P815 
Nude YAC-1 
P815 
post-infection 
3 
6 
9 
3 
6 
9 
3 
6 
9 
3 
6 
9 
VV-HA 
38 + 3 
65 +2 
67 + 12 
150 + 13 
46 + 1 
60 + 11 
71 +4 
65 + 3 
8 + 1 
29+2 
9 + 1 
12 + 1 
VV-HA-IL7 
157 + 49 
143 + 5 
85 + 17 
252 + 78c 
140 + 5c,d 
53 + lOC 
182 + 12 
128 + 14 
32 + 1 
157 + 11 c,d 
137 + 3c,d 
45 + 2c,d 
aGroups of 4 n1ice were given 107 PFU of recombinant VV i.v. and spleens were removed on 
days indicated. NK and LAK activities of pooled splenocytes against Y AC-1 or P8 l 5 cells 
were determined. 
bEach result represents the mean + SEM of total lytic units at 30o/o specific lysis in triplicate 
wells. Sin1ilar results were obtained a duplicate experiment. 
CThe lytic activities of splenocytes from mice infected with VV-HA-JL 7 against P8 l 5 were 
not significantly different from YAC-1 lysis (p > 0.6 by Student ' s t test). 
dThe differences in P815 lysis among groups of mice infected with VV-HA-IL7 and control 
viru were significant (p < 0.001 by Student's t test). 
P815 targets at greater levels than Y AC-1 ·targets, however little difference was observed at 
days 6 and 9 post-infection. Hence, LAK responses were induced in mice given control 
virus and these were elevated, particularly at days 3 and 6 post-infection, in mice infected 
with the IL-7-expressing recombinant VY. These findings demonstrate an enhancement 
of LAK activity by VY-encoded IL-7 in vivo, in addition to the increased CTL activity 
shown above. 
Previous reports have shown that nude mice mount antiviral NK responses to 
recombinant VY infection and that these responses are elevated by expression of IL-2 by 
the recombinant virus (Karupiah et al., 1990b ). Here, the effects of VY-encoded IL-7 on 
the generation of host immune responses to infection were also studied in athymic nude 
rruce. 
Table 5 .6 also shows the lytic activity of splenocytes taken from VY-infected nude 
mice against Y AC-1 and P815 target cells. There was greater lytic activity against Y AC-1 
cells compared to P8 l 5 targets mediated by splenocytes taken at 3 or 6 days after 
infection with VV-HA, thus confirming that NK responses were elicited by VY in nude 
mice. However, in mice given VV-HA-IL7, levels of P815 cell lysis by splenocytes taken 
at days 3 or 6 post-infection were as higher as those of Y AC-1 targets. These levels of 
P815 lysis were higher than those observed in mice infected with control virus. These 
findings suggest that LAK responses were markedly elevated in nudes due to the 
expression of IL-7. 
While these data suggest that virus-encoded IL-7 augmented CTL and LAK 
responses in vivo, the levels of specific antibody responses in CBA/H mice were not 
greatly enhanced by VY-expressed IL-7 (Table 5.7). 
Together, these findings suggest that VY-encoded IL-7 selectively enhances 
cell-mediated immune responses in vivo. 
101 
TABLE 5.7. Systemic anti-VV lgG responsesa 
Time post-infection (wk) Reciprocal of end-point IgG titres in mice infected withb: 
VV-HA VV-HA-IL7 
1 51 200 102 400 
2 51 200 102 400 
aoroups of 4 CBA/H mice were given 107 PFU of recombinant VV i.v. and anti-VY 
antibody responses were determined at time intervals as indicated. 
bResults shown are the mean of reciprocal end-point titres for sera taken · from 4 
individual mice. The titres for 4 sera were the same and hence there were no SEM. 
Results are representative of 2 experiments. 
5.3.6 Proliferation and cytokine secretion of splenocytes in vitro 
The proliferation of spleen cells taken from VY-infected euthymic mice in 
response to stimulation with anti-CD3 antibody and the types of cytokines that they 
secrete following in vitro stimulation were compared. This experiment was performed 
because recombinant IL-7 has been shown to enhance proliferative responses of lymphoid 
cells (Komschlies et al., 1994) and their secretion of cytokines in vitro (Armitage et al., 
1992b). Six days after infection with recombinant VV, at the peak of CTL responses, 
splenocytes from CBA/H mice were stimulated with plate-bound anti-CD3 antibodies. 
Splenocytes taken from mice infected with VV-HA-IL 7 exhibited significantly higher 
rates of proliferation (11.9 + 1.0 x 104 cpm; significantly different, p < 0.01 by Student's 
t test) than those taken from VY-HA-infected mice (7 .3 + 1.2 x 104 cpm). In addition, 
supernatants from the former contained greater levels of IL-2 and IL-6 than the control 
group (Table 5.8; p < 0.05 by Student's t test). No significant differences in the levels of 
IL-4, TNF or IFN-y were noted. 
Others have shown that IL-7 supports extrathymic differentiation ~f a~+ T 
lymphocytes in nude mice (Kenai et al., 1993 ). Therefore, the effects of VY-encoded 
IL-7 on immune cells in nude mice were investigated. Splenocytes from nude mice given 
VV-HA-IL7 14 days earlier showed greater proliferation (4.0 + 0.3 x 104 cpm; 
significantly different, p < 0.00 l by Student's t test) in response to stimulation with 
plate-bound anti-CD3 antibody than splenocytes taken from mice infected with VV-HA 
( 1.1 + 0.1 x l 04 cpm). Besides secreting more IL-2 and IL-6, splenocytes from 
VV-HA-IL7-infected nude mice also produced higher levels of IFN-y than those taken 
from control vin1s-infected animals (Table 5.8). 
Hence, it appears that expression of virus-encoded IL-7 enhanced responsiveness 
to CD3 stimulation and increased secretion of IL-2, IL-6 (nude and CBA/H mice) , and 
IFN-y (nude mice only) by splenocytes. 
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TABLE 5.8. Cytokine production by splenocytes after in vitro restimulationa 
Quantity of cytokine (U/rnl) produced by splenocytes in nlice given recombinant VVb: 
Cytokine CBA/H Swiss outbred nude 
Non-stimulated Anti-CD3 stimulated Non-stimulated Anti-CD3 stimulated 
W-HA W -HA-IL7 W -HA W-HA-IL7 W -HA W -HA-IL7 W-HA W -HA-IL7 
IL-2 <2 < 4 8 40 < 10 10 8 32 
IL-4 <2 < 2 32 46 < 2 < 2 < 2 4 
IL-6 <5 20 640 2560 40 80 200 3 950 
TNF 10 10 20 20 < 2 < 2 <2 <2 
IFN-y <5 <5 4 080 4 080 < 2 4 256 2 058 
aGroups of 4 mice were given 107 PFU of recombinant VY i.v. and spleens were removed on day 6 (CB A/H mice) or 14 
(nude mice) post-infection. Spleens within each group were pooled and B lyn1phocytes were depleted . After 24 h restirnulation 
with plate-bound anti-CD3 antibody, supernatants were harvested and tested for the presence of different cytokines. 
bThe n1eans of cytokine levels (units/ml) in triplicate wells are shown. SEM were< lOo/o and are onlitted for clarity. 
J 
5.3.7 In vivo interactions between virus-expressed IL-7 and host cytokines 
Given the findings that virus-encoded IL-7 alters the cytokine secretion pattern of 
splenocytes stimulated in vitro, it was of interest to study interactions of virus-encoded 
IL-7 with endogenously produced _factors in vivo. Mice depleted of IL-2 or IFN-y by 
treatment with monoclonal antibodies were infected with VV-HA-IL 7 and the effect of the 
IL-2 or IFN-y deficiency was studied. The influence of IFN-y was also examined using 
mice with targeted disruption of their genes for the IFN-yR (IFN-yR-GKO). 
Treating normal or nude mice with anti-IFN-y antibodies had no effect on the 
increased splenic cellularity induced by VV-HA-IL 7 (data not shown). IFN-yR-GKO 
mice also had similar numbers of spleen cells as wild-type control mice after infection 
with the IL-7-expressing recombinant VV ( data not shown). In addition, there was no 
difference in lytic activity of spleen cells from these mice against P815 or VY-infected 
L929 target cells. Table 5.9 shows the effects of antibodies to IFN-y on the levels of CTL 
and LAK activity in VV-HA-IL7-infected mice. Although these responses did not appear 
to be affected by abrogation of IFN-y activity, both normal and nude mice infec;ted with 
VV-HA-IL 7 displayed signs of morbidity (ruffled fur , hunched posture) that were not 
seen in the control mice. 
In contrast, treatment with anti-IL-2 monoclonal antibody reduced the number of 
splenocytes in VV-HA-IL7-infected CBAJH and nude mice to levels similar to those 
found in spleens of mice infected with VV-HA (data not shown). Accordingly, peak CTL 
or LAK responses generated in CBA/H mice 6 days after infection with VV-HA-IL 7, 
expressed as total lytic units, were reduced to levels comparable to those elicited in mice 
given control virus (Table 5.9). In nude mice treated with anti-IL2 antibodies, splenic 
LAK re ponses (day 3 post-infection) were also reduced to control levels. Moreover, the 
effect of uch depletion in nude mice were more dramatic than in CBA/H mice. All nude 
mice (n=6) given VV-HA-IL 7 and depleted of IL-2 developed generalised vaccinal disease 
and died within 8-10 days (data not shown). 
-
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T'ABLE 5.9. Effects of antibodies to IL-2 or IFN-y on CTL and LAK activity in ,nice given recombinant vva 
Day 6 anti- VY CTL responsesc in CBA/H n1ice given: 
VY-HA 
VV-HA-1L7 
Day 6 LAK activityf in CBA/H mice given: 
VY-HA 
VV-HA-1L7 
Day 3 LAK activityf in athynlic nude rnice given: 
VY-HA 
VV-HA-IL7 
Total lytic units per spleen in mice after antibody treatment 
(mean+ SEM)b: 
GLl 13 
582 + 19 
1 049 + 38 
55 + 2 
156 + 6 
35 + 2 
142 + 10 
XMG-1.2 
612 + 24 
1132+47d 
62 + 7 
174 + 6d 
38 + 1 
154 + 9d 
S4B6 
671 + 58 
536 + 167e 
47 +4 
63 + 2oe 
26 + 1 
39 +4c 
TABLE 5.9 (continued) 
aGroups of 4 mice were given 107 PFU of recombinant VV i.v. and spleens were removed at times indicated. LAK and antiviral CTL activity 
in pooled spleens were determined as described in Section 5 .2.10. 
bAntibody treatments were performed as described in Section 5.2.12. Data shown are the means+ SEM of total lytic units at 30% specific 
lysis in triplicate wells. These results are representative of 2 experiments. 
cAnti-VV CTL responses were detern1ined by lysis of VY-infected L929 targets (see Section 5.2.10). 
dThe differences after treatment with antibodies to IFN-y, XMG-1.2, are not significant (p > 0.1 by Student's t tests). 
CThe reduction of lytic activity after treatment with S4B6 (anti-IL-2) was significantly different in comparison to treatment with control GLl 13 
(p < 0.05 by Student's t test). 
ILAK activity was n1easured as described in Section 5 .2.10. 
' 
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These results clearly indicate that the attenuating effects of IL-7 on the growth of 
VV are mediated by host IL-2. 
5.3.8 Effects of virus-encoded IL-7 on CD4+ and CD8+ lymphocytes, and the 
consequences of cytokine depletion 
The influence of VY-encoded IL-7 on priming for CD4+ and CDS+ lymphocytes 
in the spleens of VY-infected CBNH mice was examined by flow cytometry. There was 
a significant increase in the number of CD4+ or CDS+ lymphocytes in spleens of mice 
infected with VV-HA-IL 7 over those infected with control virus, although the percentages 
of these lymphocytes were relatively similar (Table 5.10). The CDS+ lymphocytes were 
shown to n1ediate antiviral cytotoxic activity, as abolition of CTL activity occurred 
following in vivo depletion of CDS+ lymphocytes by anti-CDS+ antibodies (data not 
shown). 
Next, the involvement of host IL-2 and IFN-y in generating increased numbers of 
CD4 + and CDS+ splenocytes was determined. Increases in both CD4+ and CDS+ 
lymphocyte numbers in mice infected with IL-7-expressing recombinant VY were blocked 
following administration of antibodies against IL-2 (Table 5.10). No such effect was 
observed, however, in anti-IFN-y antibody-treated mice (Table 5.10) or in IFN-yR-GKO 
ni.ice (data not shown). 
These results reveal that virus-encoded IL-7 augn1ents both CDS+ and CD4+ 
numbers in an IL-2-dependent but IFN-y-independent manner. 
--
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TABLE 5.10. Numbers of CD4+ and CD8+ cells in spleens of ,nice given 
recombinant vva 
Total numbers x 106/spleen [Percentage of cells] 
Virus Antibody (mean+ SEM)C 
treatmentb 
CD4+ CDS+ 
VV-HA GL113 4.50 + 0.22 [10.4 + 0.5] 6.80 + 1.08 [ 15.7 + 2.5] 
S4B6 4.24 + 0.37 [10.4 + 0.9] 6.49 + 0.57 [15.9 + 1.4] 
XMG-1.2 5.10 + 0.21 [11.2 + 0.7] 7 .31 + 0.87 [ 16.4 + 1.2] 
VV-HA-IL7 GLl 13 12.04 + 1.33 [ 13.5 + 1.5] 18.91 + 3.39d [21.2 + 3.8]e 
S4B6 5.89 + 1.83 [12.4 + 3.9] 7.79 + 2.42e [16.4 + 5. l]e 
XMG-1.2 11.12 + 1.49 [12.9 + 2.0] 20.21 + 3.76d [18.6 + 2.7)C 
aoroups of 4 CBA/H mice were given 107 PFU of recombinant VV i.v. and spleens 
were removed on day 6 post-infection. Splenocytes from pooled spleens were stained 
with PE-conjugated anti-mouse L3T4 (CD4; Becton Dickson Immunocytometry System, 
CA, USA) or biotin-conjugated anti-mouse Lyt-2 (CD8; Becton Dickson 
Immunocytometry System). Cell surface-bound anti-CD8 antibodies were detected 
using FITC- or PE-conjugated streptavidin (Amersham International Plc. , UK). These 
cells were analysed by FACScan as described in Section 5.2.15 . 
bAntibody treatments were performed as described in Section 5.2.12. 
cEach result represents the mean + SEM of triplicate samples from the pooled spleens . 
Results are representative of 2 experiments. 
dSignificantly different in comparison to mice infected with control virus (p < 0 .03 by 
Student's t test). 
cNot significantly diffe rent in comparison to mice infected with control virus (p > 0 .05 
by Student' t test). 
..... 
5.4 DISCUSSION 
The expression of cytokine genes by recombinant VV has previously been shown 
to markedly alter the pathogenecity of the virus (Ramshaw et al., 1992). Local production 
of encoded cytokines by recombin~nt VV at sites of infection has allowed studies of the 
immunobiology of these factors during antiviral immunity. While the expression of IL-4 
enhanced viral pathogenicity (Sharma et al., 1995), VY-encoded IFN-y or TNF exhibited 
direct anti viral activities (Kohonen-Corish et al., 1990; Sambhi et al., 1991) and 
VY-encoded IL-2 stimulated an antiviral host immune response dependent on IFN-y 
(Karupiah et al., 1990b and 1991). Here, the attenuation of recombinant VV in normal 
and immunodeficient mice by expression of another factor, IL-7, is reported. The 
influence of this cytokine on host immune responses to VV infection was investigated. 
Virus-encoded IL-7 dramatically increased the cellularity of the spleens of normal 
and nude mice. Splenomegaly or splenic leukocytosis has also been reported in mice 
given recombinant human IL-7 (Faltynek et al., 1992; Komschlies et al., 1994 ). While 
recombinant human IL-7 preferentially elevated splenic CD8+ lymphocyte_numbers 
(Faltynek et al., 1992; Komschlies et al., 1994 ), the present experiments have shown a 
generalised increase in both CD4+ and CD8+ lymphocyte numbers in normal euthymic 
mice. These findings may have been due to the activity of IL-7 as a cell growth factor. 
IL-7 has been shown to stimulate the development of both pre-T lymphocytes as well as 
mature cells of the T lineage (Morrissey et al., 1989; Murray et al., 1989; Welch et al., 
1989; Varma et al., 1990; Tushinski et al., 1991). Vector-derived IL-7 may also have 
prevented death of splenic cells by apoptosis. Cytokines, such as IL-2, have been 
demonstrated to prevent apoptosis (Pericle et al., 1994) and may prevent activated immune 
cells from progressing to apoptosis (Salmon et al., 1994 ). IL-7 has been reported to 
prevent apoptosis of dendritic epidermal T lymphocytes (Matsue et al., 1993) and 
TNF-mediated apoptosis of mouse thymocytes upon stimulation with PHA 
(Hernandez-Caselles and Stutman, 1993). Very recently, IL-7 expression during cell-cell 
interaction through integrins was shown to prevent apoptosis of leukemic cells from 
patients with chronic B-lymphocytic leukemia (Long et al., 1995). 
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Along with a general proliferat1on of spleen cells, total splenic CTL and LAK 
activities were augmented in mice given VV-HA-IL 7 compared to control virus-infected 
mice. The induction of enhanced antiviral CTL responses conforms with the reported 
in vitro actions of this cytokine in ~timulating CTL proliferation (Alderson et al., 1990; 
Lynch and Miller, 1990; Kos and Mi.illbacher, 1992). Given that CD8+ CTL play an 
important role in resolving pox virus infections (Blanden, 1971 and 1974 ), it is likely that 
the augmentation in numbers of these cells has contributed to the accelerated clearance of 
VV -HA-IL 7 from infected mice. 
The elevated LAK activity stimulated in nude mice by vector-encoded IL-7 may 
also have accelerated clearance of the virus, given that LAK cells have been demonstrated 
to have antiviral activity, particularly in immunodeficient animals (Bukowski et al., 1988). 
Infection of nude mice with VV-HA-IL2 resulted in activation of NK activity that could 
resolve infection within 6-8 days (Karupiah et al., 1990b and 1991). Although human 
IL-7 has been shown to stimulate NK cells in vitro (N aume and Espevik, 1991 ), murine 
IL-7 encoded by VV preferentially stimulated LAK activity in vivo in this stu_dy. This 
finding disagrees with the reported absence of LAK activity in mice given recombinant 
human IL-7 and challenged with tumour cells (Komschlies et al., 1994 ). The inability of 
human IL-7 to induce LAK activity in mice may be due to species specificity of the 
cytokine. Enhancement of in vitro LAK activity by IL-7, however, has been widely 
reported (Alderson et al., 1990; Hickman et al., 1990; Lynch and Miller, 1990; N aume 
and Espevik, 1991; Stotter et al., 1991; Kos and MUllbacher, 1992). Furthermore, data 
obtained in this study also show that VV-HA-IL 7 infections persisted for longer periods 
than those involving the IL-2-encoding VV, suggesting that the antiviral properties of 
LAK cell induced by vector-expressed IL-7 may not have been as effective as the 
antiviral effector function of NK and NK-like cells elicited by virus-encoded IL-2 
(Karupiah et al., 1990b ). Nevertheless, the ability to induce antiviral LAK activity in vivo 
by delivery of vector-expre ed IL-7 in immunodeficient individuals, as described in this 
tudy, may be an important therapy for infections with some viruses, such as CMV 
(Bukow ki et al., 1988). 
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Vector-expressed IL-7 primed splenocytes from euthymic mice for enhanced and 
accelerated proliferative responses, and greater production of IL-2 and IL-6 following 
stimulation with anti-CD3 antibody in vitro. Others have also reported enhanced 
proliferative responses of splenocy~es to various T lymphocyte stimuli, including con A 
and anti-CD3 monoclonal antibodies, in the presence of recombinant IL-7 (Komschlies 
et al., 1994 ). Moreover, T lymphocytes stimulated with IL-7 in vitro, in the absence of 
co-mitogen, secreted IL-2, IL-4, IL-6 and IFN-y when restimulated with phorbol ester and 
ionomycin (Armitage et al., 1992b ). It is interesting that IL-7 also primed splenocytes 
from nude mice to respond to anti-CD3 in the present study, with resultant IL-2, IL-6 and 
IFN-y production, despite their supposed lack of thymus-derived T lymphocytes. 
VY-expressed IL-7 may have stimulated a~+ T lymphocytes, given that IL-7 has been 
reported to support extrathymic differentiation of a~+ T lymphocytes in nude mice 
(Kenai et al., 1993). While it is possible that small numbers of these T lymphocytes n1ay 
have been present due to the reported " leaky" nature of the nu/nu mutation (Kishihara 
et al., 1987; MacDonald et al., 1987; Payer et al., 1992), it is also possible that IL-7 has 
expanded a small proportion of T lymphocytes of the y8 phenotype in nude mice. Such a 
population has been identified among peripheral blood CD3+ T lymphocytes of 
immunodeficient humans (Borst et al., 1987). These lymphocytes are extrathymic and 
derive from organs such as the spleen, skin, intestine, lymph nodes, lungs and liver (Haas 
et al., 1993). In nude Balb/c mice, alloreactive T lymphocyte clones with y8 TCR have 
also been isolated after allogeneic stimulation (Blues tone et al., 1988). Such y8+ T 
lymphocytes may have provided a source of IL-2 in nude mice infected with VV-HA-IL7, 
given that splenic and intestinal y8+ T lymphocytes have been shown to secrete cytokines, 
including IL-2 and IFN-y, in response to anti-CD3 stimulation (Bluestone et al., 1991). 
In addition, IL-7 has been shown to act on y8+ lymphocytes, together with IL-1, 
st imulating these lymphocytes to proliferation (Skeen and Ziegler, 1993), while cell lines 
express ing IL-7 have been show n to support the generation of y8+ T lymphocytes after 
injection into spleens of young athymic nude mice (Gutierrez and Palacios, 1991 ). 
Human T lymphocytes with y8 TCR have been shown to display cytotoxic effector 
activity (Borst et al., 1987; Brenner et al., 1987), while in mice, y8 T lymphocytes play a 
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role in immunity against influenza virus (Carding et al., 1990; Eichelberger et al., 1991) 
and HSV-1 (Johnson et al., 1992) infections. In the light of these findings, it is possible 
that vector-encoded IL-7 stimulates antiviral LAK activity and cytokine production among 
y8+ T lymphocytes in nude mice. ~ttempts to measure increased levels of a~+ or y8+ T 
lymphocytes in nude mice given VV-HA-IL7 gave inconclusive results. 
While IL-7 has been shown to induce the expression of IL-2 and IL-2 receptor by 
NK cells (N aume and Espevik, 1991) and T lymphocytes (Morrissey et al., 1989), the 
interactions of IL-7 with IL-2, as well as with other cytokines, have not been clearly 
elucidated. The generation of CTL by IL-7 in vitro has been reported to occur 
independently of IL-2 (Kos and Mlillbacher, 1992; Kos and Mi.illbacher, 1993; Carini and 
Essex, 1994 ), although IL-2-dependency has also been suggested (Alderson et al., 1990). 
The data obtained in this study support the latter findings. The activity of vector-encoded 
IL-7 in enhancing CTL and LAK responses in vivo was critically dependent on host IL-2. 
Vector-expressed IL-7 primed splenocytes to IL-2 production, as shown upon in vitro 
restimulation with antibodies to CD3, and the resultant IL-2 appeared to be essential for 
the IL-7-mediated enhancement of cell-mediated immune responses. The augmented 
responses were apparently due to an IL-2-mediated increase in splenocyte numbers rather 
than a selective expansion of CTL. The dependency on host IL-2 for the attenuation of 
IL-7-encoding VV was more clearly shown in nude mice, where removal of IL-2 activity 
totally reversed the virus attenuation. In these mice, vector-expressed IL-7 may have 
induced LAK cells to secrete IL-2, given that LAK cells have been shown to be capable of 
ecreting this factor and IFN-y (Moretta et al., 1986). Blockade of IFN-y activity did not 
abrogate IL-7-mediated atten uation of VV infection, although there were signs of 
pathology in mice deficient of IFN-y. This suggests that IFN-y may have contributed 
ome important antiviral functions . Previous studies using lF.\l"-y-expressing recombinant 
VV have demonstrated the direct antiviral activity of this factor (Kohonen-Corish et al., 
1990). Taking these findings together, it is possible that vector-expressed IL-7 may have 
stimulated CTL or LAK cells to produce IL-2, with resultant autocrine stimulation of 
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proliferation leading to increased CTL or LAK cell numbers and elevated immune 
responses. 
The finding that VY-encoded IL-7 primed splenocytes for elevated IL-6 secretion 
is in agreement with previous reports. Murine peripheral blood T lymphocytes, when 
stimulated with con A in vitro, produced high levels of IL-6, while antibodies to IL-6 do 
not affect the ability of IL-7 to stimulate proliferation of T lymphocytes (Morrissey et al., 
1989). Given that IL-6 has many functions, including that of a growth and differentiation 
factor for CTL (Van Snick, 1990), it is possible that host-derived IL-6 induced by 
vector-expressed IL-7 may have acted to expand activated immune cells in an interaction 
similar to that described for IL-2. Greater insights into the interactions between IL-6 and 
IL-7 in vivo could be attained using mice lacking IL-6 functions either by treatment with 
specific antibodies or targeted disruption of the IL-6 gene. 
It has previously been shown that IL-7 is a growth factor for activated B 
lymphocytes (Joshi and Choi, 1991). Although virus-expressed IL-7 was shown to have 
significant effects on the induction of antiviral cell-mediated immune responses, this factor 
had no major effects on the generation of specific antiviral antibody responses. This may 
be due to the production of virus-encoded IL-7 in sites other than those in the vicinity of 
activated B lymphocytes. It could also be, as previously suggested by Joshi and Choi 
(1991), that IL-7 may not induce activated B lymphocytes to IgG secretion. The adjuvant 
effect of IL-7 in preferentially inducing augmented cell-mediated responses may be 
important for the control of intracellular pathogens, such as that suggested for 
prophylactic and therapeutic strategies against HIV (Salk et al., 1993). Indeed, such 
vaccine strategies might be implemented using recombinant FPV, a virus successfully 
used as a safe and effective vaccine vector in Chapter 3. 
In summary, the ex pre sion of IL-7 by a recombinant VY attenuated the 
recombinant virus and selectively augmented cell-mediated responses in a manner 
critically dependent on host IL-2. 
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CHAPTER6 
General Discussion 
... 
This thesis describes the selective induction of immune responses by 
poxvirus-encoded cytokines and the development of novel immunisation strategies 
using recombinant FPV and NA V vectors either alone or in combination. 
The profile of cytokines present during the development of immune responses 
may critically influence the type of response generated against a particular antigen 
(Mosmann et al., 1986; Mosmann and Coffman, 1989a; Sher and Coffman, 1992). 
Interleukin 2 and IFN-y, produced by Th 1 clones, promote cell-mediated immunity 
(Mosmann et al., 1986; Mosmann and Coffman, 1989a) whereas IL-4, IL-5 and IL-10, 
secreted by Th2 lymphocytes, direct antibody responses (Mosmann et al., 1986; 
Mosmann and Coffman, 1989a; Sher and Coffman, 1992). These Th 1 and Th2 subsets 
also cross-regulate, i.e. IFN-y inhibits Th2 lymphocyte proliferation (Femandaz-Botran 
et al., 1988; Gajewski and Fitch, 1988), while IL-4 and IL-10 down-regulate Thl 
responses (Powrie and Coffman, 1993a and 1993b). 
Cytokines expressed by recombinant VV in vzvo have profound effects on 
immune responses elicited against the virus (Karupiah et al., 1990b; Ramshaw et al., 
1992; Ran1say and Kohonen-Corish, 1993; Ramsay et al., 1994a and 1994b ). Local 
production of these VY-encoded cytokines, at sites of infection, has also provided an 
effective tool for in vivo investigations into the biology of the encoded cytokine. For 
exan1ple, IL-2, when expressed by a recombinant VV, dramatically attenuated the 
pathogenicity of the virus (Ramshaw et al., 1987; Flexner et al., 1987). The attenuating 
effect of IL-2 was due to the induction of NK or NK-like cells to produce IFN-y 
(Karupiah et al., 1990b and 1991). The authors concluded that host IFN-y had direct 
antiviral activities. Handa et al. (1983) have previously reported activity of IL-2 on NK 
cells and IFN-y production in vitro. The evidence for direct antiviral activity by IFN-y 
came when Kohonen-Corish et al. ( 1990) showed that recombinant VY encoding IFN-y 
wa highly attenuated in immunodeficient athymic or y-irradiated mice. Very recently, 
in agreement with report that IL-4 promotes Th2 immune responses (Le Gros et al., 
1990; Sadick et al., 1990; Swain et al., 1990; Chatelain et al., 1992; Hsieh et al., 1992; 
Romani et al. 1992; Seder et al., 1992) and inhibits Th 1 responses (Hsieh et al., 1992; 
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Seder et al., 1992; Powrie and Coffman, 1993a and 1993 b; Powrie et al., 1994 ), 
VY-encoded IL-4 was shown to enhance virus pathogenicity by suppressing the 
induction of antiviral CTL (Sharma et al., 1995). This inhibition of CTL generation 
was associated with the down-regulation of IL-2, IFN-y and IL-12, as determined by 
PCR. 
In the present study, the immunobiology of IL-6 and IFN-y encoded by 
recombinant FPV vectors and of IL-7 encoded by recombinant VV were examined, 
together with their influence on immune responses to vaccination. IL-6 is a strong 
signal for B lymphocyte differentiation (Vink et al., 1988) and acts on terminally 
differentiated plasma cells (Kishimoto and Hirano, 1988). This factor may be 
particularly important for the development of mucosa! antibody responses (Beagley 
et al., 1989). Indeed, expression of IL-6 by a recombinant VV in mutant mice deficient 
for this factor has substantiated its pivotal role in the development of antibody 
responses at the mucosae (Ramsay et al., 1994a). The influence of IL-6 in stimulating 
production of IgG 1 antibody in other in vivo models (Suematsu et al., 1989) _was also 
observed in normal mice infected with IL-6-expressing recombinant VV (Ramshaw 
et al., 1992). The activity of FPV-encoded IL-6, in the present study, confirms these 
observations. Moreover, results described in Chapters 3 and 4 have extended these 
findings and suggest that IL-6 may also expand lymphocyte populations during recall 
antibody responses. These findings provide further insight into the biology of IL-6 
in vivo and also indicate that strategies for the delivery of IL-6, as described in this 
thesis, may have major benefits in immunoprophylaxis for enhanced antibody 
responses, particularly at the mucosae. 
IFN-y has been shown to directly inhibit the development of Th2 responses 
(Fernandaz-Botran et al., 1988; Gajewski and Fitch, 1988); this inhibition occurs during 
the early phases of the immune response (Belosevic et al., 1989; Scott, 1991 ). Mice 
infected with IFN-y-expre sing recombinant VY mounted poor systemic anti-VY 
antibody re ponses (Kohonen-Corish et al., 1990). This suppression was even more 
pronounced when IFN-y was encoded in recombinant FPV in the present study, 
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however there was no reduction in the development of antiviral cell-mediated 
immunity. The inhibition of antibody responses by IFN-y appeared to occur early in the 
generation of immunity, as FPV-expressed IFN-y had little effect in suppressing 
antibody responses already establi~hed by NA V immunisation (Chapter 4). Recently , 
IL-12 was shown to be an important early factor in IFN-y production and establishing 
cell-n1ediated immunity (Gazzinelli et al., 1993; Heinzel et al., 1993; Hsieh et al., 
1993b; Manetti et al., 1993 and 1994; Seder et al., 1993; Sypek et al., 1993; Sieling 
et al., 1994). When given in vivo, IL-12 promoted Thl responses, through elevation of 
IFN-y production by NK cells or T lymphocytes (Gazzinelli et al., 1993; Heinzel et al., 
1993; Sypek et al., 1993). Encoding IL-12 into recombinant FPV or VY would allow a 
critical analysis of its role in immune regulation. It would be predicted that the 
cytokine would preferentially induce cell-mediated immune responses which may be 
critical in protection against certain pathogens. 
IL-7 has been reported to elevate the generation of CTL (Alderson et al., 1990; 
Hickman et al., 1990; Kos and MUllbacher, 1992) and LAK (Alderson et al., 1990; 
Hickman et al., 1990; Lynch and Miller, 1990; Nau me and Espevik, 1991; Stotter et al., 
1991; Kos and MUllbacher, 1992) activity in vitro. Little is known about the interaction 
of this cytokine with other immune modulators. Data in Chapter 5 reveal that IL-7, 
expressed by recombinant VY, selectively augmented CTL and LAK responses and that 
this enhancement was mediated through host IL-2. This dependency on IL-2 supports 
similar in vitro findings by Morrissey et al. ( 1989), Okazaki et al. ( 1989) and Alderson 
et al. (1990). The ability to electively generate cell-mediated immune responses by the 
action of IL-7 or IFN-y may have important implications for the development of 
vaccine where immunisation for such responses may be essential for effective 
prophylaxi uch as again t viru infections. 
Data presented here reveal that in vzvo activitie elucidated by encoding 
cytokine in FPV not only agree with those obtained using VY expression, or by other 
in vitro and in vivo tudie but also gave further in ights into their biology. 
Recombinant poxviru e particularly FPV, hould prove useful for further 
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investigations into the immunobiology of other cytokines, such as IL-4, IL-7, IL-12 and 
other co-stimulatory molecules, for example B7 and CD40L. As a vector, recombinant 
FPV offers several advantages over VV for this purpose, such as prolonged expression 
of encoded genes in infected ceJis and the lack of interference from endogenous 
virus-encoded proteins. This approach may also allow the studies of cytokine 
interactions, by the use of viruses harbouring multiple cytokine genes. The technology 
of local cytokine gene expression, described here, has recently been extended to other 
expression systems, namely bacteria, retrovirus-transformed tumour cells and other 
viruses. Expression of IL-4 by Salmonella inhibited macrophage killing and increased 
the pathogenicity of the recombinant bacteria (Denich et al., 1993 ), while IL-1-~ 
expression protected mice from y-irradiation-induced death (Carrier et al., 1992). 
Studies into the biology of cytokines expressed by recombinant cytomegaloviruses are 
now being attempted (W.H. Burns, The John Hopkins University, personal 
co1nmunication). Transformed tumour cells expressing cytokines have also been 
shown to generate anti tumour responses in syngeneic recipients (Alosco et al., 1993; 
Gansbacher et al., 1990). Recently, cytokine genes encoded by recombinant plasmids, 
when delivered into mouse muscles, were shown to have profound effects on the 
immune responses generated against challenge antigens (Raz et al., 1993 ). 
The acceptability of any virus as a potential vaccine vector depends mainly on 
its safety and efficacy (Ada, 1991 and 1994). The use of conventional vaccines and 
son1e recombinant virus vectors, particularly VV, has certain inherent limitations in 
these respects. The most notorious side-effect is the occasional reversion of attenuated 
strains to virulent phenotypes giving rise to vaccine-induced or vaccine-associated 
complications (Lane et al., 1969; Lane et al., 1970; Behbehami, 1983; Norrby, 1987). 
The u e of vaccine strategies described in this thesis may overcome these limitations 
and offer potentially safe approaches to vaccination. 
The safety of recombinant FPV lies in the host-restriction of this virus to avian 
cells. FPV infection in mammalian cells is non-productive or abortive (Taylor and 
Paoletti , 1988). In this tudy, severely immunodeficient mice did not succumb when 
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given recombinant FPV (Chapter 3). Earlier, avipoxvirus vectors were shown to be 
non-pathogenic in test animals (Paoletti et al., 1994) and well-tolerated in human 
volunteers (Cadoz et al., 1992). Nevertheless, foreign genes under the transcriptional 
control of early poxvirus promoter~ are expressed during abortive infection, resulting in 
presentation of heterologous proteins to the immune system and induction of immune 
responses (Taylor et al., 1988b; Cox et al., 1993b). 
Intramuscular immunisation with NA V offers another potentially useful vaccine 
strategy. Although safety considerations are still being investigated, the induction of 
antibodies against DNA (Jiao et al., 1992) or integration of plasmids in the host genome 
(Wolff et al., 1992) have not been demonstrated. NA V can also be delivered via other 
routes, such as i.d. and i.v. (Fynan et al., 1993; Zhu et al., 1993), however the particle 
bombardment ('gene-gun') method (Fynan et al., 1993) may represent an optimal mode 
of NA V immunisation. Besides offering a practical and easy vaccine delivery site, i.e. 
the epidermis, the gene-gun method provides a direct and intracellular delivery of very 
small quantities of NAY(< 1 µg; Haynes et al., 1994), all these are i~portant 
considerations for the use of vaccines in developing countries. The use of the gene-gun 
for NA V deli very may also enable a cocktail of recombinant plasmids expressing 
different genes to be delivered into individual cells. In this way, cytokine-expressing 
NA V can be given together with NA V encoding vaccine antigens in attempts to modify 
immune responses elicited against the vaccine antigen. In any case, cheap, stable and 
potentially effective vaccines for priming immune responses may be established using 
novel, non-replicating NA V and recombinant FPV vectors. 
Another concern pertaining to the use of VY-based vaccines is whether prior 
expo ure to the immunising vehicle will prevent the induction of optimal immune 
re pon es upon revaccination (Rooney et al. , 1988; Cooney et al., 1991; Etlinger and 
ltenburger, 1991) . This concern aro e, for example , when ome volunteer for 
vaccination with a recombinant VY expressing gp 160 of HIV were found to possess 
antibodie to VY (Cooney et al. , 1991 ), even though they were vaccinated against 
mall pox many year earlier during the Smallpox Eradication campaign (Fenner et al. , 
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1988). Pre-existing immunity from smallpox vaccination has been found to modulate 
immune responses to a novel antigen expressed by a recombinant VV (Rooney et al., 
1988; Cooney et al., 1991; Etlinger and Altenburger, 1991). The demonstration that 
there is no immunological cross-reactivity between FPV and VV in Chapter 3 suggests 
that the use of FPV as a vaccine vector would overcome this problem. Moreover, VV 
infections may expose many endogenous virus-encoded antigens, besides the 
heterologous vaccine antigen, that will also stimulate the immune system. Antigen 
competition between such proteins may modulate immune responses generated against 
the vaccine antigen (Andrew et al., 1986). The use of recombinant FPV and NAY, 
which do not produce vector-encoded proteins, may offer the further advantage of a 
reduction in antigenic competition between vector and vaccine proteins. The resultant 
poor immune response mounted against recombinant FPV or NA V vectors may delay 
their clearance and allow prolonged expression of the vaccine antigen. Indeed, in 
Chapter 3, recombinant FPV was shown to persist in immunised animals. Others have 
found that muscle cells retain plasmids for prolonged periods (Wolff et al., 1992). 
Such persistence of vaccine vectors may account for the induction of long-lasting 
immunity in recipient animals, a feature observed in the present study. 
In the event of reduced primary immune responses generated against the vector, 
booster immunisations are likely to be more effective. According! y, prior exposure to 
the vaccine vector did not inhibit boosting of immune responses by recombinant 
avipoxviruses, as shown in Chapter 3 and by Cadoz et al. ( 1992). Fynan et al. ( 1993) 
and Ulmer et al. (1993) have also demonstrated the feasibility of multiple 
immunisations using NA V for boosting. To further improve the efficacy of multiple 
immunisations, non-cross reactive vaccine vectors encoding the same vaccine antigen 
could be used (Li et al., 1993). Such immunisation protocols, using recombinant NA V 
and FPV vectors, proved highly successful in Chapter 4 and may provide a potentially 
effective vaccination regime where previous approaches have given poor immune 
re pan es. One potential application using such a consecutive immunisation strategy 
would be the boosting of the low levels of immunity usually induced against gag-pol 
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antigens of HIV (Walker et al., 1987). Cooney et al. ( 1993) have successfully elevated 
specific T lymphocyte and antibody responses by using sequential vaccination with 
recombinant VV expressing the env of HIV and boosting with recombinant gp 160. 
The efficacy of a vaccine also lies in its ability to generate an appropriate 
immune response, given that some pathogens are most effectively controlled by the 
induction of either cell-mediated or antibody responses (Scott and Kaufmann, 1991; 
Sher and Coffman, 1992; Sher et al., 1992; Urban et al., 1992). A correlation also 
exists between Th lymphocyte phenotype dominance and susceptibility in many 
diseases, such as in infections by Leishmania or HIV, toxoplasma or helminth 
infestations, or in tuberculosis and listeriosis. Furthermore, an uncontrolled or chronic 
Th lymphocyte response can also lead to the immunopathology seen in vernal 
conjunctivitis or exposure to allergens and during infections with respiratory syncytial 
virus or Borrelia (Wierrenga et al., 1990; Maggi et al., 1991; Parronchi et al., 1991 ; 
Yssel et al., 1991; Yssel et al., 1992; Alwan et al., 1994). Therefore, the ability to 
selectively generate an appropriate immune response to vaccination, as illus_trated in 
this thesis, may not only offer advantages in improving prophylactic strategies, but may 
also allow modification of immune responses for a specific pathogen with minimum 
pathology during immunotherapy. 
Several therapeutic vaccines against tuberculosis , and herpesvirus or hepatitis 
VlfUS infections are currently under development (Cohen, 1994). In addition, 
immunotherapy to boost or modify the immune systems of individuals infected with 
HIV has lately begun to receive much attention. Although antibodies may be important 
for preventing initial infection by the virus, high levels of antibodies in seropositive 
individual s do not prevent progression to AIDS. For treatment of an established 
infection, the induction of cell-mediated responses may be more beneficial (Clerici 
et al., 1992). It has been hown that IL-12 can restore lost HIV- and influenza 
virus- pecific cell-mediated responses among peripheral mononuclear cells cultured 
fron1 asymptomatic seropositives (Clerici et al., 1993b), that IFN-y inhibits HIV 
replication (Rosenberg and Fauci, 1991) and selectively induces cell-mediated 
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immunity (Chapter 3), and that IL-7 augments CTL responses (Chapter 5). On this 
basis, immunotherapy to boost cell-mediated immune responses might be achieved 
using vaccine vectors encoding IL-7, IL-12 or IFN-y together with an HIV antigen. 
Similar approaches may also hav~ considerable implications for HIV prophylaxis, in 
that the preferential generation of cell-mediated immune responses may be of 
paran1ount importance for successful vaccination against HIV (Salk et al., 1993). 
There are several potential antigens of HIV that could be used in a vaccine, however 
perhaps the most suitable would be the gag-pol protein. This antigen has major CTL 
determinants and is highly conserved (Nixon et al., 1988), as opposed to the highly 
divergent env of HIV (Siliciano et al., 1988). Moreover, the loss of T lymphocyte 
function in AIDS appears to be related to the sensitivity of lymphocytes to apoptosis 
(Clerici et al., 1994a). Stimulation of lymphocytes from HIV-infected individuals 
results in apoptosis which can be reversed with selected cytokines, such as IL-2. It has 
been shown that cytokines, such as IL-2, can prevent apoptosis of activated immune 
cells (Salmon et al., 1994 ). IL-7 has also been reported to prevent apoptosis of 
dendritic epidermal T lymphocytes (Matsue et al., 1993) and TNF-mediated apoptosis 
of mouse thymocytes upon stimulation with PHA (Hernandez-Caselles and Stutman, 
1993). Hence, the prevention of apoptosis by vector-directed delivery of cytokines, as 
described in this thesis, may be an important factor for HIV immunotherapy. 
Besides the prophylactic and therapeutic ramifications for infectious disease, the 
ability to preferentially manipulate the immune system using vector-encoded cytokines 
n1ay al o be important for cancer treatment and prophylaxis. Many tumours are 
non-immunogenic , as their antigens are not presented to the immune system and due to 
a lack of costimulation of immune cells (Hewitt et al., 1976) . Recently, animals given 
tumour cells transfected with cytokine genes or co-stimulatory molecules have not only 
rejected these transfectants, but were also resistant to a subsequent challenge with the 
original tumour. Cytokine found to possess antitumour-inducing capacity include IL-2 
(Fearon et al., 1990), IL-4 (Tepper et al., 1989), IL-7 (Lynch et al., 1991; Komschlies 
et al., 1994 ), IL-12 (Nog uchi et al., 1995), IFN-y (Gansbacher et al., 1990), TNF 
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(Blankenstein et al., 1991) and GM-CSF (Colombo et al., 1991). Activation molecules, 
such as B7, have also been found to possess anti tumour activities, in that immunisation 
with tumour cells tranduced with B7 generated strong antitumour cell-mediated 
immunity in test animals (B aska~ et al., 1993). Transfections of tumour cells are 
usually performed ex vivo with recombinant retroviruses, however the vectors described 
in this study represent alternatives for the delivery of cytokines and/or other immune 
activation molecules for cancer therapy in vivo. Recently , the co-administration of 
recombinant IL-12 during p53 peptide vaccination has led to regression of established 
Meth A sarcoma in mice (Noguchi et al., 1995). Recombinant FPV or NA V could be 
constructed to express tumour-specific or associated antigens, such as p53 and other 
intracellular antigens prevalent in tumour cells (Melief and Kast, 1993) together with 
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selected cytokines, and used for cancer p.rophyia'1'Cis. 
Studies using recombinant VY expressing cytokine genes to overcome 
deficiencies in mutant mice with targeted gene disruptions (Ramsay et al., 1994a) point 
to another potential application for FPV or NA V vectors - gene therapy . . Indeed, 
attempts using recombinant plasmids to complement defects in muscular dystrophy 
have already been initiated (Acsadi et al., 1991 a). Although successful expression of 
human factor VIII by recombinant adenovirus vectors may have important implications 
for gene therapy for haemophilia A (Connelly et al., 1995), recombinant avipoxviruses 
and NA V are potentially superior to other vectors used in gene therapy because of their 
persistence and the protracted expression of encoded foreign genes in recipient animals. 
Indeed , NA V immunisation was shown to be more effective than recombinant 
adenoviruses or retroviruses for the delivery of antigen to muscle cells (Davis et al., 
1993). 
In conclusion, vectors expressing cytokines represent an effective strategy that 
may be u ed to selectively manipulate the immune response to a variety of diseases 
including cancer, AIDS and other infections. 
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APPENDICES 
Primer 
P330 
P348 
PHA- 1 
Pl IA-2 
PI L6- l 
PIL6-2 
PIFNG - 1 
PIFNG -2 
Sequences (5' .... 3') 
TAGGTATAGACGAGGC 
ATCGAACTCCATTCCG 
APPENDIX I 
Sequences of priniers used in this thesis 
ACTGGATCCATGAAGGCAAACCTA 
ACIGGATCCAGATCTAAAAAAMTCAGATGCATATICTGCACIGCAMGATCC 
ACTGGATCCATGAAGTTCCTCTCT 
ACTGGATCCAAAAAAAACTAGGTITGCCGAGTAGATCTCAAAGTGAC 
ACTGGATCCATGAACGCTACACACTGCATCTTGGCT 
ACTGGATCCAAAAAAAA TCAGCAGCGACTCCTI'ITCCGCTTCCT 
asec al so Appendi x II 
Description 
PCR analysis of recombinant ppya 
PCR cloning of HA gene 
PCR cloning of IL-6 gene 
PCR cloning of IFN-y gene 
Clal 
APPENDIX II 
P330 Xbal 
... 
FPV tk 
Location of primers P330 and P348 in the genome of fowlpox virus (FPV) 
Sacl 
Smal 
ORF 
Hindlll 
Xbal 
These primers were used to detect insertion of foreign genes at the single site down-stream of the tk gene. Under PCR conditions outlined in Section 2.2.5, a 
DNA fragment of about 0.4-kb long was produced after PCR with DNA prepared from FPV-M3 (wild-type virus). Insertion of foreign genes downstream of 
the tk gene in recombinant FPV generated PCR fragments of> 3-kb long. 
ORF, open reading frame; tk , thymidine kinase gene 
APPENDIX III 
10 20 30 40 50 60 70 
* * * * * * * 
ATGAAGGCAAACCTACTGGTCCTGTTATGTGCACTTGCAGCTGCAGATGCAGACACAATATGTATAGGCT 
80 90 100 110 120 130 140 
* * * * * * * 
ACCATGCGAACAATTCAACCGACACTGTTGACACAGTGCTCGAGAAGAATGTGACAGTGACACACTCTGT 
150 160 170 180 190 200 210 
* * * * * * * 
TAACCTGCTCGAAGACAGCCACAACGGAAAACTATGTAGATTAAAAGGAATAGCCCCACTACAATTGGGG 
220 230 240 250 260 270 280 
* * * * * * * 
AAATGTAACATCGCCGGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGT 
290 300 310 320 330 340 350 
* * * * * * * 
CCTACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAGGAGATTTCATCGACTATGAGGA 
PlOO llt 
360 370 380 390 400 410 420 
* * * * * * * 
GCTGAGGGAGCAATTGAGCTCAGTGTCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGG 
430 440 450 460 470 480 490 
* * * * * * * 
CCCAACCACAACACAACCAAAGGAGTAACGGCAGCATGCTCCCATGCGGGGAAAAGCAGTTTTTACAGAA 
500 510 520 530 540 550 560 
* * * * * * * 
ATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCAAAGCTGAAAAATTCTTATGTGAACAAGAAAGG 
570 580 590 600 610 620 630 
* * * * * * * 
GAAAGAAGTCCTTGTACTGTGGGGTATTCATCACCCGTCTAACAGTAAGGATCAACAGAATATCTATCAG 
640 650 660 670 680 690 700 
* * * * * * * 
AATGAAAATGCTTATGTCTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAATAGCAGAAA 
710 720 730 740 750 760 770 
* * * * * * * 
GACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGACACAAT 
780 790 800 810 820 830 840 
* * * * * * * 
AATATTTGAGGCAAATGGAAATCTAATAGCACCAAGGTATGCTTTCGCACTGAGTAGAGGCTTTGGGTCC 
850 860 870 880 890 900 910 
* * * * * * * 
GGCATCATCACCTCAAACGCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGA GCTATAA 
- P200 
920 930 940 950 960 970 980 
* * * * * * * 
ACAGCAGTCTCCCTTTCCAGAATATACACCCAGTCACAATAGGAGAGTGCCCAAAATACGTCAGGAGTGC 
990 1000 1010 1020 1030 1040 1050 
* * * * * * * 
CAAATTGAGGATGGTTACAGGACTAAGGAACATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCCATT 
1060 1070 1080 1090 1100 1110 1120 
* * * * * * * 
GCCGGTTTTATTGAAGGGGGATGGACTGGAATGATAGATGGATGGTACGGTTATCATCATCAGAATGAAC 
1130 1140 1150 1160 1170 1180 1190 
* * * * * * * 
AGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAAAATGCCATTAACGGGATTACAAACAAGGTGAA 
1200 1210 1220 1230 1240 1250 1260 
* * * * * * * 
CTCTGTTATCGAGAAAATGAACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTAGAAAAAAGG 
1270 1280 1290 1300 1310 1320 1330 
* * * * * * * 
ATGGAAAATTTAAATAAAAAAGTTGATGATGGATTTCTGGACATTTGGACATATAATGCAGAATTGTTAG 
1340 1350 1360 1370 1380 1390 1400 
* * * * * * 
* 
TTCTACTGGAAAATGAAAGGACTCTGGATTTCCATGACTCAAATGTGAAGAATCTGTATGAGAAAGTAAA 
1410 1420 1430 1440 1450 1460 1470 
* * * * * * * 
AAGCCAATTAAAGAATAATGCCAAAGAAATCGGAAATGGATGTTTTGAGTTCTACCACAAGTGTGACAAT 
1480 1490 1500 1510 1520 1530 1540 
* * * * * * * 
GAATGCATGGAAAGTGTAAGAAATGGGACTTATGATTATCCCAAATATTCAGAAGAGTCAAAGTTGAACA 
1550 1560 1570 1580 1590 1600 1610 
* * * * * * * 
GGGAAAAGGTAGATGGAGTGAAATTGGAATCAATGGGGATCTATCAGATTCTGGCGATCTACTCAACTGT 
1620 1630 1640 1650 1660 1670 1680 
* * * * * * * 
CGCCAGTTCACTGGTGCTTTTGGTCTCCCTGGGGGCAATCAGTTTCTGGATGTGTTCTAATGGATCTTTG 
1690 1700 
* * 
CAGTGCAGAATATGCATCTGA 
Location of primers PJOO and P200 in the gene of influenza virus A/PRIS hemagglutinin 
glycoprotein 
Primer P 100 and P200 were used to detect the presence of the HA gene. Under PCR 
conditions outlined in Section 3.2.8, a DNA fragment of about 0.5-kb long was produced 
after PCR with DNA prepared from FPV-HA. 
pCMVIA/ 
control 
(5.5 kb) 
APPENDIX IV 
t-PA 
BGH polyA 
pCMVIA/Hl 
(7.2 kb) 
BGH polyA 
Schematic representation of nucleic acid vaccines pCMVIAJcontrol and 
pCMVIA/Hl 
CMV-int A, promoter-enhancer and intron A sequences of cytomegalovirus; t-PA, peptide 
signal of human tissue plasminogen activator; BGH poly A, polyadenyl sequences of bovine 
growth hormone gene; HA, hemagglutinin gene of influenza virus A/PR/8 
pl, lin 5: 
p2, lin 13: 
p2, lin 19: 
p2, line 24: 
p16,lin 11: 
p16, lin 12: 
p16, line 15: 
pl 9, line 23: 
p26, lin 17: 
p26, line 21: 
p30, line 3: 
p30, line 15: 
p45, line 18: 
p64, line 1: 
p65, line 15: 
p65, line 16: 
Table 3.3, footnote c: 
p85, line 10: 
p96, lines 26 and 27: 
p97, line 2,6,7,15 & 16: 
pl 1 I lin 12: 
p122: 
ADDE DUM 
ERRATA 
delete 'in ' after ' ... immune system which' 
replace 'recognises' with 'recognise' 
insert 'Bjorkman et al., 1987a and 1987b;' before 'Zhang et al., 
1992)' 
replace 'proteosomes' with proteasomes' 
insert 'CD40' after ' ... a ligand for' 
delete 'receptor ' after 'TNF' 
replace 'tumour' with 'transforming' 
replace 'The nature and quantity of antigen has also influenced 
the development of cell-mediated or antibody responses' with 
'The development of cell-mediated or antibody responses is also 
influenced by the nature and quantity of antigen' 
replace 'the virus' after' ... does not always neutralise' with all 
viruses, for example paramyxovirus' 
insert 'respiratory syncytial' after' ... affords protection against' 
replace 'bacterial ' with 'bacteria' 
replace' ... such as atypical measles may arise following 
vaccination with formalin-treated measles virus' with' ... for 
example atypical measles may arise following measles virus 
infection of individuals vaccinated with formalin-treated measles 
virus' 
replace 'augment' with 'augmented' 
insert sentence 'One LDso represents the quantity of influenza 
virus required to kill 50% of infected mice (n=6) within 1 week 
past-infection.' before 'Intravenous inocula ... ' 
insert 'or anti-FPV' after 'Specific anti-HA' 
insert 'or FPV (103 PFU/ml)' after' ... influenza virus (5 HAU/ml)' 
delete 'effector' after' ... the restimulated' 
insert 'for the CTL assay' after 'used' 
insert 'alone' after' ... pCMVIA/Hl i.m.' 
replace 'flourochrome' with 'fluorochrome' 
replace 'flourochrome' with 'fluorochrome' 
insert 'for use in cancer therapy' after 'cytokines' 
delete 'and used for cancer prophylaxis' 
insert the following references before 'Blanden, 1970' 
Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. 
Strominger, and D.C. Wiley. 1987a. Structure of the human 
class I histocompatibility antigen, HLA-A2. Nature 329:506-512. 
Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. 
Strominger, and D.C. Wiley. 1987b. The foreign antigen binding 
ite and T cell recognition regions of class I histocompatibility 
antigen . ature 329:512-518. 
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Avipoxviruses have recently been studied as potential vectors for the delivery of heterologous vaccine 
antigen. Because these viruses abortively infect mammalian cells yet still effectively present encoded foreign 
genes to the host immune system, they offer a safer but effective alternative to other live virus vectors. We have 
examined the effect of coexpressing the cytokine interleukin-6 or gamma interferon on immune responses to a 
recombinant fowlpox virus expressing influenza virus hemagglutinin. The encoded cytokine was expressed for 
prolonged periods in infected cell culture with little cytopathic effect due to the abortive nature of the infection. 
In mice, vector-expressed cytokine dramatically altered immune responses induced by the coexpressed 
hemagglutinin antigen. Expression of interleukin-6 augmented both primary systemic and mucosa! antibody 
responses and primed for enhanced recall responses. In contrast, expression of gamma interferon markedly 
inhibited antibody responses without affecting the generation of cell-mediated immunity. The safety of these 
constructs was demonstrated in mice with severe combined immunodeficiency, and no side effects due to 
cytokine expression were observed. In summary, fowlpox virus vectors encoding cytokines represent a safe and 
effective vaccine strategy which may be used to selectively manipulate the immune response. 
Fowlpox virus (FPV), a member of the Avipoxvirus genus 
with a double-stranded DNA genome of about 300 kb (12) , has 
recently been developed as a live virus vector for delivery of 
antigens both to its natural avian hosts (17, 26) as well as a 
potentially safe vaccine vector to mammalian hosts (13). 
Although FPV replication is blocked in mammalian cells (35, 
38), foreign genes under transcriptional control of early pro-
moters are expressed, resulting in presentation of heterologous 
protein to the immune system (13, 39). R ecently, immuniza-
tion of humans with vaccines based on recombinant canarypox 
virus, another avipoxvirus, has been reported (8). 
Effective vaccination lies in the development and mainte-
nance of long-term protective immunity. For many diseases, 
protection is determined by the type of immune response 
induced. Whether the immune response is driven toward 
humoral or cell-mediated responses is critically influenced by 
the profile of cytokines produced by subpopulations of T 
helper cells (25). To modify the immune responses elicited by 
vaccine antigens, we have constructed recombinant vaccinia 
viruses (rVVs) engineered to express cytokine genes (27-30). 
R e ults from studie with these rVVs suggest that the encoded 
cytokines either alter the pathogenicity of the vector virus (20, 
30) or selectively augment immune responses generated to-
ward the coexpre sed heterologous antigen (27-29). 
H ere, we describe (i) the construction of recombinant FPV 
(rFPVs) coexpre sing the hemagglutinin (HA) gene of influ-
enza virus A/PR/8 together with the gene for murine interleu-
kin-6 (IL-6) or gamma interferon (IFN--y) and (ii) the influ-
ence of the e virus-encoded factors on immune responses. 
Strong systemic anti-HA cytotoxic T lymphocyte (CTL) re-
ponses were generated upon re timulation of splenocytes 
from rFPV-primed mice; however, the levels of these re-
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sponses were not influenced by the coexpressed cytokines. 
When given intranasally (i .n.), anti-HA CTL responses were 
also elicited in the lungs at similar levels by all of the 
recombinant viruses. Systemic and mucosa! anti-HA antibody 
responses were selectively augmented by the expression of 
IL-6, as were recall responses following boosting with rFPV or 
challenge with wild-type influenza virus. Expression of IFN--y, 
on the other hand, suppressed antibody responses at the 
mucosae but did not affect the generation of CTL responses. 
These findings have implications for the development of 
improved vaccination strategies. 
MATERIALS AND METHODS 
Mice. SCID (severely combined immunodeficient) and 
CBNH mice, 6 to 8 weeks old, were raised under specific-
pathogen-free conditions in the Animal Breeding Establish-
ment of the John Curtin School of Medical Research. 
Cells. Chicken embryo skin cell monolayers were prepared 
as described previously (7). Human 143B cells (American Type 
Culture Collection, Rockville, Md.) and murine L929 cells 
were grown in F15 medium (GIBCO, Grand Island, N.Y.) 
supplemented with 5% fetal calf serum (Flow Laboratories, 
North Ryde, Australia). 
Viruses. FPV-M3, a tissue culture passage strain derived 
from the mild vaccine strain FPV-Web (Arthur Webster Pty. 
Ltd., Northmead, Australia), was grown in chicken embryo 
skin cell monolayers as described previously (7). Influenza 
virus A/PR/8 and rVV were grown and purified according to 
standard techniques (19, 20). 
DNA manipulation and sequencing. Molecular cloning, re-
striction enzyme dige tion, and other recombinant DNA tech-
niques were performed by conventional procedures (33). For 
equencing, single-stranded DNA templates were prepared 
from recombinant phagemid pTZ19U and sequenced by the 
dideoxy-chain termination method of Sanger et al. (34 ), using 
the PRISM R eady R eaction DyeD eoxy Terminator Cycle 
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Fowlpox virus (FPV), a member of the Avipoxvirus genus 
with a double-stranded DNA genome of about 300 kb (12), has 
recently been developed as a live virus vector for delivery of 
antigens both to its natural avian hosts (17, 26) as well as a 
potentially safe vaccine vector to mammalian hosts (13). 
Although FPV replication is blocked in mammalian cells (35, 
38), foreign genes under transcriptional control of early pro-
moters are expressed, resulting in presentation of heterologous 
protein to the immune system (13, 39). R ecently, immuniza-
tion of humans with vaccines based on recombinant canarypox 
virus, another avipoxvirus, has been reported (8). 
Effective vaccination lies in the development and main te-
nance of long-term protective immuni ty. For many diseases, 
pro tection is determined by the type of immune response 
induced. Whether the immune response is driven toward 
humoral or cell-mediated responses is critically influenced by 
the profile of cytokines produced by subpopulations of T 
helper cells (25). To modify the immune responses elicited by 
vaccine antigens, we have constructed recombinan t vaccinia 
viruses (rVVs) engineered to express cytokine genes (27-30). 
R esults from studies with these rVVs suggest that the encoded 
cytokines either alter the pathogenicity of the vector virus (20, 
30) or selectively augment immune responses generated to-
ward the coexpressed heterologous antigen (27-29). 
H ere, we describe (i) the construction of recombinant FPV 
(rFPVs) coexpressing the hemagglutinin (HA) gene of influ-
enza virus A/PR/8 together with the gene for murine interleu-
kin-6 (IL-6) or gamma interferon (IFN--y) and (ii) the influ-
ence of these viru -encoded fac tors on immune responses. 
Strong systemic anti-HA cytotoxic T lymphocyte (CTL) re-
sponses were generated upon restimulation of splenocytes 
from rFPV-primed mice; however, the level of these re-
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sponses were not influenced by the coexpressed cytokines. 
When given intranasally (i .n.), anti-HA CTL responses were 
also elicited in the lungs at similar levels by all of the 
recombinant viruses. Systemic and mucosa! anti-HA antibody 
responses were selectively augmented by the expression of 
IL-6, as were recall responses following boosting with rFPV or 
challenge with wild-type influenza virus. Expression of IFN--y, 
on the other hand, suppressed antibody responses at the 
mucosae bu t did not affect the generation of CTL responses. 
These findings have implications for the development of 
improved vaccination strategies. 
MATERIALS AND METHODS 
Mice. SCID (severely combined immunodeficient) and 
CBNH mice, 6 to 8 weeks old, were raised under specific-
pathogen-free conditions in the Animal Breeding Establish-
ment of the John Curtin School of Medical Research. 
Cells. Chicken embryo skin cell monolayers were prepared 
as described previously (7). Human 143B cells (American Type 
Culture Collection, Rockville, Md.) and murine L929 cells 
were grown in F15 medium (GIBCO, Grand Island, N.Y.) 
supplemented with 5% fetal calf serum (Flow Laboratories, 
North Ryde, Australia). 
Viruses. FPV-M3, a tissue culture passage strain derived 
from the mild vaccine strain FPV-Web (Arthur Webster Pty. 
Ltd., Northmead, Australia), was grown in chicken embryo 
kin cell monolayers as described previously (7). Influenza 
virus A/PR/8 and rVV were grown and purified according to 
standard techniques (19, 20). 
DNA manipulation and sequencing. Molecular cloning, re-
striction enzyme digestion, and other recombinant DNA tech-
niques were performed by conventional procedures (33). For 
equencing, single-stranded DNA templates were prepared 
from recombinant phagemid pTZ19U and sequenced by the 
dideoxy-chain termination method of Sanger et al. (34 ), using 
the PRISM Ready Reaction DyeDeoxy Terminator Cycle 
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sequencing kit (Applied Biosystems, Inc., Foster City, Calif.). 
Analysis of DNA sequences was performed with SeqEd ver-
sion 1.0 (Applied Biosystems, Inc.). 
PCR primers P330 (5'TAGGTATAGACGAGGC3') and 
P348 (5' ATCGAACTCCATTCCG3') homologous to the 
FPV tk gene and the Ncol site downstream of the tk gene (17), 
respectively, were used for PCR analysis of rFPV genome 
arrangements. 
Primers PHA-1 (5'ACTGGATCCATGAAGGCAAACCT 
A3 ') and PHA-2 (5'ACTGGATCCAGATCTAAAAAAAAT 
CAGATGCATATTCTGCACTGCAAAGATCC3'), comple-
mentary to the 5' and 3' ends of the open reading frame of the 
HA gene of influenza virus A/PR/8, respectively, were de-
igned with BamHI and Bglll restriction sites for PCR frag-
ment subcloning. PHA-2 also contains two overlapping tran-
scriptional termination signals, T8 ( 4 ), and an in-frame 
translational stop codon for termination of expression at the 3' 
end. 
PIL6-1 (5' ACTGGATCCATGAAGTTCCTCTCT3') and 
PIL6-2 (5' ACTGGATCCAAAAAAAACTAGGTTTGCCG 
AGTAGATCTCAAAGTGAC3'), containing transcriptional 
and translational stop signals and BamHI restriction sites for 
subcloning of PCR fragments, were used for preparation of 
murine IL-6 gene for subcloning. 
For subcloning the murine IFN-)' gene, primers PIFNG-1 
(5' ACTGGATCCATGAACGCTACACACTGCATCTTGG 
CT3') and PIFNG-2 (5'ACTGGATCCAAAAAAAATCAG 
CAGCGACTCCTTTTCCGCTTCCT3'), with similar features 
to those of the primers for IL-6, were used. 
Isolation of rFPVs. rFPVs were constructed as described 
elsewhere (6), using the coexpressed Escherichia coli gpt gene 
for recombinant virus amplification and selection (5). Recom-
binant viruses ( containing a Lacz gene) were then purified by 
plaguing under nonselective conditions with 5-bromo-4-
chloro-3-indolyl-(3-D-galactopyranoside (Bethesda Research 
Laboratories, Gaithersburg, Md.). DNA from recombinant 
viruses was analyzed by PCR, as described previously (17), to 
confirm both the predicted structure of the genome and the 
absence of wild-type FPV-M3. 
Cytotoxicity assays. Cytotoxic activity was measured in 51 Cr 
release assays (20). L929 target cells were infected with 
wild-type FPV-M3, rFPV, or rVV at a multiplicity of infection 
of 10 or with 5 x 10- 3 hemagglutinating units of influenza 
virus per cell during 51Cr labeling. 
Antibody assays. Anti-HA-specific antibodies were assayed 
by enzyme-linked immunosorbent assay (ELISA) (3). Anti-HA 
antibody-secreting cells (ASC) among lung and spleen lym-
phoid cell isolates were enumerated by using an ELISPOT 
assay described elsewhere (28). 
Cytokine assays. Supernatants from cell cultures infected 
with rFPV were assayed for IL-6 by [3H]thymidine incorpora-
tion by using the IL-6-dependent cell line B9 (1) or for IFN-)' 
by indirect ELISA, as described elsewhere (9), using the 
purified rat anti-murine IFN-)' antibody R4.6A2 as the capture 
antibody and a polyclonal rabbit anti-murine IFN-)' antibody 
as the secondary antibody. 
RESULTS 
Construction of FPV plasmid insertion vectors. A novel 
FPV insertion plasmid, pLRBlOO, was derived from pAF09 
(17) (Fig. 1). Plasmid pLRBlOO contains the HA gene inserted 
as a 1.8-kb Bglll fragment proximal to the early promoter of an 
FPV bidirectional promoter, P.E/L (23) , and an additional 
copy of the P.E/L promoter at the 3' end of the HA gene. In 
this plasmid , the ATG initiation codon of HA is preceded by 
J. VTROL. 
pLRB130 
BamHI 
(MCS) 
pAF09 
(9.50 kb) 
Bg!IIBamHI Bgill 
~
P.E/L HA 
(from pAF03-HA) 
Ecogpt 
P7.5 
pLRB120 or pLRB140 
i Insertion of Il..,-6 or IFNy gene 
pLRBlOO 
(11.5 kb) 
P7.5 
P.E/L>ATG GAC GGA TCC ATG 
___. HA 
FIG. 1. Schematic illustrations of the construction of FPV insertion 
plasmids pLRBlOO, pLRB120, pLRB130, and pLRB140. The HA gene 
was amplified by PCR from pJZ102 ( 40) , using PCR primers PHA-1 
and PHA-2, and subcloned into pAF03. The HA gene and an inverted 
repeat P.E/L promoter at the 3' end flanking a BamHI site were 
recovered as a 1.8-kb BglU fragment. This fragment was then sub-
cloned into pAF09 (17) to produce pLRBlOO, a novel FPV insertion 
plasmid vector into which a Ba,nHI fragment of murine IL-6 or IFN--y 
was then subcloned. Plasmid pLRB120 contains a copy of the IL-6 
gene, derived from pCD-muIL6 (10) by PCR using primers PIL6-1 and 
PIL6-2, at the BaniHI site of pLRBlOO. Insertion of an IFN--y gene, 
amplified from pCD-muIFN-y (16), at the BamHI site of pLRBlOO 
gave rise to pLRB140. A control virus expressing only HA but no 
cytokine genes, pLRB130, was constructed by insertion of a PCR-
derived HA gene into pAF09. Ecogpt, E. coli gpt; MCS, multiple 
cloning site. 
four codons in alignment to the ATG initiation codon of the 
P.E/L promoter. In addition, pLRBlOO contains a BamHI site 
in front of the second P.E/L promoter for further insertion of 
cytokine genes. 
Plasmids pLRB120 and pLRB140 contain a copy of PCR-
derived IL-6 and IFN-)' genes, respectively, at the BamHI site 
of pLRBlOO. Insertion of a PCR-derived HA gene into pAF09 
gave rise to pLRB130 (Fig. 1). Nucleotide sequences of the 
PCR-derived HA, IL-6, and IFN-)' genes were confirmed by 
sequencmg. 
Expression of HA and cytokine genes by rFPVs in vitro. 
Transfection of FPV-M3-infected chicken embryo skin cells 
with plasmid insertion vectors pLRB130, pLRB120, and 
pLRB140 resulted in isolation of recombinants FPV-HA, 
FPV-HA-IL-6, and FPV-HA-IFN-)', respectively. The genomic 
arrangement of these rFPVs was confirmed by PCR and 
Southern blot analyses ( data not shown) and is illustrated in 
Fig. 2. Expression of HA on the surface of rFPV-infected 
human 143B cells was shown by immunofluorescent staining 
( data not shown), while secretion of biologically active IL-6 
and IFN-)' was confirmed by bioassay and ELISA, respectively 
(Table 1). Biological activity of secreted IFN-)' was confirmed 
by bioassay using WEHI-279 cells (31) (data not shown). 
Table 1 shows daily production of IL-6 and IFN-)' from 143B 
cells infected with either rFPV or rVV. Expression of these 
factors was more protracted in cultures infected with rFPV. 
Microscopic examination at day 3 after inoculation revealed 
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FPV tk 
FPV-M3 
- -
FPV tk lacZ !IA 
FPV-HA 
- ?"7 .5 PEIL 
FPV tk lacZ !IA IL-6 
FPV-HA-IL6 
-
" 
PEIL Pl:/L 
FPV tk lacZ !IA 
FPV-HA-IFNy 
P"7 5 PFJL PHI 
FIG. 2. Genomic configuration of r P on.:1gn gene were 
in ert data ingle ite dowm,trcam of the t/... gene. C. colt i;pt (Lw~pr : 
under control of a P7.5 promoter) ancJ lacZ (under control of the 
late P. promot r) genes \ ere U'>CU for '>Cle Lion ancJ punficatton, 
re pectivel , of rFP . or the control\ iru'> FP - f IA the 11 gene of 
influenza \ iru wa, ubclonccJ prm.imal to the earl) I.Ile P.L .... L pro-
mot r. FP -HA-IL-6 ancJ FP - H - fF --y contain the munnc 1 L-<) 
and IF --y g n , r pecti\Cl), ca h unJer the tr,1t1'>crtpt1onal control 
of earl /late P. /L promoters. The r r , I L-6, ancJ I r --y gene cont.tin 
tran criptional , top . ignal'> at 3' cncJ . he u c of 1mcrtccJ repc.it of 
the identical promoter. in thi ca e P. L. cn urc the t.ibiltt\ ol 
r ombinant (36). T achic\ c thi , 1 l .111cJ ) tOklllC gcnc 111 r i f \ 
, ere expre ·ed in ppo'>itc cJirccli )n'> anJ lllUcpcn lent!) of each other 
by inclu ion of tran criptional tcrmin<1tor '>tgnal'> .it Y cncJ of e.ich 
gene. 
ell had unc.krg me cell h'>i..,, \\ hilc 
..... . 
ell , \vhi h arc abortiH!l1 ink tcd. ,,ere till 
urviH infe tion \\ith rl•P mi c lach. 
functional and I mph yte , and arc th ref 1rc highh 
u c ptible t iru. infe ti n. he c ,,ere u cd to tc t the 
af ty f r P . Pathogen-free I mi ' ,,ere inoculated 
intra nou I (i .. ) , ith up to 10 P of P -I I nr r r 
HA- IL-6 and \: r monitor d fc r up to month.., po..,timmu-
nization. m rtalit , a. b. f\Cd in am mice gi,cn r -P . 
Hi t logical , amination of ti , ue f n m p-lccn, m~1ric , lung . . 
and li er obtain d from inf ct d mi e revealed no ob\ i )LJ', 
pathol gica l change ( dat·1 n t , hm: n ). 
Induction of temic TL r pon ) ionifi ant primary 
plenic CTL re pon again. t th P , tor or coc"Xprc..,..,cd 
HA wer found at ither l or 4 \: eek after i.v. inoculation with 
FP -HA FPV- HA-IL-6, r P - H - 1 --y (data not 
hown ). In c ntra t, trong TL r , pon. e. against H \: ere 
found among plenoc te tak n 3 eeks po, timmunization and 
re timulated with influ nza iru, in itro. or clarit , onl) data 
obtained from mice gi en control iru ., FP -H , are shm: n 
24-h 
period 
24 
4 
72 
144 
TABL l. Daily in itro production of c tokine<," 
of cytokine/ml of supernatant from cell\ infected w1tlr 
FPV-H - V -HA- VV II -
IL-6h IL-6" l F --y' 
65,301 31,512 650 J, 175 
21,541 9,360 370 126 
9,057 348 117 <5 
4,374 < 100 6 <5 
a upernatants from 143B monolayer infected at a multiplicity of infection of 
l were passed through 0.1-µm-pore-size filters to remove virus particles. 
" IL-6 was a ayed by using the IL-6-dependent cell line 89. I L-6 was detected 
at very low background leve ls from 143B cells infected with a control virus, either 
FPV-HA or VY-HA (2). 
c IF --y activity was assayed by LISA o IF --y wa detected in upernatants 
overlying eel I infected with control vi ruses. 
T BL ') ystemic TL respon es in mice given FPV-HA" 
In , 1tro pecinc lys is" of L929 cells infected with: 
restimulat,on FPV-M3 lnOuenza virus VV(WR) 
ii 4.9 5.6 15.6 2.7 
FP -II 14. l 86.l 82.0 18.6 
PR 8 -+ .6 2t.O 73.7 16.0 
'' roups of lour mice ,,ere g1n:n 10~ Pf7U of FP -IIA 1.,. Spleen cells taken 
lrom mice at ,,ed. 3 post1mmun1Z,1t1on were rcst11nulated in \Jlro for 5 days. 
" Tlmt) -three percent ol the restimulatcd eflector cell cultures were used. The 
stand,1rd error ol the mean ,,as 5r, 
( able-). 1orcmcr, in, itro re timulation of effector with th 
corrc ponding r P U\Cd for priming aL o resulted in marked 
anti- I I L rc..,pon"c" and rc..,pon\c\ again t th vector. o 
liffcrcn c in the I \cl of \econdal") TL rc\pon~e wa ob-
\Cf\ eel ,, hen ..,plcnoc) tC\ \\ ere taken from mice given r PY 
c\prc . ing I L-6 or I --y. In addition, P -primed eff ctor. 
,, ere unable to ly c -inlcctcd target cell\, c en aft r ec-
rndar) re..,timulation, pointing to a lack of cro\s-reacti it of 
r p and 
lode t anti-I 11\ and anti- P ere found in 
mice lx o tccJ tit \\eek J \\ ith r P . 80thling v.ith -H after 
pnm1ng ,, 1th £-P -I IA ,11..,o induced anti-H TL re. pon. e 
(cJat<1 not hm, n). Again, no effect due to the oexprc.- ion of 
ll -hor lf- -"y \\tl Oh\Cf\cd. 
I ndu tion of . t mic anti bod. re pon ·. Mice were gi en 
r P\ -11 \ or r I 11 \ l l -6 i., ., and primary anti-H antibod_ 
re pon..,c'> \\ere monitOI cd for 12 ,,eek\. t I week after 
pnrrnng. n.>,ptHl\c mounted in mice given ~p - H - IL-6 
,,ere t\\Ofold higher than tho c rnca ured in animal· gi en 
r P -I IA: hm, c, er, little d11lcrcncc in the le, cl.., of anti bod 
re pon..,c \\i.\', noted later (data not hm,n). nti- P anti-
body titer ,, ere lo,,. 80th anti-I I and anti- P 1mmuno-
globulin , ( lg,) titer.., ,,ere enhanced after boo ting with 
r P , ,, hilc recall anti- I I antibody titer were markedly 
clc, atcd upon challenge with ,, ild -ty pc inOucnza viru,. The 
higher le, cl of anti- I I antibod) \\Crc \U , tained for at lea, t 9 
week.., after im111uniD.1tinn ,, ith the I -6-exprcs\ing rFPV. 
oil()\\ ing ubcla .., anal ..,i.., of the c rc<;,pOn\C , it w,L found 
that the TL-6-cxprc ..,ing r P tirnulated heightened lg l 
rc..,ponse\, ,, hich were maintained for at lea. t 4 week. (Table 
J ). I Im e, er, bomting , ith r P or challenge with wild-l pe 
inOucnza \ iru.., induced high level.., of lg 2a antibod , which 
accounted for the great majorit_ of the lg respon e. 
Induction of muco al immune re pon e . While no signifi-
cant antibod re. ponses were detected in , pleem, of mice gi en 
r P i.n. (data not hown), marked difference. in mucosa! 
antibod re. pon. e were found in mice. trong IgA and IgG 
respon . e were found in the lung. of mice gi en FP - H -
IL-6 b I week after immunization, whereas low re ponse. 
were detected in mice gi en control viru, (Table 4 ). IgA 
re, pon. e. ere two- to , ixfold high r in mice gi en FPV-HA-
IL-6 than in control., while the increase in IgG was le , 
pronounced . Intere tingly, coexpre. ion of I N--y , uppre .. ed 
muco. al antibody respon, es. 
Muco al antibody respons , were greatly augmented follow-
ing boo, ting with FPV-H - IL-6 but, again, were , uppre,, ed 
in mice r challenged with FPV-H - IF --y (Table 5). Muco. al 
anti-H antibody re, pon c in mice primed with FPV-HA-
IL-6 were also grea tly enhanced following challenge with 
wild-type influenza viru (Table 6). 
TL re ponsc. were detected al , imilar level in the lung of 
mice given each of these rFPV (data not shown). 
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TABLE 3. Systemic anti-HA IgG subclass responses0 
Immuniza tion Reciprocal of endpoint IgG titer 
Time 
Primary responses 
Wk 1 
Wk4 
Wk 12 
Boosting at 3 wk after immuniza tion 
Wkl 
Wk 9 
Challenge at 3 wk after immuniza tion 
Wk 1 
Wk 9 
Primary 
FPV-HA 
FPV- HA- IL-6 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV- HA- IL-6 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV-HA- IL-6 
ii 
Nil 
Nil 
Nil 
Nil 
ii 
Secondary 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV-HA-IL-6 
Influenza virus 
Influenza virus 
Influenza virus 
Influenza virus 
IgGl 
2,133 
17,067 
5,333 
10,667 
1,867 
2,133 
34,133 
59,733 
5,333 
5,333 
34,133b 
29,867b 
3,733d 
10,667d 
IgG2a 
10,667 
10,067 
25,600 
25,600 
10,667 
10,667 
204,800 
273,067 
10,667 
34,133 
170,667c 
204,800c 
25,600e 
42,667e 
a Groups of four mice were give n 107 PFU of virus i.v., and antigen-specific antibody responses were determined at time intervals as indicated. At week 3 
postimmunization, mice were given a booster, similar to the priming dose, or chall enged with 10
3 hemagg lutinating units of wild-type influenza virus i.v. R ecall antibody 
responses were determined l or 9 weeks later. 
" Titer in con trol groups that were not given rFPV prior to challenge was < 400. 
c Titer in cont rol groups that were not given rFPV prior to chall e nge was 25,600. 
d Titer in contro l grou ps that were not given rFPV prior to chall e nge was < 400. 
e Titer in control groups that were not given rFPV prior to challenge was 6,667. 
DISCUSSION 
We have previously shown that the immune response can be 
markedly influenced by cytokines expressed by rVV (20, 
27-30). In the present study, we have investigated whether the 
expression of cytokines can also influence immune responses 
to FPV, a nonreplicating viral vector. We found that recombi-
nant FPV vectors expressing HA induced poor primary splenic 
CTL responses, although strong secondary responses could be 
generated following restimulation in vitro. This finding indi-
cates that anti-HA CTL precursors were generated following 
the primary infection. Levels of secondary CTL responses were 
not influenced by virus-encoded IL-6 or IFN--y, however, 
sugges ting that optimum levels of these cytokines, if required, 
are already provided by the host immune system. Although 
CTL responses were not apparently influenced by virus-en-
coded cytokines, antibody responses against the heterologous 
antigen were markedly and selectively augmented by IL-6 and 
were suppressed by IFN--y. The IL-6-encoding virus induced a 
TABLE 4. Primary mucosa! anti-HA antibody responses" 
No. of anti -HA ASC/106 cell s 
Time (wk) Immunizat ion (mean ± SD) 
IgG IgA 
1 FPV-HA 50.4 ± 17.3 21.0 ± 6.0 
FPV-HA-IL-6 > 200 122.0 ± 18.0 
FPV-HA-IFN--y < 101, 7.0 ± 2.6 
2 FPV-HA 20.0 ± 1.7 13.3 ± 1.2 
FPV-HA-IL-6 20.0 ± 1.0 33.3 ± 2.3 
FPV-HA-IFN--y < lOb < 10" 
3 FPV-HA 32.3 ± 2.4 10.2 ± 2.9 
FPV- HA- IL-6 41.2 ± 3.1 21.4 ± 4.2 
FPV-HA-IFN--y < lOb < 10" 
0 Groups of four mice were given 107 PFU of virus i.n., and anti-HA ASC in 
the lungs were enumerated at the times indicated. The data shown are from a 
single exper iment representative of three such experiments. 
" Limit of detection. 
heightened IgG response which was predominantly of the IgG 1 
subclass. The preferential induction of this antibody subclass is 
consistent with our previous findings (30) and with other in 
vivo actions of this cytokine (37). Interestingly, on subsequent 
boosting or challenge with wild-type influenza virus, the ma-
jority of the HA-specific IgG response was of the IgG2a 
subclass, which is typically elicited by virus infection (18). 
Although virus-encoded IL-6 did not alter peak levels of HA 
antibody, the response declined much more slowly in mice 
given FPV-HA-IL-6 than in those given control virus. Thus, 9 
weeks after the last boost, antibody titers against the HA 
antigen were two- to threefold higher in mice given FPV-HA-
IL-6. It is not clear how IL-6 might influence the longevity of 
the response, given that this molecule is thought to act on 
terminally differentiated plasma cells (22). A possible explana-
tion is that there is low but prolonged expression of the 
heterologous genes encoded in rFPV during clearance of the 
virus. We are currently investigating the stability of FPV-
encoded genes in inoculated animals. 
More dramatic enhancement of antibody responses was 
demonstrated when the recombinant IL-6 FPV was adminis-
tered i.n. Anti-HA ASC appeared earlier at mucosae and at 
significantly elevated levels in mice given FPV-HA-IL-6. We 
have previously shown that antibody responses at mucosae are 
critically dependent on IL-6, as mice with targeted disruption 
of the IL-6 gene mount negligible such responses following 
antigenic challenge (27). These responses are fully restored, 
however, following challenge with rVV expressing IL-6. In the 
experiments reported here, the supplementation of host-de-
rived IL-6 by FPV-encoded cytokine clearly enhances the 
mucosal antibody response. Antibody responses peaked early 
and were sustained at higher levels in mice boosted with 
FPV-HA-IL-6 than control virus. FPV-encoded IL-6 also 
primed for enhanced local antibody responses to coexpressed 
HA antigen upon subsequent i.n. challenge with wild-type 
influenza virus, a finding of potential importance for resistance 
to infection. Together, these results suggest an important role 
I 
\ 
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TABLE 5. Recall mucosal anti-HA antibody responsesa 
No. of anti-HA ASC/106 cells (mean ±: SD) at wk: 
Virus 
Expt lb 
FPV-HA 
FPV-HA-IL-6 
FPV-HA-IF --y 
Expt 2c1 
FPV-HA 
FPV-HA-IL-6 
FPV-HA-IFN--y 
IgG 
93.3 ± 14.0 
486.7 ± 11.9 
< 20c 
34.3 ± 6.2 
262.2 ± 52.1 
De 
1 
IgA 
40.0 ± 12.0 
1,320 ± 52.9 
< 20c 
33.3 ± 4.5 
496.7 ± 70.1 
ND 
2 
IgG IgA 
85.0 ± 30.0 30.0 ± 17.0 
180.0 ± 47.5 163.5 ± 55.5 
< 20c < 20c 
IgG 
9.3 ± 2.2 
100.3 ± 13.2 
ND 
3 
IgA 
37.3 ± 3.6 
142.0 ± 9.1 
ND 
a Groups of four mice were given 107 PFU of virus i.n. and an i.n. booster similar to the priming dose at the times indicated . Recall antibody responses in the lungs 
were determined as indicated. In each case, data are from a single experiment representative of three such experiments. 
b Mice were boosted at 1 week postimmunization, and recall antibody responses in the lungs were determined at 1 and 2 weeks after boosting. 
c Limit of detection. 
c1 Mice were boosted at 3 weeks postimmunization, and recall a ntibody responses in the lungs were determined at 1 and 3 weeks after boosting. 
e D, not determined. 
for IL-6 in the expansion of immune cells during the develop-
ment of the immune response. Therefore, strategies for the 
delivery of IL-6, such as described in this report, may have 
major benefits in the development of improved mucosa! vac-
cmes. 
Our results clearly show that expression of virus-encoded 
IFN--y suppressed antibody responses at the mucosae. Greatly 
reduced systemic antibody responses were also observed in 
mice given i.v. inocula of IFN--y-expressing rFPV despite 
increased cellularity of the spleen (unpublished data). More-
over, systemic anti-VY antibody titers were significantly lower 
in mice infected with IFN--y-expressing rVV (21). While mu-
cosa! antibody responses were markedly suppressed in the 
present study, CTL responses to FPV-HA-IFN--y were as high 
as those generated by control virus. The ability to selectively 
generate a strong cell-mediated immune response may have 
important implications in the development of vaccines against 
intracellular pathogens. For example, it has been suggested 
that the preferential induction of such responses may be of 
paramount importance for successful vaccination against hu-
man immunodeficiency virus (32). 
An important factor governing the use of vaccine vectors is 
the question of safety. Because avipoxviruses abortively infect 
mammalian cells, they offer, in theory, a safer alternative to 
replication-competent viruses. Although further testing should 
TABLE 6. Mucosa! antibody responses after challenge with 
influenza virusa 
Time (wk) 
postchallenge Immunization 
FPV-HA 
FPV-HA-IL-6 
FPV-HA 
FPV-HA-IL-6 
o. of anti-HA ASC/106 cells 
(mean ±: SD) 
IgG 
59.0 ± i5.6 
312.2 ± 23.4 
11.0 ± 4.1 
58.3 ± 17.2 
IgA 
95.7 ± 47.9 
569.7 ± 72.6 
28.8 ± 9.2 
97.3 ± 5.5 
a Groups of four mice were immunized with 107 PFU of virus i.n., and at 3 
weeks postimmunization, mice were challenged with a sublethal dose (10 3 
hemagglutinating units) of wild-type influenza virus i.n . Recall a ntibody re-
sponses in the lungs were determined as indicated. The data shown are from a 
single experiment representative of three such experiments. 
b Anti-HA IgG and IgA ASC number in control mice that were not primed 
with rFPYs before challenge were 5.4/106 and 9.7/106 lung cells, respectively. 
c Anti-HA IgG and IgA ASC numbers in control mice that were not primed 
with rFPYs before challenge were 12.3/106 and 27.2/106 lung cells, respectively. 
be undertaken, we have demonstrated the safety of rFPV in a 
model of immunodeficiency (SCID mice). Moreover, the co-
expression of cytokines did not modify this feature of the 
vector. 
Interestingly, the nature of the abortive infection may be an 
important element in promoting immune responses toward the 
heterologous antigen. Failure to produce FPV proteins would 
be expected to reduce antigenic competition between viral and 
heterologous protein, and the immune response would, there-
fore, be directed toward the encoded antigens driven by early 
promoters. The poor immune response mounted against FPV 
may also retard clearance of the virus, allowing more pro-
longed expression of the vaccine antigens. Furthermore, 
booster immunizations are likely to be more effective in 
situations in which there is a reduced primary immune re-
sponse to the vector itself. Indeed, prior exposure to the vector 
did not inhibit boosting of antibodies against rabies virus 
glycoprotein by recombinant canarypox virus expressing this 
antigen in humans (8). 
The finding that there was no immunological cross-reactivity 
between FPV and VV may have important practical applica-
tions. A major problem in using VV as a vaccine vector is that 
a proportion of the population have already been immunized 
with the virus during the smallpox eradication campaign (15). 
In consequence, these individuals mount lower antibody re-
sponses to coexpressed vaccine antigens when given rVV than 
their nonvaccinated counterparts (11, 14). Our results suggest 
that this would not be a problem if FPV is used as a vaccine 
vector. Furthermore, it may be possible to use these different 
vectors encoding the same vaccine antigen to enhance the 
efficacy of multiple immunizations. Other vectors have been 
combined successfully in this respect (24). 
In summary, our results demonstrate not only the efficacy 
and safety of FPV vectors but also the use of coexpressed 
cytokines to selectively manipulate the immune response. 
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